#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Neural mechanisms of extinguishing drug and pleasant cue associations in human addiction: role of the VMPFC
#Text=The neurobiological mechanisms that underlie the resistance of drug cue associations to extinction in drug addiction remain unknown.
1-1	0-6	Neural	_	
1-2	7-17	mechanisms	_	
1-3	18-20	of	_	
1-4	21-34	extinguishing	_	
1-5	35-39	drug	_	
1-6	40-43	and	_	
1-7	44-52	pleasant	_	
1-8	53-56	cue	_	
1-9	57-69	associations	_	
1-10	70-72	in	_	
1-11	73-78	human	_	
1-12	79-88	addiction	_	
1-13	88-89	:	_	
1-14	90-94	role	_	
1-15	95-97	of	_	
1-16	98-101	the	_	
1-17	102-107	VMPFC	_	
1-18	108-111	The	_	
1-19	112-127	neurobiological	_	
1-20	128-138	mechanisms	_	
1-21	139-143	that	_	
1-22	144-152	underlie	_	
1-23	153-156	the	_	
1-24	157-167	resistance	_	
1-25	168-170	of	_	
1-26	171-175	drug	_	
1-27	176-179	cue	_	
1-28	180-192	associations	_	
1-29	193-195	to	_	
1-30	196-206	extinction	_	
1-31	207-209	in	_	
1-32	210-214	drug	_	
1-33	215-224	addiction	_	
1-34	225-231	remain	_	
1-35	232-239	unknown	_	
1-36	239-240	.	_	

#Text=Fear extinction critically depends on the ventromedial prefrontal cortex (VMPFC).
2-1	241-245	Fear	_	
2-2	246-256	extinction	_	
2-3	257-267	critically	_	
2-4	268-275	depends	_	
2-5	276-278	on	_	
2-6	279-282	the	_	
2-7	283-295	ventromedial	_	
2-8	296-306	prefrontal	_	
2-9	307-313	cortex	_	
2-10	314-315	(	_	
2-11	315-320	VMPFC	_	
2-12	320-321	)	_	
2-13	321-322	.	_	

#Text=Here we tested if this same region plays a role in extinction of non-fear, drug and pleasant cue associations.
3-1	323-327	Here	_	
3-2	328-330	we	_	
3-3	331-337	tested	_	
3-4	338-340	if	_	
3-5	341-345	this	_	
3-6	346-350	same	_	
3-7	351-357	region	_	
3-8	358-363	plays	_	
3-9	364-365	a	_	
3-10	366-370	role	_	
3-11	371-373	in	_	
3-12	374-384	extinction	_	
3-13	385-387	of	_	
3-14	388-396	non-fear	_	
3-15	396-397	,	_	
3-16	398-402	drug	_	
3-17	403-406	and	_	
3-18	407-415	pleasant	_	
3-19	416-419	cue	_	
3-20	420-432	associations	_	
3-21	432-433	.	_	

#Text=Eighteen chronic cocaine users and 15 matched controls completed three functional MRI scans.
4-1	434-442	Eighteen	_	
4-2	443-450	chronic	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]	
4-3	451-458	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]	
4-4	459-464	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]	
4-5	465-468	and	_	
4-6	469-471	15	_	
4-7	472-479	matched	_	
4-8	480-488	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
4-9	489-498	completed	_	
4-10	499-504	three	_	
4-11	505-515	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
4-12	516-519	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
4-13	520-525	scans	_	
4-14	525-526	.	_	

#Text=Participants first learned to associate an abstract cue (the conditioned stimulus, CS) with a drug-related (CSD+) or pleasant (CSP+) image.
5-1	527-539	Participants	_	
5-2	540-545	first	_	
5-3	546-553	learned	_	
5-4	554-556	to	_	
5-5	557-566	associate	_	
5-6	567-569	an	_	
5-7	570-578	abstract	_	
5-8	579-582	cue	_	
5-9	583-584	(	_	
5-10	584-587	the	_	
5-11	588-599	conditioned	_	
5-12	600-608	stimulus	_	
5-13	608-609	,	_	
5-14	610-612	CS	_	
5-15	612-613	)	_	
5-16	614-618	with	_	
5-17	619-620	a	_	
5-18	621-633	drug-related	_	
5-19	634-635	(	_	
5-20	635-638	CSD	_	
5-21	638-639	+	_	
5-22	639-640	)	_	
5-23	641-643	or	_	
5-24	644-652	pleasant	_	
5-25	653-654	(	_	
5-26	654-657	CSP	_	
5-27	657-658	+	_	
5-28	658-659	)	_	
5-29	660-665	image	_	
5-30	665-666	.	_	

#Text=Extinction immediately followed where each CS was repeatedly presented without the corresponding image.
6-1	667-677	Extinction	_	
6-2	678-689	immediately	_	
6-3	690-698	followed	_	
6-4	699-704	where	_	
6-5	705-709	each	_	
6-6	710-712	CS	_	
6-7	713-716	was	_	
6-8	717-727	repeatedly	_	
6-9	728-737	presented	_	
6-10	738-745	without	_	
6-11	746-749	the	_	
6-12	750-763	corresponding	_	
6-13	764-769	image	_	
6-14	769-770	.	_	

#Text=Participants underwent a second identical session 24 h later to assess retention of extinction learning.
7-1	771-783	Participants	_	
7-2	784-793	underwent	_	
7-3	794-795	a	_	
7-4	796-802	second	_	
7-5	803-812	identical	_	
7-6	813-820	session	_	
7-7	821-823	24	_	
7-8	824-825	h	_	
7-9	826-831	later	_	
7-10	832-834	to	_	
7-11	835-841	assess	_	
7-12	842-851	retention	_	
7-13	852-854	of	_	
7-14	855-865	extinction	_	
7-15	866-874	learning	_	
7-16	874-875	.	_	

#Text=Results showed that like fear extinction, non-fear based extinction relies on the VMPFC.
8-1	876-883	Results	_	
8-2	884-890	showed	_	
8-3	891-895	that	_	
8-4	896-900	like	_	
8-5	901-905	fear	_	
8-6	906-916	extinction	_	
8-7	916-917	,	_	
8-8	918-926	non-fear	_	
8-9	927-932	based	_	
8-10	933-943	extinction	_	
8-11	944-950	relies	_	
8-12	951-953	on	_	
8-13	954-957	the	_	
8-14	958-963	VMPFC	_	
8-15	963-964	.	_	

#Text=However, extinction-related changes in the VMPFC differed by cue valence and diagnosis.
9-1	965-972	However	_	
9-2	972-973	,	_	
9-3	974-992	extinction-related	_	
9-4	993-1000	changes	_	
9-5	1001-1003	in	_	
9-6	1004-1007	the	_	
9-7	1008-1013	VMPFC	_	
9-8	1014-1022	differed	_	
9-9	1023-1025	by	_	
9-10	1026-1029	cue	_	
9-11	1030-1037	valence	_	
9-12	1038-1041	and	_	
9-13	1042-1051	diagnosis	_	
9-14	1051-1052	.	_	

#Text=In controls, VMPFC activation to the CSD+ (which was unpleasant for participants) gradually increased as in fear extinction, while it decreased to the CSP+, consistent with a more general role of the VMPFC in flexible value updating.
10-1	1053-1055	In	_	
10-2	1056-1064	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
10-3	1064-1065	,	_	
10-4	1066-1071	VMPFC	_	
10-5	1072-1082	activation	_	
10-6	1083-1085	to	_	
10-7	1086-1089	the	_	
10-8	1090-1093	CSD	_	
10-9	1093-1094	+	_	
10-10	1095-1096	(	_	
10-11	1096-1101	which	_	
10-12	1102-1105	was	_	
10-13	1106-1116	unpleasant	_	
10-14	1117-1120	for	_	
10-15	1121-1133	participants	_	
10-16	1133-1134	)	_	
10-17	1135-1144	gradually	_	
10-18	1145-1154	increased	_	
10-19	1155-1157	as	_	
10-20	1158-1160	in	_	
10-21	1161-1165	fear	_	
10-22	1166-1176	extinction	_	
10-23	1176-1177	,	_	
10-24	1178-1183	while	_	
10-25	1184-1186	it	_	
10-26	1187-1196	decreased	_	
10-27	1197-1199	to	_	
10-28	1200-1203	the	_	
10-29	1204-1207	CSP	_	
10-30	1207-1208	+	_	
10-31	1208-1209	,	_	
10-32	1210-1220	consistent	_	
10-33	1221-1225	with	_	
10-34	1226-1227	a	_	
10-35	1228-1232	more	_	
10-36	1233-1240	general	_	
10-37	1241-1245	role	_	
10-38	1246-1248	of	_	
10-39	1249-1252	the	_	
10-40	1253-1258	VMPFC	_	
10-41	1259-1261	in	_	
10-42	1262-1270	flexible	_	
10-43	1271-1276	value	_	
10-44	1277-1285	updating	_	
10-45	1285-1286	.	_	

#Text=Supporting a specific role in extinction retention, we further observed a cross-day association between VMPFC activation and skin conductance, a classic index of conditioned responses.
11-1	1287-1297	Supporting	_	
11-2	1298-1299	a	_	
11-3	1300-1308	specific	_	
11-4	1309-1313	role	_	
11-5	1314-1316	in	_	
11-6	1317-1327	extinction	_	
11-7	1328-1337	retention	_	
11-8	1337-1338	,	_	
11-9	1339-1341	we	_	
11-10	1342-1349	further	_	
11-11	1350-1358	observed	_	
11-12	1359-1360	a	_	
11-13	1361-1370	cross-day	_	
11-14	1371-1382	association	_	
11-15	1383-1390	between	_	
11-16	1391-1396	VMPFC	_	
11-17	1397-1407	activation	_	
11-18	1408-1411	and	_	
11-19	1412-1416	skin	_	
11-20	1417-1428	conductance	_	
11-21	1428-1429	,	_	
11-22	1430-1431	a	_	
11-23	1432-1439	classic	_	
11-24	1440-1445	index	_	
11-25	1446-1448	of	_	
11-26	1449-1460	conditioned	_	
11-27	1461-1470	responses	_	
11-28	1470-1471	.	_	

#Text=Finally, cocaine users showed VMPFC abnormalities for both CSs, which in the case of the CSD+, correlated with craving.
12-1	1472-1479	Finally	_	
12-2	1479-1480	,	_	
12-3	1481-1488	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[3]	
12-4	1489-1494	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[3]	
12-5	1495-1501	showed	_	
12-6	1502-1507	VMPFC	_	
12-7	1508-1521	abnormalities	_	
12-8	1522-1525	for	_	
12-9	1526-1530	both	_	
12-10	1531-1534	CSs	_	
12-11	1534-1535	,	_	
12-12	1536-1541	which	_	
12-13	1542-1544	in	_	
12-14	1545-1548	the	_	
12-15	1549-1553	case	_	
12-16	1554-1556	of	_	
12-17	1557-1560	the	_	
12-18	1561-1564	CSD	_	
12-19	1564-1565	+	_	
12-20	1565-1566	,	_	
12-21	1567-1577	correlated	_	
12-22	1578-1582	with	_	
12-23	1583-1590	craving	_	
12-24	1590-1591	.	_	

#Text=These data suggest a global deficit in extinction learning in this group that may hinder extinction-based treatment efforts.
13-1	1592-1597	These	_	
13-2	1598-1602	data	_	
13-3	1603-1610	suggest	_	
13-4	1611-1612	a	_	
13-5	1613-1619	global	_	
13-6	1620-1627	deficit	_	
13-7	1628-1630	in	_	
13-8	1631-1641	extinction	_	
13-9	1642-1650	learning	_	
13-10	1651-1653	in	_	
13-11	1654-1658	this	_	
13-12	1659-1664	group	_	
13-13	1665-1669	that	_	
13-14	1670-1673	may	_	
13-15	1674-1680	hinder	_	
13-16	1681-1697	extinction-based	_	
13-17	1698-1707	treatment	_	
13-18	1708-1715	efforts	_	
13-19	1715-1716	.	_	

#Text=More broadly, these data show the VMPFC, when functionally intact, supports extinction learning in diverse contexts in humans.
14-1	1717-1721	More	_	
14-2	1722-1729	broadly	_	
14-3	1729-1730	,	_	
14-4	1731-1736	these	_	
14-5	1737-1741	data	_	
14-6	1742-1746	show	_	
14-7	1747-1750	the	_	
14-8	1751-1756	VMPFC	_	
14-9	1756-1757	,	_	
14-10	1758-1762	when	_	
14-11	1763-1775	functionally	_	
14-12	1776-1782	intact	_	
14-13	1782-1783	,	_	
14-14	1784-1792	supports	_	
14-15	1793-1803	extinction	_	
14-16	1804-1812	learning	_	
14-17	1813-1815	in	_	
14-18	1816-1823	diverse	_	
14-19	1824-1832	contexts	_	
14-20	1833-1835	in	_	
14-21	1836-1842	humans	_	
14-22	1842-1843	.	_	

#Text=Introduction
#Text=Extinction is the process by which conditioned responses to an otherwise neutral cue (a conditioned stimulus, CS) that has acquired affective properties after being paired with an arousing event (an unconditioned stimulus, US) gradually diminish when the cue is no longer reinforced.
15-1	1844-1856	Introduction	_	
15-2	1857-1867	Extinction	_	
15-3	1868-1870	is	_	
15-4	1871-1874	the	_	
15-5	1875-1882	process	_	
15-6	1883-1885	by	_	
15-7	1886-1891	which	_	
15-8	1892-1903	conditioned	_	
15-9	1904-1913	responses	_	
15-10	1914-1916	to	_	
15-11	1917-1919	an	_	
15-12	1920-1929	otherwise	_	
15-13	1930-1937	neutral	_	
15-14	1938-1941	cue	_	
15-15	1942-1943	(	_	
15-16	1943-1944	a	_	
15-17	1945-1956	conditioned	_	
15-18	1957-1965	stimulus	_	
15-19	1965-1966	,	_	
15-20	1967-1969	CS	_	
15-21	1969-1970	)	_	
15-22	1971-1975	that	_	
15-23	1976-1979	has	_	
15-24	1980-1988	acquired	_	
15-25	1989-1998	affective	_	
15-26	1999-2009	properties	_	
15-27	2010-2015	after	_	
15-28	2016-2021	being	_	
15-29	2022-2028	paired	_	
15-30	2029-2033	with	_	
15-31	2034-2036	an	_	
15-32	2037-2045	arousing	_	
15-33	2046-2051	event	_	
15-34	2052-2053	(	_	
15-35	2053-2055	an	_	
15-36	2056-2069	unconditioned	_	
15-37	2070-2078	stimulus	_	
15-38	2078-2079	,	_	
15-39	2080-2082	US	_	
15-40	2082-2083	)	_	
15-41	2084-2093	gradually	_	
15-42	2094-2102	diminish	_	
15-43	2103-2107	when	_	
15-44	2108-2111	the	_	
15-45	2112-2115	cue	_	
15-46	2116-2118	is	_	
15-47	2119-2121	no	_	
15-48	2122-2128	longer	_	
15-49	2129-2139	reinforced	_	
15-50	2139-2140	.	_	

#Text=The predominant view is that extinction does not eliminate the CS–US association; rather, it leads to a lessening in the conditioned response by creating a new (CS–no–US) association that competes for expression, leaving memory vulnerable to recovery of the conditioned response.
16-1	2141-2144	The	_	
16-2	2145-2156	predominant	_	
16-3	2157-2161	view	_	
16-4	2162-2164	is	_	
16-5	2165-2169	that	_	
16-6	2170-2180	extinction	_	
16-7	2181-2185	does	_	
16-8	2186-2189	not	_	
16-9	2190-2199	eliminate	_	
16-10	2200-2203	the	_	
16-11	2204-2209	CS–US	_	
16-12	2210-2221	association	_	
16-13	2221-2222	;	_	
16-14	2223-2229	rather	_	
16-15	2229-2230	,	_	
16-16	2231-2233	it	_	
16-17	2234-2239	leads	_	
16-18	2240-2242	to	_	
16-19	2243-2244	a	_	
16-20	2245-2254	lessening	_	
16-21	2255-2257	in	_	
16-22	2258-2261	the	_	
16-23	2262-2273	conditioned	_	
16-24	2274-2282	response	_	
16-25	2283-2285	by	_	
16-26	2286-2294	creating	_	
16-27	2295-2296	a	_	
16-28	2297-2300	new	_	
16-29	2301-2302	(	_	
16-30	2302-2310	CS–no–US	_	
16-31	2310-2311	)	_	
16-32	2312-2323	association	_	
16-33	2324-2328	that	_	
16-34	2329-2337	competes	_	
16-35	2338-2341	for	_	
16-36	2342-2352	expression	_	
16-37	2352-2353	,	_	
16-38	2354-2361	leaving	_	
16-39	2362-2368	memory	_	
16-40	2369-2379	vulnerable	_	
16-41	2380-2382	to	_	
16-42	2383-2391	recovery	_	
16-43	2392-2394	of	_	
16-44	2395-2398	the	_	
16-45	2399-2410	conditioned	_	
16-46	2411-2419	response	_	
16-47	2419-2420	.	_	

#Text=Extinction has been extensively studied in humans and non-human animals in the domain of fear learning, e.g., using electric shock, aversive sounds, and even monetary loss.
17-1	2421-2431	Extinction	_	
17-2	2432-2435	has	_	
17-3	2436-2440	been	_	
17-4	2441-2452	extensively	_	
17-5	2453-2460	studied	_	
17-6	2461-2463	in	_	
17-7	2464-2470	humans	_	
17-8	2471-2474	and	_	
17-9	2475-2484	non-human	_	
17-10	2485-2492	animals	_	
17-11	2493-2495	in	_	
17-12	2496-2499	the	_	
17-13	2500-2506	domain	_	
17-14	2507-2509	of	_	
17-15	2510-2514	fear	_	
17-16	2515-2523	learning	_	
17-17	2523-2524	,	_	
17-18	2525-2528	e.g	_	
17-19	2528-2529	.	_	
17-20	2529-2530	,	_	
17-21	2531-2536	using	_	
17-22	2537-2545	electric	_	
17-23	2546-2551	shock	_	
17-24	2551-2552	,	_	
17-25	2553-2561	aversive	_	
17-26	2562-2568	sounds	_	
17-27	2568-2569	,	_	
17-28	2570-2573	and	_	
17-29	2574-2578	even	_	
17-30	2579-2587	monetary	_	
17-31	2588-2592	loss	_	
17-32	2592-2593	.	_	

#Text=However, less is known about extinction in the appetitive domain, and while animal work suggests similarities in the neurobiological mechanisms of extinction of, e.g., drug seeking and fear, the mechanism of non-fear based extinction in humans remains unknown.
18-1	2594-2601	However	_	
18-2	2601-2602	,	_	
18-3	2603-2607	less	_	
18-4	2608-2610	is	_	
18-5	2611-2616	known	_	
18-6	2617-2622	about	_	
18-7	2623-2633	extinction	_	
18-8	2634-2636	in	_	
18-9	2637-2640	the	_	
18-10	2641-2651	appetitive	_	
18-11	2652-2658	domain	_	
18-12	2658-2659	,	_	
18-13	2660-2663	and	_	
18-14	2664-2669	while	_	
18-15	2670-2676	animal	_	
18-16	2677-2681	work	_	
18-17	2682-2690	suggests	_	
18-18	2691-2703	similarities	_	
18-19	2704-2706	in	_	
18-20	2707-2710	the	_	
18-21	2711-2726	neurobiological	_	
18-22	2727-2737	mechanisms	_	
18-23	2738-2740	of	_	
18-24	2741-2751	extinction	_	
18-25	2752-2754	of	_	
18-26	2754-2755	,	_	
18-27	2756-2759	e.g	_	
18-28	2759-2760	.	_	
18-29	2760-2761	,	_	
18-30	2762-2766	drug	_	
18-31	2767-2774	seeking	_	
18-32	2775-2778	and	_	
18-33	2779-2783	fear	_	
18-34	2783-2784	,	_	
18-35	2785-2788	the	_	
18-36	2789-2798	mechanism	_	
18-37	2799-2801	of	_	
18-38	2802-2810	non-fear	_	
18-39	2811-2816	based	_	
18-40	2817-2827	extinction	_	
18-41	2828-2830	in	_	
18-42	2831-2837	humans	_	
18-43	2838-2845	remains	_	
18-44	2846-2853	unknown	_	
18-45	2853-2854	.	_	

#Text=Addiction is characterized by continued drug seeking and use despite reduced pleasure derived from the drug and catastrophic health and social consequences.
19-1	2855-2864	Addiction	_	
19-2	2865-2867	is	_	
19-3	2868-2881	characterized	_	
19-4	2882-2884	by	_	
19-5	2885-2894	continued	_	
19-6	2895-2899	drug	_	
19-7	2900-2907	seeking	_	
19-8	2908-2911	and	_	
19-9	2912-2915	use	_	
19-10	2916-2923	despite	_	
19-11	2924-2931	reduced	_	
19-12	2932-2940	pleasure	_	
19-13	2941-2948	derived	_	
19-14	2949-2953	from	_	
19-15	2954-2957	the	_	
19-16	2958-2962	drug	_	
19-17	2963-2966	and	_	
19-18	2967-2979	catastrophic	_	
19-19	2980-2986	health	_	
19-20	2987-2990	and	_	
19-21	2991-2997	social	_	
19-22	2998-3010	consequences	_	
19-23	3010-3011	.	_	

#Text=This behavior is assumed to be at least partly driven by a learning process in which cues associated with drug consumption acquire excessive and persistent salience, perpetuating drug seeking.
20-1	3012-3016	This	_	
20-2	3017-3025	behavior	_	
20-3	3026-3028	is	_	
20-4	3029-3036	assumed	_	
20-5	3037-3039	to	_	
20-6	3040-3042	be	_	
20-7	3043-3045	at	_	
20-8	3046-3051	least	_	
20-9	3052-3058	partly	_	
20-10	3059-3065	driven	_	
20-11	3066-3068	by	_	
20-12	3069-3070	a	_	
20-13	3071-3079	learning	_	
20-14	3080-3087	process	_	
20-15	3088-3090	in	_	
20-16	3091-3096	which	_	
20-17	3097-3101	cues	_	
20-18	3102-3112	associated	_	
20-19	3113-3117	with	_	
20-20	3118-3122	drug	_	
20-21	3123-3134	consumption	_	
20-22	3135-3142	acquire	_	
20-23	3143-3152	excessive	_	
20-24	3153-3156	and	_	
20-25	3157-3167	persistent	_	
20-26	3168-3176	salience	_	
20-27	3176-3177	,	_	
20-28	3178-3190	perpetuating	_	
20-29	3191-3195	drug	_	
20-30	3196-3203	seeking	_	
20-31	3203-3204	.	_	

#Text=The persistence of drug seeking despite negative consequences and a reduction in the drug’s rewarding effects suggests that addicted individuals may have diminished ability to form and/or maintain new associations for cues that were previously, although no longer, predictive of drug rewards (e.g., learning that the drug or drug-associated cues are no longer as valuable).
21-1	3205-3208	The	_	
21-2	3209-3220	persistence	_	
21-3	3221-3223	of	_	
21-4	3224-3228	drug	_	
21-5	3229-3236	seeking	_	
21-6	3237-3244	despite	_	
21-7	3245-3253	negative	_	
21-8	3254-3266	consequences	_	
21-9	3267-3270	and	_	
21-10	3271-3272	a	_	
21-11	3273-3282	reduction	_	
21-12	3283-3285	in	_	
21-13	3286-3289	the	_	
21-14	3290-3294	drug	_	
21-15	3294-3295	’	_	
21-16	3295-3296	s	_	
21-17	3297-3306	rewarding	_	
21-18	3307-3314	effects	_	
21-19	3315-3323	suggests	_	
21-20	3324-3328	that	_	
21-21	3329-3337	addicted	_	
21-22	3338-3349	individuals	_	
21-23	3350-3353	may	_	
21-24	3354-3358	have	_	
21-25	3359-3369	diminished	_	
21-26	3370-3377	ability	_	
21-27	3378-3380	to	_	
21-28	3381-3385	form	_	
21-29	3386-3389	and	_	
21-30	3389-3390	/	_	
21-31	3390-3392	or	_	
21-32	3393-3401	maintain	_	
21-33	3402-3405	new	_	
21-34	3406-3418	associations	_	
21-35	3419-3422	for	_	
21-36	3423-3427	cues	_	
21-37	3428-3432	that	_	
21-38	3433-3437	were	_	
21-39	3438-3448	previously	_	
21-40	3448-3449	,	_	
21-41	3450-3458	although	_	
21-42	3459-3461	no	_	
21-43	3462-3468	longer	_	
21-44	3468-3469	,	_	
21-45	3470-3480	predictive	_	
21-46	3481-3483	of	_	
21-47	3484-3488	drug	_	
21-48	3489-3496	rewards	_	
21-49	3497-3498	(	_	
21-50	3498-3501	e.g	_	
21-51	3501-3502	.	_	
21-52	3502-3503	,	_	
21-53	3504-3512	learning	_	
21-54	3513-3517	that	_	
21-55	3518-3521	the	_	
21-56	3522-3526	drug	_	
21-57	3527-3529	or	_	
21-58	3530-3545	drug-associated	_	
21-59	3546-3550	cues	_	
21-60	3551-3554	are	_	
21-61	3555-3557	no	_	
21-62	3558-3564	longer	_	
21-63	3565-3567	as	_	
21-64	3568-3576	valuable	_	
21-65	3576-3577	)	_	
21-66	3577-3578	.	_	

#Text=This is also predicted by the neural circuitry that supports extinction learning, which overlaps extensively with that directly impacted by addictive substances and addiction, potentially rendering this process especially vulnerable in this population.
22-1	3579-3583	This	_	
22-2	3584-3586	is	_	
22-3	3587-3591	also	_	
22-4	3592-3601	predicted	_	
22-5	3602-3604	by	_	
22-6	3605-3608	the	_	
22-7	3609-3615	neural	_	
22-8	3616-3625	circuitry	_	
22-9	3626-3630	that	_	
22-10	3631-3639	supports	_	
22-11	3640-3650	extinction	_	
22-12	3651-3659	learning	_	
22-13	3659-3660	,	_	
22-14	3661-3666	which	_	
22-15	3667-3675	overlaps	_	
22-16	3676-3687	extensively	_	
22-17	3688-3692	with	_	
22-18	3693-3697	that	_	
22-19	3698-3706	directly	_	
22-20	3707-3715	impacted	_	
22-21	3716-3718	by	_	
22-22	3719-3728	addictive	_	
22-23	3729-3739	substances	_	
22-24	3740-3743	and	_	
22-25	3744-3753	addiction	_	
22-26	3753-3754	,	_	
22-27	3755-3766	potentially	_	
22-28	3767-3776	rendering	_	
22-29	3777-3781	this	_	
22-30	3782-3789	process	_	
22-31	3790-3800	especially	_	
22-32	3801-3811	vulnerable	_	
22-33	3812-3814	in	_	
22-34	3815-3819	this	_	
22-35	3820-3830	population	_	
22-36	3830-3831	.	_	

#Text=Substantial work in the fear domain demonstrates a central role for the ventromedial prefrontal cortex (VMPFC) in the formation, retention, and later retrieval of extinction learning.
23-1	3832-3843	Substantial	_	
23-2	3844-3848	work	_	
23-3	3849-3851	in	_	
23-4	3852-3855	the	_	
23-5	3856-3860	fear	_	
23-6	3861-3867	domain	_	
23-7	3868-3880	demonstrates	_	
23-8	3881-3882	a	_	
23-9	3883-3890	central	_	
23-10	3891-3895	role	_	
23-11	3896-3899	for	_	
23-12	3900-3903	the	_	
23-13	3904-3916	ventromedial	_	
23-14	3917-3927	prefrontal	_	
23-15	3928-3934	cortex	_	
23-16	3935-3936	(	_	
23-17	3936-3941	VMPFC	_	
23-18	3941-3942	)	_	
23-19	3943-3945	in	_	
23-20	3946-3949	the	_	
23-21	3950-3959	formation	_	
23-22	3959-3960	,	_	
23-23	3961-3970	retention	_	
23-24	3970-3971	,	_	
23-25	3972-3975	and	_	
23-26	3976-3981	later	_	
23-27	3982-3991	retrieval	_	
23-28	3992-3994	of	_	
23-29	3995-4005	extinction	_	
23-30	4006-4014	learning	_	
23-31	4014-4015	.	_	

#Text=In humans, VMPFC activity increases during fear extinction and extinction retrieval, and both neural activity and cortical thickness in this region correlate with psychophysiological indices of extinction success [e.g., lowered skin conductance response (SCR) to the CS].
24-1	4016-4018	In	_	
24-2	4019-4025	humans	_	
24-3	4025-4026	,	_	
24-4	4027-4032	VMPFC	_	
24-5	4033-4041	activity	_	
24-6	4042-4051	increases	_	
24-7	4052-4058	during	_	
24-8	4059-4063	fear	_	
24-9	4064-4074	extinction	_	
24-10	4075-4078	and	_	
24-11	4079-4089	extinction	_	
24-12	4090-4099	retrieval	_	
24-13	4099-4100	,	_	
24-14	4101-4104	and	_	
24-15	4105-4109	both	_	
24-16	4110-4116	neural	_	
24-17	4117-4125	activity	_	
24-18	4126-4129	and	_	
24-19	4130-4138	cortical	_	
24-20	4139-4148	thickness	_	
24-21	4149-4151	in	_	
24-22	4152-4156	this	_	
24-23	4157-4163	region	_	
24-24	4164-4173	correlate	_	
24-25	4174-4178	with	_	
24-26	4179-4198	psychophysiological	_	
24-27	4199-4206	indices	_	
24-28	4207-4209	of	_	
24-29	4210-4220	extinction	_	
24-30	4221-4228	success	_	
24-31	4229-4230	[	_	
24-32	4230-4233	e.g	_	
24-33	4233-4234	.	_	
24-34	4234-4235	,	_	
24-35	4236-4243	lowered	_	
24-36	4244-4248	skin	_	
24-37	4249-4260	conductance	_	
24-38	4261-4269	response	_	
24-39	4270-4271	(	_	
24-40	4271-4274	SCR	_	
24-41	4274-4275	)	_	
24-42	4276-4278	to	_	
24-43	4279-4282	the	_	
24-44	4283-4285	CS	_	
24-45	4285-4286	]	_	
24-46	4286-4287	.	_	

#Text=Beyond fear extinction, the VMPFC along with the striatum form what is known as the ‘brain’s valuation system’, a set of regions that represent (and possibly update) value in a domain-general manner.
25-1	4288-4294	Beyond	_	
25-2	4295-4299	fear	_	
25-3	4300-4310	extinction	_	
25-4	4310-4311	,	_	
25-5	4312-4315	the	_	
25-6	4316-4321	VMPFC	_	
25-7	4322-4327	along	_	
25-8	4328-4332	with	_	
25-9	4333-4336	the	_	
25-10	4337-4345	striatum	_	
25-11	4346-4350	form	_	
25-12	4351-4355	what	_	
25-13	4356-4358	is	_	
25-14	4359-4364	known	_	
25-15	4365-4367	as	_	
25-16	4368-4371	the	_	
25-17	4372-4373	‘	_	
25-18	4373-4378	brain	_	
25-19	4378-4379	’	_	
25-20	4379-4380	s	_	
25-21	4381-4390	valuation	_	
25-22	4391-4397	system	_	
25-23	4397-4398	’	_	
25-24	4398-4399	,	_	
25-25	4400-4401	a	_	
25-26	4402-4405	set	_	
25-27	4406-4408	of	_	
25-28	4409-4416	regions	_	
25-29	4417-4421	that	_	
25-30	4422-4431	represent	_	
25-31	4432-4433	(	_	
25-32	4433-4436	and	_	
25-33	4437-4445	possibly	_	
25-34	4446-4452	update	_	
25-35	4452-4453	)	_	
25-36	4454-4459	value	_	
25-37	4460-4462	in	_	
25-38	4463-4464	a	_	
25-39	4465-4479	domain-general	_	
25-40	4480-4486	manner	_	
25-41	4486-4487	.	_	

#Text=In addiction, the VMPFC and striatum are implicated in the experience of craving, a motivational state often triggered by drug-associated cues that can promote drug seeking.
26-1	4488-4490	In	_	
26-2	4491-4500	addiction	_	
26-3	4500-4501	,	_	
26-4	4502-4505	the	_	
26-5	4506-4511	VMPFC	_	
26-6	4512-4515	and	_	
26-7	4516-4524	striatum	_	
26-8	4525-4528	are	_	
26-9	4529-4539	implicated	_	
26-10	4540-4542	in	_	
26-11	4543-4546	the	_	
26-12	4547-4557	experience	_	
26-13	4558-4560	of	_	
26-14	4561-4568	craving	_	
26-15	4568-4569	,	_	
26-16	4570-4571	a	_	
26-17	4572-4584	motivational	_	
26-18	4585-4590	state	_	
26-19	4591-4596	often	_	
26-20	4597-4606	triggered	_	
26-21	4607-4609	by	_	
26-22	4610-4625	drug-associated	_	
26-23	4626-4630	cues	_	
26-24	4631-4635	that	_	
26-25	4636-4639	can	_	
26-26	4640-4647	promote	_	
26-27	4648-4652	drug	_	
26-28	4653-4660	seeking	_	
26-29	4660-4661	.	_	

#Text=This more general role of the VMPFC in valuation and craving suggests the VMPFC may also be a candidate region involved in extinction of non-fear-based and secondary reinforcers, including drug-related and appetitive cues.
27-1	4662-4666	This	_	
27-2	4667-4671	more	_	
27-3	4672-4679	general	_	
27-4	4680-4684	role	_	
27-5	4685-4687	of	_	
27-6	4688-4691	the	_	
27-7	4692-4697	VMPFC	_	
27-8	4698-4700	in	_	
27-9	4701-4710	valuation	_	
27-10	4711-4714	and	_	
27-11	4715-4722	craving	_	
27-12	4723-4731	suggests	_	
27-13	4732-4735	the	_	
27-14	4736-4741	VMPFC	_	
27-15	4742-4745	may	_	
27-16	4746-4750	also	_	
27-17	4751-4753	be	_	
27-18	4754-4755	a	_	
27-19	4756-4765	candidate	_	
27-20	4766-4772	region	_	
27-21	4773-4781	involved	_	
27-22	4782-4784	in	_	
27-23	4785-4795	extinction	_	
27-24	4796-4798	of	_	
27-25	4799-4813	non-fear-based	_	
27-26	4814-4817	and	_	
27-27	4818-4827	secondary	_	
27-28	4828-4839	reinforcers	_	
27-29	4839-4840	,	_	
27-30	4841-4850	including	_	
27-31	4851-4863	drug-related	_	
27-32	4864-4867	and	_	
27-33	4868-4878	appetitive	_	
27-34	4879-4883	cues	_	
27-35	4883-4884	.	_	

#Text=However, while the effect of extinction-based therapy on drug-cue reactivity has just begun to be examined, no studies to date have investigated the role of the VMPFC in extinction learning itself in human addiction.
28-1	4885-4892	However	_	
28-2	4892-4893	,	_	
28-3	4894-4899	while	_	
28-4	4900-4903	the	_	
28-5	4904-4910	effect	_	
28-6	4911-4913	of	_	
28-7	4914-4930	extinction-based	_	
28-8	4931-4938	therapy	_	
28-9	4939-4941	on	_	
28-10	4942-4950	drug-cue	_	
28-11	4951-4961	reactivity	_	
28-12	4962-4965	has	_	
28-13	4966-4970	just	_	
28-14	4971-4976	begun	_	
28-15	4977-4979	to	_	
28-16	4980-4982	be	_	
28-17	4983-4991	examined	_	
28-18	4991-4992	,	_	
28-19	4993-4995	no	_	
28-20	4996-5003	studies	_	
28-21	5004-5006	to	_	
28-22	5007-5011	date	_	
28-23	5012-5016	have	_	
28-24	5017-5029	investigated	_	
28-25	5030-5033	the	_	
28-26	5034-5038	role	_	
28-27	5039-5041	of	_	
28-28	5042-5045	the	_	
28-29	5046-5051	VMPFC	_	
28-30	5052-5054	in	_	
28-31	5055-5065	extinction	_	
28-32	5066-5074	learning	_	
28-33	5075-5081	itself	_	
28-34	5082-5084	in	_	
28-35	5085-5090	human	_	
28-36	5091-5100	addiction	_	
28-37	5100-5101	.	_	

#Text=Such an investigation has important implications for the potential utility of extinction-based therapies for addiction, and for the basic neuroscientific understanding of non-fear-based extinction more generally.
29-1	5102-5106	Such	_	
29-2	5107-5109	an	_	
29-3	5110-5123	investigation	_	
29-4	5124-5127	has	_	
29-5	5128-5137	important	_	
29-6	5138-5150	implications	_	
29-7	5151-5154	for	_	
29-8	5155-5158	the	_	
29-9	5159-5168	potential	_	
29-10	5169-5176	utility	_	
29-11	5177-5179	of	_	
29-12	5180-5196	extinction-based	_	
29-13	5197-5206	therapies	_	
29-14	5207-5210	for	_	
29-15	5211-5220	addiction	_	
29-16	5220-5221	,	_	
29-17	5222-5225	and	_	
29-18	5226-5229	for	_	
29-19	5230-5233	the	_	
29-20	5234-5239	basic	_	
29-21	5240-5255	neuroscientific	_	
29-22	5256-5269	understanding	_	
29-23	5270-5272	of	_	
29-24	5273-5287	non-fear-based	_	
29-25	5288-5298	extinction	_	
29-26	5299-5303	more	_	
29-27	5304-5313	generally	_	
29-28	5313-5314	.	_	

#Text=Modeled after classical fear-conditioning studies, here we examined the neural correlates of extinction learning for drug and pleasant cue associations in non-treatment seeking, chronic cocaine users and socio-demographically matched healthy non-drug users in a 2-day functional magnetic resonance imaging (fMRI) study.
30-1	5315-5322	Modeled	_	
30-2	5323-5328	after	_	
30-3	5329-5338	classical	_	
30-4	5339-5356	fear-conditioning	_	
30-5	5357-5364	studies	_	
30-6	5364-5365	,	_	
30-7	5366-5370	here	_	
30-8	5371-5373	we	_	
30-9	5374-5382	examined	_	
30-10	5383-5386	the	_	
30-11	5387-5393	neural	_	
30-12	5394-5404	correlates	_	
30-13	5405-5407	of	_	
30-14	5408-5418	extinction	_	
30-15	5419-5427	learning	_	
30-16	5428-5431	for	_	
30-17	5432-5436	drug	_	
30-18	5437-5440	and	_	
30-19	5441-5449	pleasant	_	
30-20	5450-5453	cue	_	
30-21	5454-5466	associations	_	
30-22	5467-5469	in	_	
30-23	5470-5483	non-treatment	_	
30-24	5484-5491	seeking	_	
30-25	5491-5492	,	_	
30-26	5493-5500	chronic	_	
30-27	5501-5508	cocaine	_	
30-28	5509-5514	users	_	
30-29	5515-5518	and	_	
30-30	5519-5540	socio-demographically	_	
30-31	5541-5548	matched	_	
30-32	5549-5556	healthy	_	
30-33	5557-5565	non-drug	_	
30-34	5566-5571	users	_	
30-35	5572-5574	in	_	
30-36	5575-5576	a	_	
30-37	5577-5578	2	_	
30-38	5578-5579	-	_	
30-39	5579-5582	day	_	
30-40	5583-5593	functional	_	
30-41	5594-5602	magnetic	_	
30-42	5603-5612	resonance	_	
30-43	5613-5620	imaging	_	
30-44	5621-5622	(	_	
30-45	5622-5626	fMRI	_	
30-46	5626-5627	)	_	
30-47	5628-5633	study	_	
30-48	5633-5634	.	_	

#Text=The study comprised an acquisition phase, where participants learned to associate an abstract cue with a drug-related (CSD+) or pleasant (CSP+) image, and two extinction phases (the latter for assessing the retention of extinction from day 1), where the abstract cues were repeatedly presented without the corresponding images.
31-1	5635-5638	The	_	
31-2	5639-5644	study	_	
31-3	5645-5654	comprised	_	
31-4	5655-5657	an	_	
31-5	5658-5669	acquisition	_	
31-6	5670-5675	phase	_	
31-7	5675-5676	,	_	
31-8	5677-5682	where	_	
31-9	5683-5695	participants	_	
31-10	5696-5703	learned	_	
31-11	5704-5706	to	_	
31-12	5707-5716	associate	_	
31-13	5717-5719	an	_	
31-14	5720-5728	abstract	_	
31-15	5729-5732	cue	_	
31-16	5733-5737	with	_	
31-17	5738-5739	a	_	
31-18	5740-5752	drug-related	_	
31-19	5753-5754	(	_	
31-20	5754-5757	CSD	_	
31-21	5757-5758	+	_	
31-22	5758-5759	)	_	
31-23	5760-5762	or	_	
31-24	5763-5771	pleasant	_	
31-25	5772-5773	(	_	
31-26	5773-5776	CSP	_	
31-27	5776-5777	+	_	
31-28	5777-5778	)	_	
31-29	5779-5784	image	_	
31-30	5784-5785	,	_	
31-31	5786-5789	and	_	
31-32	5790-5793	two	_	
31-33	5794-5804	extinction	_	
31-34	5805-5811	phases	_	
31-35	5812-5813	(	_	
31-36	5813-5816	the	_	
31-37	5817-5823	latter	_	
31-38	5824-5827	for	_	
31-39	5828-5837	assessing	_	
31-40	5838-5841	the	_	
31-41	5842-5851	retention	_	
31-42	5852-5854	of	_	
31-43	5855-5865	extinction	_	
31-44	5866-5870	from	_	
31-45	5871-5874	day	_	
31-46	5875-5876	1	_	
31-47	5876-5877	)	_	
31-48	5877-5878	,	_	
31-49	5879-5884	where	_	
31-50	5885-5888	the	_	
31-51	5889-5897	abstract	_	
31-52	5898-5902	cues	_	
31-53	5903-5907	were	_	
31-54	5908-5918	repeatedly	_	
31-55	5919-5928	presented	_	
31-56	5929-5936	without	_	
31-57	5937-5940	the	_	
31-58	5941-5954	corresponding	_	
31-59	5955-5961	images	_	
31-60	5961-5962	.	_	

#Text=Throughout, we collected SCR and blood-oxygen-level-dependent (BOLD) response, time-locked to the presentation of the abstract cue, as indices of the conditioned response.
32-1	5963-5973	Throughout	_	
32-2	5973-5974	,	_	
32-3	5975-5977	we	_	
32-4	5978-5987	collected	_	
32-5	5988-5991	SCR	_	
32-6	5992-5995	and	_	
32-7	5996-6024	blood-oxygen-level-dependent	_	
32-8	6025-6026	(	_	
32-9	6026-6030	BOLD	_	
32-10	6030-6031	)	_	
32-11	6032-6040	response	_	
32-12	6040-6041	,	_	
32-13	6042-6053	time-locked	_	
32-14	6054-6056	to	_	
32-15	6057-6060	the	_	
32-16	6061-6073	presentation	_	
32-17	6074-6076	of	_	
32-18	6077-6080	the	_	
32-19	6081-6089	abstract	_	
32-20	6090-6093	cue	_	
32-21	6093-6094	,	_	
32-22	6095-6097	as	_	
32-23	6098-6105	indices	_	
32-24	6106-6108	of	_	
32-25	6109-6112	the	_	
32-26	6113-6124	conditioned	_	
32-27	6125-6133	response	_	
32-28	6133-6134	.	_	

#Text=We hypothesized that the VMPFC and striatum would exhibit parametric changes across the learning phases as participants form new, affectively neutral, associations with the CSD+ and CSP+.
33-1	6135-6137	We	_	
33-2	6138-6150	hypothesized	_	
33-3	6151-6155	that	_	
33-4	6156-6159	the	_	
33-5	6160-6165	VMPFC	_	
33-6	6166-6169	and	_	
33-7	6170-6178	striatum	_	
33-8	6179-6184	would	_	
33-9	6185-6192	exhibit	_	
33-10	6193-6203	parametric	_	
33-11	6204-6211	changes	_	
33-12	6212-6218	across	_	
33-13	6219-6222	the	_	
33-14	6223-6231	learning	_	
33-15	6232-6238	phases	_	
33-16	6239-6241	as	_	
33-17	6242-6254	participants	_	
33-18	6255-6259	form	_	
33-19	6260-6263	new	_	
33-20	6263-6264	,	_	
33-21	6265-6276	affectively	_	
33-22	6277-6284	neutral	_	
33-23	6284-6285	,	_	
33-24	6286-6298	associations	_	
33-25	6299-6303	with	_	
33-26	6304-6307	the	_	
33-27	6308-6311	CSD	_	
33-28	6311-6312	+	_	
33-29	6313-6316	and	_	
33-30	6317-6320	CSP	_	
33-31	6320-6321	+	_	
33-32	6321-6322	.	_	

#Text=We expected cocaine users to show abnormalities in these regions for both cues.
34-1	6323-6325	We	_	
34-2	6326-6334	expected	_	
34-3	6335-6342	cocaine	_	
34-4	6343-6348	users	_	
34-5	6349-6351	to	_	
34-6	6352-6356	show	_	
34-7	6357-6370	abnormalities	_	
34-8	6371-6373	in	_	
34-9	6374-6379	these	_	
34-10	6380-6387	regions	_	
34-11	6388-6391	for	_	
34-12	6392-6396	both	_	
34-13	6397-6401	cues	_	
34-14	6401-6402	.	_	

#Text=Materials and Methods
#Text=Participants
#Text=Participants were native English speakers recruited from the community through advertisements and by word of mouth who provided written informed consent to participate in accordance with the local institutional review board.
35-1	6403-6412	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
35-2	6413-6416	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
35-3	6417-6424	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
35-4	6425-6437	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-5	6438-6450	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-6	6451-6455	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-7	6456-6462	native	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-8	6463-6470	English	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-9	6471-6479	speakers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-10	6480-6489	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-11	6490-6494	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-12	6495-6498	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-13	6499-6508	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-14	6509-6516	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-15	6517-6531	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-16	6532-6535	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-17	6536-6538	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-18	6539-6543	word	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-19	6544-6546	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-20	6547-6552	mouth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-21	6553-6556	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-22	6557-6565	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-23	6566-6573	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-24	6574-6582	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-25	6583-6590	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-26	6591-6593	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-27	6594-6605	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-28	6606-6608	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-29	6609-6619	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-30	6620-6624	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-31	6625-6628	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-32	6629-6634	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-33	6635-6648	institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-34	6649-6655	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-35	6656-6661	board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
35-36	6661-6662	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=Participants were chronic cocaine users and healthy individuals with no history of drug or psychiatric illness.
36-1	6663-6675	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
36-2	6676-6680	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
36-3	6681-6688	chronic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[6]	
36-4	6689-6696	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[6]	
36-5	6697-6702	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[6]	
36-6	6703-6706	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
36-7	6707-6714	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
36-8	6715-6726	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
36-9	6727-6731	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
36-10	6732-6734	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
36-11	6735-6742	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
36-12	6743-6745	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
36-13	6746-6750	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
36-14	6751-6753	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
36-15	6754-6765	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
36-16	6766-6773	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
36-17	6773-6774	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=To minimize the influence of factors other than those related to cocaine addiction, the groups were selected to match on multiple socio-demographic characteristics and cigarette smoking status (see Table 1).
37-1	6775-6777	To	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-2	6778-6786	minimize	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-3	6787-6790	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-4	6791-6800	influence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-5	6801-6803	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-6	6804-6811	factors	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-7	6812-6817	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-8	6818-6822	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-9	6823-6828	those	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-10	6829-6836	related	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-11	6837-6839	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-12	6840-6847	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-13	6848-6857	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-14	6857-6858	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-15	6859-6862	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-16	6863-6869	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-17	6870-6874	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-18	6875-6883	selected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-19	6884-6886	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-20	6887-6892	match	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-21	6893-6895	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-22	6896-6904	multiple	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-23	6905-6922	socio-demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-24	6923-6938	characteristics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-25	6939-6942	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-26	6943-6952	cigarette	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-27	6953-6960	smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-28	6961-6967	status	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-29	6968-6969	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-30	6969-6972	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-31	6973-6978	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-32	6979-6980	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-33	6980-6981	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
37-34	6981-6982	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=All participants were asked to complete study procedures on two separate days (psychophysiological measures and fMRI; see below).
38-1	6983-6986	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-2	6987-6999	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-3	7000-7004	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-4	7005-7010	asked	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-5	7011-7013	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-6	7014-7022	complete	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-7	7023-7028	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-8	7029-7039	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-9	7040-7042	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-10	7043-7046	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-11	7047-7055	separate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-12	7056-7060	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-13	7061-7062	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-14	7062-7081	psychophysiological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-15	7082-7090	measures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-16	7091-7094	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-17	7095-7099	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[8]	
38-18	7099-7100	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-19	7101-7104	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-20	7105-7110	below	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-21	7110-7111	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
38-22	7111-7112	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=The final sample consisted of 18 cocaine users and 15 healthy controls.
39-1	7113-7116	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-2	7117-7122	final	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-3	7123-7129	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-4	7130-7139	consisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-5	7140-7142	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-6	7143-7145	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-7	7146-7153	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
39-8	7154-7159	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]	
39-9	7160-7163	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-10	7164-7166	15	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
39-11	7167-7174	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
39-12	7175-7183	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
39-13	7183-7184	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=G*Power 3.1.9.2 was used to determine whether this sample was sufficiently powered.
40-1	7185-7186	G	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
40-2	7186-7187	*	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
40-3	7187-7192	Power	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
40-4	7193-7200	3.1.9.2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
40-5	7201-7204	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
40-6	7205-7209	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
40-7	7210-7212	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
40-8	7213-7222	determine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
40-9	7223-7230	whether	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
40-10	7231-7235	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
40-11	7236-7242	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
40-12	7243-7246	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
40-13	7247-7259	sufficiently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
40-14	7260-7267	powered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
40-15	7267-7268	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=Given a 2 (group) × 3 (learning phase) mixed design, 80% desired power, α error probability=0.05, and a within-between subject interaction of a large effect size (Cohen’s d, henceforth referred to simply as d, of 0.8), it was determined that N=12 participants would be needed.
41-1	7269-7274	Given	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-2	7275-7276	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-3	7277-7278	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-4	7279-7280	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-5	7280-7285	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-6	7285-7286	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-7	7287-7288	×	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-8	7289-7290	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-9	7291-7292	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-10	7292-7300	learning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-11	7301-7306	phase	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-12	7306-7307	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-13	7308-7313	mixed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-14	7314-7320	design	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-15	7320-7321	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-16	7322-7325	80%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-17	7326-7333	desired	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-18	7334-7339	power	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-19	7339-7340	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-20	7341-7342	α	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-21	7343-7348	error	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-22	7349-7360	probability	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-23	7360-7361	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-24	7361-7365	0.05	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-25	7365-7366	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-26	7367-7370	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-27	7371-7372	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-28	7373-7387	within-between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-29	7388-7395	subject	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-30	7396-7407	interaction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-31	7408-7410	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-32	7411-7412	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-33	7413-7418	large	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-34	7419-7425	effect	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-35	7426-7430	size	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-36	7431-7432	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-37	7432-7437	Cohen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-38	7437-7438	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-39	7438-7439	s	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-40	7440-7441	d	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-41	7441-7442	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-42	7443-7453	henceforth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-43	7454-7462	referred	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-44	7463-7465	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-45	7466-7472	simply	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-46	7473-7475	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-47	7476-7477	d	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-48	7477-7478	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-49	7479-7481	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-50	7482-7485	0.8	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-51	7485-7486	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-52	7486-7487	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-53	7488-7490	it	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-54	7491-7494	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-55	7495-7505	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-56	7506-7510	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-57	7511-7512	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-58	7512-7513	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-59	7513-7515	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-60	7516-7528	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-61	7529-7534	would	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-62	7535-7537	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-63	7538-7544	needed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
41-64	7544-7545	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=For a medium effect size (d=0.5), N=28 participants would be needed.
42-1	7546-7549	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-2	7550-7551	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-3	7552-7558	medium	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-4	7559-7565	effect	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-5	7566-7570	size	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-6	7571-7572	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-7	7572-7573	d	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-8	7573-7574	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-9	7574-7577	0.5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-10	7577-7578	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-11	7578-7579	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-12	7580-7581	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-13	7581-7582	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-14	7582-7584	28	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-15	7585-7597	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-16	7598-7603	would	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-17	7604-7606	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-18	7607-7613	needed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-19	7613-7614	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Thus, our sample of N=33 was sufficiently powered for effect sizes of d≥0.5.
43-1	7615-7619	Thus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-2	7619-7620	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-3	7621-7624	our	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-4	7625-7631	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-5	7632-7634	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-6	7635-7636	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-7	7636-7637	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-8	7637-7639	33	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-9	7640-7643	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-10	7644-7656	sufficiently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-11	7657-7664	powered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-12	7665-7668	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-13	7669-7675	effect	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-14	7676-7681	sizes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-15	7682-7684	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-16	7685-7686	d	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-17	7686-7687	≥	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-18	7687-7690	0.5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
43-19	7690-7691	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=All participants were in good health and not currently taking medication.
44-1	7692-7695	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
44-2	7696-7708	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
44-3	7709-7713	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
44-4	7714-7716	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
44-5	7717-7721	good	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
44-6	7722-7728	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
44-7	7729-7732	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
44-8	7733-7736	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
44-9	7737-7746	currently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
44-10	7747-7753	taking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
44-11	7754-7764	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
44-12	7764-7765	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Drug use and psychiatric histories were ascertained by a comprehensive clinical interview administered by trained research staff with extensive experience evaluating drug addicted populations, consisting of the Structured Clinical Interview for DSM-IV Axis I Disorders [research version ] and the Addiction Severity Index.
45-1	7766-7770	Drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-2	7771-7774	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-3	7775-7778	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-4	7779-7790	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-5	7791-7800	histories	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-6	7801-7805	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-7	7806-7817	ascertained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-8	7818-7820	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-9	7821-7822	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-10	7823-7836	comprehensive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-11	7837-7845	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-12	7846-7855	interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-13	7856-7868	administered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-14	7869-7871	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-15	7872-7879	trained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-16	7880-7888	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-17	7889-7894	staff	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-18	7895-7899	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-19	7900-7909	extensive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-20	7910-7920	experience	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-21	7921-7931	evaluating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-22	7932-7936	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-23	7937-7945	addicted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-24	7946-7957	populations	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-25	7957-7958	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-26	7959-7969	consisting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-27	7970-7972	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-28	7973-7976	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-29	7977-7987	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-30	7988-7996	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-31	7997-8006	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-32	8007-8010	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-33	8011-8017	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-34	8018-8022	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-35	8023-8024	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-36	8025-8034	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-37	8035-8036	[	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-38	8036-8044	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-39	8045-8052	version	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-40	8053-8054	]	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-41	8055-8058	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-42	8059-8062	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
45-43	8063-8072	Addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex[12]	
45-44	8073-8081	Severity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex[12]	
45-45	8082-8087	Index	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex[12]	
45-46	8087-8088	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Exclusion criteria for both groups were: (A) history of head trauma, neurological disease, or loss of consciousness >30 min; (B) abnormal vital signs; (C) history of major medical conditions; (D) history of major psychiatric disorders (other than substance use disorders in the cocaine group, and nicotine use disorder in both groups); (E) positive urine pregnancy test in females; (F) contraindications to MRI; and (G) except for cocaine in the cocaine user group, positive urine screens for psychoactive drugs or their metabolites.
46-1	8089-8098	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-2	8099-8107	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-3	8108-8111	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-4	8112-8116	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-5	8117-8123	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-6	8124-8128	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-7	8128-8129	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-8	8130-8131	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-9	8131-8132	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-10	8132-8133	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-11	8134-8141	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-12	8142-8144	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-13	8145-8149	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-14	8150-8156	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-15	8156-8157	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-16	8158-8170	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-17	8171-8178	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-18	8178-8179	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-19	8180-8182	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-20	8183-8187	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-21	8188-8190	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-22	8191-8204	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-23	8205-8206	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-24	8206-8208	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-25	8209-8212	min	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-26	8212-8213	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-27	8214-8215	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-28	8215-8216	B	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-29	8216-8217	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-30	8218-8226	abnormal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-31	8227-8232	vital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-32	8233-8238	signs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-33	8238-8239	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-34	8240-8241	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-35	8241-8242	C	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-36	8242-8243	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-37	8244-8251	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-38	8252-8254	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-39	8255-8260	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-40	8261-8268	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-41	8269-8279	conditions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-42	8279-8280	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-43	8281-8282	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-44	8282-8283	D	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-45	8283-8284	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-46	8285-8292	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-47	8293-8295	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-48	8296-8301	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-49	8302-8313	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-50	8314-8323	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-51	8324-8325	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-52	8325-8330	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-53	8331-8335	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-54	8336-8345	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-55	8346-8349	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-56	8350-8359	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-57	8360-8362	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-58	8363-8366	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-59	8367-8374	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-60	8375-8380	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-61	8380-8381	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-62	8382-8385	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-63	8386-8394	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-64	8395-8398	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-65	8399-8407	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-66	8408-8410	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-67	8411-8415	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-68	8416-8422	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-69	8422-8423	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-70	8423-8424	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-71	8425-8426	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-72	8426-8427	E	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-73	8427-8428	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-74	8429-8437	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-75	8438-8443	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-76	8444-8453	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-77	8454-8458	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-78	8459-8461	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-79	8462-8469	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-80	8469-8470	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-81	8471-8472	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-82	8472-8473	F	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-83	8473-8474	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-84	8475-8492	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-85	8493-8495	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-86	8496-8499	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-87	8499-8500	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-88	8501-8504	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-89	8505-8506	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-90	8506-8507	G	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-91	8507-8508	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-92	8509-8515	except	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-93	8516-8519	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-94	8520-8527	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-95	8528-8530	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-96	8531-8534	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-97	8535-8542	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-98	8543-8547	user	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-99	8548-8553	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-100	8553-8554	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-101	8555-8563	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-102	8564-8569	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-103	8570-8577	screens	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-104	8578-8581	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-105	8582-8594	psychoactive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-106	8595-8600	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-107	8601-8603	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-108	8604-8609	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-109	8610-8621	metabolites	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
46-110	8621-8622	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Cocaine users were non-treatment seeking individuals who reported an average lifetime history of 17 years of cocaine use, 2 days/week of cocaine use in the past 30 days, and some cocaine use within the past 4 months (see Table 1 for detailed drug use information).
47-1	8623-8630	Cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[13]	
47-2	8631-8636	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[13]	
47-3	8637-8641	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-4	8642-8655	non-treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-5	8656-8663	seeking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-6	8664-8675	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-7	8676-8679	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-8	8680-8688	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-9	8689-8691	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-10	8692-8699	average	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-11	8700-8708	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-12	8709-8716	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-13	8717-8719	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-14	8720-8722	17	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-15	8723-8728	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-16	8729-8731	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-17	8732-8739	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-18	8740-8743	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-19	8743-8744	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-20	8745-8746	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-21	8747-8751	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-22	8751-8752	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-23	8752-8756	week	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-24	8757-8759	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-25	8760-8767	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-26	8768-8771	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-27	8772-8774	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-28	8775-8778	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-29	8779-8783	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-30	8784-8786	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-31	8787-8791	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-32	8791-8792	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-33	8793-8796	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-34	8797-8801	some	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-35	8802-8809	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-36	8810-8813	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-37	8814-8820	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-38	8821-8824	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-39	8825-8829	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-40	8830-8831	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-41	8832-8838	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-42	8839-8840	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-43	8840-8843	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-44	8844-8849	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-45	8850-8851	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-46	8852-8855	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-47	8856-8864	detailed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-48	8865-8869	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-49	8870-8873	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-50	8874-8885	information	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-51	8885-8886	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
47-52	8886-8887	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Participants identified cocaine as their primary drug of choice, meeting criteria for cocaine dependence (n=17) or abuse (n=1) [in early full (n=2) or partial (n=1) remission].
48-1	8888-8900	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-2	8901-8911	identified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-3	8912-8919	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-4	8920-8922	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-5	8923-8928	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-6	8929-8936	primary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-7	8937-8941	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-8	8942-8944	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-9	8945-8951	choice	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-10	8951-8952	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-11	8953-8960	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-12	8961-8969	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-13	8970-8973	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-14	8974-8981	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[14]	
48-15	8982-8992	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[14]	
48-16	8993-8994	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-17	8994-8995	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-18	8995-8996	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-19	8996-8998	17	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-20	8998-8999	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-21	9000-9002	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-22	9003-9008	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-23	9009-9010	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-24	9010-9011	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-25	9011-9012	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-26	9012-9013	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-27	9013-9014	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-28	9015-9016	[	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-29	9016-9018	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-30	9019-9024	early	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-31	9025-9029	full	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-32	9030-9031	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-33	9031-9032	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-34	9032-9033	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-35	9033-9034	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-36	9034-9035	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-37	9036-9038	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-38	9039-9046	partial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-39	9047-9048	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-40	9048-9049	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-41	9049-9050	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-42	9050-9051	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-43	9051-9052	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-44	9053-9062	remission	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-45	9062-9063	]	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
48-46	9063-9064	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Current comorbid disorders included alcohol dependence (n=2) and marijuana abuse (n=2); one participant also met criteria for a current depressive episode.
49-1	9065-9072	Current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-2	9073-9081	comorbid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-3	9082-9091	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-4	9092-9100	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-5	9101-9108	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-6	9109-9119	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-7	9120-9121	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-8	9121-9122	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-9	9122-9123	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-10	9123-9124	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-11	9124-9125	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-12	9126-9129	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-13	9130-9139	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-14	9140-9145	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-15	9146-9147	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-16	9147-9148	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-17	9148-9149	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-18	9149-9150	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-19	9150-9151	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-20	9151-9152	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-21	9153-9156	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-22	9157-9168	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-23	9169-9173	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-24	9174-9177	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-25	9178-9186	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-26	9187-9190	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-27	9191-9192	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-28	9193-9200	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-29	9201-9211	depressive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-30	9212-9219	episode	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-31	9219-9220	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Thirteen cocaine users and 6 controls were cigarette smokers.
50-1	9221-9229	Thirteen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-2	9230-9237	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[15]	
50-3	9238-9243	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[15]	
50-4	9244-9247	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-5	9248-9249	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-6	9250-9258	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[16]	
50-7	9259-9263	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-8	9264-9273	cigarette	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-9	9274-9281	smokers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
50-10	9281-9282	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Six participants tested positive for cocaine on day 1 (indicating use ≤72 h) and 4 tested positive for cocaine on day 2.
51-1	9283-9286	Six	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-2	9287-9299	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-3	9300-9306	tested	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-4	9307-9315	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-5	9316-9319	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-6	9320-9327	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[17]	
51-7	9328-9330	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-8	9331-9334	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-9	9335-9336	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-10	9337-9338	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-11	9338-9348	indicating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-12	9349-9352	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-13	9353-9354	≤	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-14	9354-9356	72	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-15	9357-9358	h	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-16	9358-9359	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-17	9360-9363	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-18	9364-9365	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-19	9366-9372	tested	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-20	9373-9381	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-21	9382-9385	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-22	9386-9393	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[18]	
51-23	9394-9396	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-24	9397-9400	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-25	9401-9402	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
51-26	9402-9403	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Controls tested negative for all drugs on both study days.
52-1	9404-9412	Controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[19]	
52-2	9413-9419	tested	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
52-3	9420-9428	negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
52-4	9429-9432	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
52-5	9433-9436	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
52-6	9437-9442	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
52-7	9443-9445	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
52-8	9446-9450	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
52-9	9451-9456	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
52-10	9457-9461	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
52-11	9461-9462	.	_	

#Text=Apart from number of days since last use (Z=1.87, P=0.06), cocaine urine positive and cocaine urine negative participants (based on day 1 status) did not differ in their clinical profile (i.e., they did not differ in any of the drug use variables listed in Table 1; P>0.086).
53-1	9463-9468	Apart	_	
53-2	9469-9473	from	_	
53-3	9474-9480	number	_	
53-4	9481-9483	of	_	
53-5	9484-9488	days	_	
53-6	9489-9494	since	_	
53-7	9495-9499	last	_	
53-8	9500-9503	use	_	
53-9	9504-9505	(	_	
53-10	9505-9506	Z	_	
53-11	9506-9507	=	_	
53-12	9507-9511	1.87	_	
53-13	9511-9512	,	_	
53-14	9513-9514	P	_	
53-15	9514-9515	=	_	
53-16	9515-9519	0.06	_	
53-17	9519-9520	)	_	
53-18	9520-9521	,	_	
53-19	9522-9529	cocaine	_	
53-20	9530-9535	urine	_	
53-21	9536-9544	positive	_	
53-22	9545-9548	and	_	
53-23	9549-9556	cocaine	_	
53-24	9557-9562	urine	_	
53-25	9563-9571	negative	_	
53-26	9572-9584	participants	_	
53-27	9585-9586	(	_	
53-28	9586-9591	based	_	
53-29	9592-9594	on	_	
53-30	9595-9598	day	_	
53-31	9599-9600	1	_	
53-32	9601-9607	status	_	
53-33	9607-9608	)	_	
53-34	9609-9612	did	_	
53-35	9613-9616	not	_	
53-36	9617-9623	differ	_	
53-37	9624-9626	in	_	
53-38	9627-9632	their	_	
53-39	9633-9641	clinical	_	
53-40	9642-9649	profile	_	
53-41	9650-9651	(	_	
53-42	9651-9654	i.e	_	
53-43	9654-9655	.	_	
53-44	9655-9656	,	_	
53-45	9657-9661	they	_	
53-46	9662-9665	did	_	
53-47	9666-9669	not	_	
53-48	9670-9676	differ	_	
53-49	9677-9679	in	_	
53-50	9680-9683	any	_	
53-51	9684-9686	of	_	
53-52	9687-9690	the	_	
53-53	9691-9695	drug	_	
53-54	9696-9699	use	_	
53-55	9700-9709	variables	_	
53-56	9710-9716	listed	_	
53-57	9717-9719	in	_	
53-58	9720-9725	Table	_	
53-59	9726-9727	1	_	
53-60	9727-9728	;	_	
53-61	9729-9730	P	_	
53-62	9730-9731	>	_	
53-63	9731-9736	0.086	_	
53-64	9736-9737	)	_	
53-65	9737-9738	.	_	

#Text=Nevertheless, because the passage of time from last use (day 1 to day 2) was associated with a reduction in craving and withdrawal (Table 1) and because there is some clinical and preclinical evidence to suggest that recent cocaine exposure impacts learning, we tested if cocaine urine status modified any of the observed diagnostic group effects.
54-1	9739-9751	Nevertheless	_	
54-2	9751-9752	,	_	
54-3	9753-9760	because	_	
54-4	9761-9764	the	_	
54-5	9765-9772	passage	_	
54-6	9773-9775	of	_	
54-7	9776-9780	time	_	
54-8	9781-9785	from	_	
54-9	9786-9790	last	_	
54-10	9791-9794	use	_	
54-11	9795-9796	(	_	
54-12	9796-9799	day	_	
54-13	9800-9801	1	_	
54-14	9802-9804	to	_	
54-15	9805-9808	day	_	
54-16	9809-9810	2	_	
54-17	9810-9811	)	_	
54-18	9812-9815	was	_	
54-19	9816-9826	associated	_	
54-20	9827-9831	with	_	
54-21	9832-9833	a	_	
54-22	9834-9843	reduction	_	
54-23	9844-9846	in	_	
54-24	9847-9854	craving	_	
54-25	9855-9858	and	_	
54-26	9859-9869	withdrawal	_	
54-27	9870-9871	(	_	
54-28	9871-9876	Table	_	
54-29	9877-9878	1	_	
54-30	9878-9879	)	_	
54-31	9880-9883	and	_	
54-32	9884-9891	because	_	
54-33	9892-9897	there	_	
54-34	9898-9900	is	_	
54-35	9901-9905	some	_	
54-36	9906-9914	clinical	_	
54-37	9915-9918	and	_	
54-38	9919-9930	preclinical	_	
54-39	9931-9939	evidence	_	
54-40	9940-9942	to	_	
54-41	9943-9950	suggest	_	
54-42	9951-9955	that	_	
54-43	9956-9962	recent	_	
54-44	9963-9970	cocaine	_	
54-45	9971-9979	exposure	_	
54-46	9980-9987	impacts	_	
54-47	9988-9996	learning	_	
54-48	9996-9997	,	_	
54-49	9998-10000	we	_	
54-50	10001-10007	tested	_	
54-51	10008-10010	if	_	
54-52	10011-10018	cocaine	_	
54-53	10019-10024	urine	_	
54-54	10025-10031	status	_	
54-55	10032-10040	modified	_	
54-56	10041-10044	any	_	
54-57	10045-10047	of	_	
54-58	10048-10051	the	_	
54-59	10052-10060	observed	_	
54-60	10061-10071	diagnostic	_	
54-61	10072-10077	group	_	
54-62	10078-10085	effects	_	
54-63	10085-10086	.	_	

#Text=Study Procedures & fMRI Task
#Text=All participants completed three fMRI sessions conducted over two consecutive days (99 total sessions; Figure 1).
55-1	10087-10092	Study	_	
55-2	10093-10103	Procedures	_	
55-3	10104-10105	&	_	
55-4	10106-10110	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
55-5	10111-10115	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
55-6	10116-10119	All	_	
55-7	10120-10132	participants	_	
55-8	10133-10142	completed	_	
55-9	10143-10148	three	_	
55-10	10149-10153	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
55-11	10154-10162	sessions	_	
55-12	10163-10172	conducted	_	
55-13	10173-10177	over	_	
55-14	10178-10181	two	_	
55-15	10182-10193	consecutive	_	
55-16	10194-10198	days	_	
55-17	10199-10200	(	_	
55-18	10200-10202	99	_	
55-19	10203-10208	total	_	
55-20	10209-10217	sessions	_	
55-21	10217-10218	;	_	
55-22	10219-10225	Figure	_	
55-23	10226-10227	1	_	
55-24	10227-10228	)	_	
55-25	10228-10229	.	_	

#Text=To ensure comparable experiences between sessions and across the two study days, and to control the time in-between, participants were overnighted in the laboratory.
56-1	10230-10232	To	_	
56-2	10233-10239	ensure	_	
56-3	10240-10250	comparable	_	
56-4	10251-10262	experiences	_	
56-5	10263-10270	between	_	
56-6	10271-10279	sessions	_	
56-7	10280-10283	and	_	
56-8	10284-10290	across	_	
56-9	10291-10294	the	_	
56-10	10295-10298	two	_	
56-11	10299-10304	study	_	
56-12	10305-10309	days	_	
56-13	10309-10310	,	_	
56-14	10311-10314	and	_	
56-15	10315-10317	to	_	
56-16	10318-10325	control	_	
56-17	10326-10329	the	_	
56-18	10330-10334	time	_	
56-19	10335-10345	in-between	_	
56-20	10345-10346	,	_	
56-21	10347-10359	participants	_	
56-22	10360-10364	were	_	
56-23	10365-10376	overnighted	_	
56-24	10377-10379	in	_	
56-25	10380-10383	the	_	
56-26	10384-10394	laboratory	_	
56-27	10394-10395	.	_	

#Text=On day 1, after a period of acclimation to the scanner environment, participants first learned to associate a colored square, the CS, with different types of “USs”.
57-1	10396-10398	On	_	
57-2	10399-10402	day	_	
57-3	10403-10404	1	_	
57-4	10404-10405	,	_	
57-5	10406-10411	after	_	
57-6	10412-10413	a	_	
57-7	10414-10420	period	_	
57-8	10421-10423	of	_	
57-9	10424-10435	acclimation	_	
57-10	10436-10438	to	_	
57-11	10439-10442	the	_	
57-12	10443-10450	scanner	_	
57-13	10451-10462	environment	_	
57-14	10462-10463	,	_	
57-15	10464-10476	participants	_	
57-16	10477-10482	first	_	
57-17	10483-10490	learned	_	
57-18	10491-10493	to	_	
57-19	10494-10503	associate	_	
57-20	10504-10505	a	_	
57-21	10506-10513	colored	_	
57-22	10514-10520	square	_	
57-23	10520-10521	,	_	
57-24	10522-10525	the	_	
57-25	10526-10528	CS	_	
57-26	10528-10529	,	_	
57-27	10530-10534	with	_	
57-28	10535-10544	different	_	
57-29	10545-10550	types	_	
57-30	10551-10553	of	_	
57-31	10554-10555	“	_	
57-32	10555-10558	USs	_	
57-33	10558-10559	”	_	
57-34	10559-10560	.	_	

#Text=This created three cue types: CSD+ (CS paired with a drug-related image of a person smoking crack), CSP+ (CS paired with a pleasant image of a smiling baby), and CS− (CS paired with a neutral image of an unadorned wooden basket).
58-1	10561-10565	This	_	
58-2	10566-10573	created	_	
58-3	10574-10579	three	_	
58-4	10580-10583	cue	_	
58-5	10584-10589	types	_	
58-6	10589-10590	:	_	
58-7	10591-10594	CSD	_	
58-8	10594-10595	+	_	
58-9	10596-10597	(	_	
58-10	10597-10599	CS	_	
58-11	10600-10606	paired	_	
58-12	10607-10611	with	_	
58-13	10612-10613	a	_	
58-14	10614-10626	drug-related	_	
58-15	10627-10632	image	_	
58-16	10633-10635	of	_	
58-17	10636-10637	a	_	
58-18	10638-10644	person	_	
58-19	10645-10652	smoking	_	
58-20	10653-10658	crack	_	
58-21	10658-10659	)	_	
58-22	10659-10660	,	_	
58-23	10661-10664	CSP	_	
58-24	10664-10665	+	_	
58-25	10666-10667	(	_	
58-26	10667-10669	CS	_	
58-27	10670-10676	paired	_	
58-28	10677-10681	with	_	
58-29	10682-10683	a	_	
58-30	10684-10692	pleasant	_	
58-31	10693-10698	image	_	
58-32	10699-10701	of	_	
58-33	10702-10703	a	_	
58-34	10704-10711	smiling	_	
58-35	10712-10716	baby	_	
58-36	10716-10717	)	_	
58-37	10717-10718	,	_	
58-38	10719-10722	and	_	
58-39	10723-10725	CS	_	
58-40	10725-10726	−	_	
58-41	10727-10728	(	_	
58-42	10728-10730	CS	_	
58-43	10731-10737	paired	_	
58-44	10738-10742	with	_	
58-45	10743-10744	a	_	
58-46	10745-10752	neutral	_	
58-47	10753-10758	image	_	
58-48	10759-10761	of	_	
58-49	10762-10764	an	_	
58-50	10765-10774	unadorned	_	
58-51	10775-10781	wooden	_	
58-52	10782-10788	basket	_	
58-53	10788-10789	)	_	
58-54	10789-10790	.	_	

#Text=The acquisition phase consisted of 13 paired trials in which each CS presentation co-terminated with presentation of the corresponding US and 7 unpaired trials in which each CS was presented without the US, for a total of 20 trials per cue type (60 total).
59-1	10791-10794	The	_	
59-2	10795-10806	acquisition	_	
59-3	10807-10812	phase	_	
59-4	10813-10822	consisted	_	
59-5	10823-10825	of	_	
59-6	10826-10828	13	_	
59-7	10829-10835	paired	_	
59-8	10836-10842	trials	_	
59-9	10843-10845	in	_	
59-10	10846-10851	which	_	
59-11	10852-10856	each	_	
59-12	10857-10859	CS	_	
59-13	10860-10872	presentation	_	
59-14	10873-10886	co-terminated	_	
59-15	10887-10891	with	_	
59-16	10892-10904	presentation	_	
59-17	10905-10907	of	_	
59-18	10908-10911	the	_	
59-19	10912-10925	corresponding	_	
59-20	10926-10928	US	_	
59-21	10929-10932	and	_	
59-22	10933-10934	7	_	
59-23	10935-10943	unpaired	_	
59-24	10944-10950	trials	_	
59-25	10951-10953	in	_	
59-26	10954-10959	which	_	
59-27	10960-10964	each	_	
59-28	10965-10967	CS	_	
59-29	10968-10971	was	_	
59-30	10972-10981	presented	_	
59-31	10982-10989	without	_	
59-32	10990-10993	the	_	
59-33	10994-10996	US	_	
59-34	10996-10997	,	_	
59-35	10998-11001	for	_	
59-36	11002-11003	a	_	
59-37	11004-11009	total	_	
59-38	11010-11012	of	_	
59-39	11013-11015	20	_	
59-40	11016-11022	trials	_	
59-41	11023-11026	per	_	
59-42	11027-11030	cue	_	
59-43	11031-11035	type	_	
59-44	11036-11037	(	_	
59-45	11037-11039	60	_	
59-46	11040-11045	total	_	
59-47	11045-11046	)	_	
59-48	11046-11047	.	_	

#Text=Participants were instructed to “try and figure out which color predicted which image.”
60-1	11048-11060	Participants	_	
60-2	11061-11065	were	_	
60-3	11066-11076	instructed	_	
60-4	11077-11079	to	_	
60-5	11080-11081	“	_	
60-6	11081-11084	try	_	
60-7	11085-11088	and	_	
60-8	11089-11095	figure	_	
60-9	11096-11099	out	_	
60-10	11100-11105	which	_	
60-11	11106-11111	color	_	
60-12	11112-11121	predicted	_	
60-13	11122-11127	which	_	
60-14	11128-11133	image	_	
60-15	11133-11134	.	_	
60-16	11134-11135	”	_	

#Text=Day 1 extinction immediately followed, and began with 2 paired trials followed by 20 unpaired trials for each cue type (66 total).
61-1	11136-11139	Day	_	
61-2	11140-11141	1	_	
61-3	11142-11152	extinction	_	
61-4	11153-11164	immediately	_	
61-5	11165-11173	followed	_	
61-6	11173-11174	,	_	
61-7	11175-11178	and	_	
61-8	11179-11184	began	_	
61-9	11185-11189	with	_	
61-10	11190-11191	2	_	
61-11	11192-11198	paired	_	
61-12	11199-11205	trials	_	
61-13	11206-11214	followed	_	
61-14	11215-11217	by	_	
61-15	11218-11220	20	_	
61-16	11221-11229	unpaired	_	
61-17	11230-11236	trials	_	
61-18	11237-11240	for	_	
61-19	11241-11245	each	_	
61-20	11246-11249	cue	_	
61-21	11250-11254	type	_	
61-22	11255-11256	(	_	
61-23	11256-11258	66	_	
61-24	11259-11264	total	_	
61-25	11264-11265	)	_	
61-26	11265-11266	.	_	

#Text=Participants completed another, identical extinction session ~24 h later but without the paired reminder trials.
62-1	11267-11279	Participants	_	
62-2	11280-11289	completed	_	
62-3	11290-11297	another	_	
62-4	11297-11298	,	_	
62-5	11299-11308	identical	_	
62-6	11309-11319	extinction	_	
62-7	11320-11327	session	_	
62-8	11328-11329	~	_	
62-9	11329-11331	24	_	
62-10	11332-11333	h	_	
62-11	11334-11339	later	_	
62-12	11340-11343	but	_	
62-13	11344-11351	without	_	
62-14	11352-11355	the	_	
62-15	11356-11362	paired	_	
62-16	11363-11371	reminder	_	
62-17	11372-11378	trials	_	
62-18	11378-11379	.	_	

#Text=Trial order was pseudo-randomized in all sessions and CS color assignment was counterbalanced across participants.
63-1	11380-11385	Trial	_	
63-2	11386-11391	order	_	
63-3	11392-11395	was	_	
63-4	11396-11413	pseudo-randomized	_	
63-5	11414-11416	in	_	
63-6	11417-11420	all	_	
63-7	11421-11429	sessions	_	
63-8	11430-11433	and	_	
63-9	11434-11436	CS	_	
63-10	11437-11442	color	_	
63-11	11443-11453	assignment	_	
63-12	11454-11457	was	_	
63-13	11458-11473	counterbalanced	_	
63-14	11474-11480	across	_	
63-15	11481-11493	participants	_	
63-16	11493-11494	.	_	

#Text=SCR and fMRI data were acquired throughout.
64-1	11495-11498	SCR	_	
64-2	11499-11502	and	_	
64-3	11503-11507	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
64-4	11508-11512	data	_	
64-5	11513-11517	were	_	
64-6	11518-11526	acquired	_	
64-7	11527-11537	throughout	_	
64-8	11537-11538	.	_	

#Text=Participants earned $25/session (max $75).
65-1	11539-11551	Participants	_	
65-2	11552-11558	earned	_	
65-3	11559-11562	$25	_	
65-4	11562-11563	/	_	
65-5	11563-11570	session	_	
65-6	11571-11572	(	_	
65-7	11572-11575	max	_	
65-8	11576-11579	$75	_	
65-9	11579-11580	)	_	
65-10	11580-11581	.	_	

#Text=Participants also completed two-alternative forced choice tasks and provided subjective ratings for the task stimuli (see Supporting Information).
66-1	11582-11594	Participants	_	
66-2	11595-11599	also	_	
66-3	11600-11609	completed	_	
66-4	11610-11625	two-alternative	_	
66-5	11626-11632	forced	_	
66-6	11633-11639	choice	_	
66-7	11640-11645	tasks	_	
66-8	11646-11649	and	_	
66-9	11650-11658	provided	_	
66-10	11659-11669	subjective	_	
66-11	11670-11677	ratings	_	
66-12	11678-11681	for	_	
66-13	11682-11685	the	_	
66-14	11686-11690	task	_	
66-15	11691-11698	stimuli	_	
66-16	11699-11700	(	_	
66-17	11700-11703	see	_	
66-18	11704-11714	Supporting	_	
66-19	11715-11726	Information	_	
66-20	11726-11727	)	_	
66-21	11727-11728	.	_	

#Text=No SCR or fMRI data were collected during these tasks.
67-1	11729-11731	No	_	
67-2	11732-11735	SCR	_	
67-3	11736-11738	or	_	
67-4	11739-11743	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
67-5	11744-11748	data	_	
67-6	11749-11753	were	_	
67-7	11754-11763	collected	_	
67-8	11764-11770	during	_	
67-9	11771-11776	these	_	
67-10	11777-11782	tasks	_	
67-11	11782-11783	.	_	

#Text=These data confirmed that, as expected based on our prior work in independent samples of cocaine addicted and control subjects, participants found the drug-related image as least pleasant (and chose to view it least often) and the affectively pleasant image as most pleasant (and chose to view it most often).
68-1	11784-11789	These	_	
68-2	11790-11794	data	_	
68-3	11795-11804	confirmed	_	
68-4	11805-11809	that	_	
68-5	11809-11810	,	_	
68-6	11811-11813	as	_	
68-7	11814-11822	expected	_	
68-8	11823-11828	based	_	
68-9	11829-11831	on	_	
68-10	11832-11835	our	_	
68-11	11836-11841	prior	_	
68-12	11842-11846	work	_	
68-13	11847-11849	in	_	
68-14	11850-11861	independent	_	
68-15	11862-11869	samples	_	
68-16	11870-11872	of	_	
68-17	11873-11880	cocaine	_	
68-18	11881-11889	addicted	_	
68-19	11890-11893	and	_	
68-20	11894-11901	control	_	
68-21	11902-11910	subjects	_	
68-22	11910-11911	,	_	
68-23	11912-11924	participants	_	
68-24	11925-11930	found	_	
68-25	11931-11934	the	_	
68-26	11935-11947	drug-related	_	
68-27	11948-11953	image	_	
68-28	11954-11956	as	_	
68-29	11957-11962	least	_	
68-30	11963-11971	pleasant	_	
68-31	11972-11973	(	_	
68-32	11973-11976	and	_	
68-33	11977-11982	chose	_	
68-34	11983-11985	to	_	
68-35	11986-11990	view	_	
68-36	11991-11993	it	_	
68-37	11994-11999	least	_	
68-38	12000-12005	often	_	
68-39	12005-12006	)	_	
68-40	12007-12010	and	_	
68-41	12011-12014	the	_	
68-42	12015-12026	affectively	_	
68-43	12027-12035	pleasant	_	
68-44	12036-12041	image	_	
68-45	12042-12044	as	_	
68-46	12045-12049	most	_	
68-47	12050-12058	pleasant	_	
68-48	12059-12060	(	_	
68-49	12060-12063	and	_	
68-50	12064-12069	chose	_	
68-51	12070-12072	to	_	
68-52	12073-12077	view	_	
68-53	12078-12080	it	_	
68-54	12081-12085	most	_	
68-55	12086-12091	often	_	
68-56	12091-12092	)	_	
68-57	12092-12093	.	_	

#Text=Controls additionally rated the drug-related image as more unpleasant (and chose to view it less often) than cocaine users (Figure S1A–B).
69-1	12094-12102	Controls	_	
69-2	12103-12115	additionally	_	
69-3	12116-12121	rated	_	
69-4	12122-12125	the	_	
69-5	12126-12138	drug-related	_	
69-6	12139-12144	image	_	
69-7	12145-12147	as	_	
69-8	12148-12152	more	_	
69-9	12153-12163	unpleasant	_	
69-10	12164-12165	(	_	
69-11	12165-12168	and	_	
69-12	12169-12174	chose	_	
69-13	12175-12177	to	_	
69-14	12178-12182	view	_	
69-15	12183-12185	it	_	
69-16	12186-12190	less	_	
69-17	12191-12196	often	_	
69-18	12196-12197	)	_	
69-19	12198-12202	than	_	
69-20	12203-12210	cocaine	_	
69-21	12211-12216	users	_	
69-22	12217-12218	(	_	
69-23	12218-12224	Figure	_	
69-24	12225-12230	S1A–B	_	
69-25	12230-12231	)	_	
69-26	12231-12232	.	_	

#Text=SCR Acquisition & Analysis
#Text=Skin conductance was acquired with shielded Ag-AgCl electrodes (AD Instruments, Inc.) attached to the second and big toes of the left foot.
70-1	12233-12236	SCR	_	
70-2	12237-12248	Acquisition	_	
70-3	12249-12250	&	_	
70-4	12251-12259	Analysis	_	
70-5	12260-12264	Skin	_	
70-6	12265-12276	conductance	_	
70-7	12277-12280	was	_	
70-8	12281-12289	acquired	_	
70-9	12290-12294	with	_	
70-10	12295-12303	shielded	_	
70-11	12304-12311	Ag-AgCl	_	
70-12	12312-12322	electrodes	_	
70-13	12323-12324	(	_	
70-14	12324-12326	AD	_	
70-15	12327-12338	Instruments	_	
70-16	12338-12339	,	_	
70-17	12340-12343	Inc	_	
70-18	12343-12344	.	_	
70-19	12344-12345	)	_	
70-20	12346-12354	attached	_	
70-21	12355-12357	to	_	
70-22	12358-12361	the	_	
70-23	12362-12368	second	_	
70-24	12369-12372	and	_	
70-25	12373-12376	big	_	
70-26	12377-12381	toes	_	
70-27	12382-12384	of	_	
70-28	12385-12388	the	_	
70-29	12389-12393	left	_	
70-30	12394-12398	foot	_	
70-31	12398-12399	.	_	

#Text=The electrode cables were grounded through an RF filter panel.
71-1	12400-12403	The	_	
71-2	12404-12413	electrode	_	
71-3	12414-12420	cables	_	
71-4	12421-12425	were	_	
71-5	12426-12434	grounded	_	
71-6	12435-12442	through	_	
71-7	12443-12445	an	_	
71-8	12446-12448	RF	_	
71-9	12449-12455	filter	_	
71-10	12456-12461	panel	_	
71-11	12461-12462	.	_	

#Text=Data were continuously recorded at 200 samples/s.
72-1	12463-12467	Data	_	
72-2	12468-12472	were	_	
72-3	12473-12485	continuously	_	
72-4	12486-12494	recorded	_	
72-5	12495-12497	at	_	
72-6	12498-12501	200	_	
72-7	12502-12509	samples	_	
72-8	12509-12510	/	_	
72-9	12510-12511	s	_	
72-10	12511-12512	.	_	

#Text=Offline data analysis was performed in Matlab.
73-1	12513-12520	Offline	_	
73-2	12521-12525	data	_	
73-3	12526-12534	analysis	_	
73-4	12535-12538	was	_	
73-5	12539-12548	performed	_	
73-6	12549-12551	in	_	
73-7	12552-12558	Matlab	_	
73-8	12558-12559	.	_	

#Text=The continuous data were low-pass filtered (1 Hz) and then divided into epochs.
74-1	12560-12563	The	_	
74-2	12564-12574	continuous	_	
74-3	12575-12579	data	_	
74-4	12580-12584	were	_	
74-5	12585-12593	low-pass	_	
74-6	12594-12602	filtered	_	
74-7	12603-12604	(	_	
74-8	12604-12605	1	_	
74-9	12606-12608	Hz	_	
74-10	12608-12609	)	_	
74-11	12610-12613	and	_	
74-12	12614-12618	then	_	
74-13	12619-12626	divided	_	
74-14	12627-12631	into	_	
74-15	12632-12638	epochs	_	
74-16	12638-12639	.	_	

#Text=As in previous studies, the SCR amplitude on each trial was computed as the peak amplitude in the 0.5 to 4.5 s time window following CS onset minus the average amplitude in the 0.5 s prior to CS onset.
75-1	12640-12642	As	_	
75-2	12643-12645	in	_	
75-3	12646-12654	previous	_	
75-4	12655-12662	studies	_	
75-5	12662-12663	,	_	
75-6	12664-12667	the	_	
75-7	12668-12671	SCR	_	
75-8	12672-12681	amplitude	_	
75-9	12682-12684	on	_	
75-10	12685-12689	each	_	
75-11	12690-12695	trial	_	
75-12	12696-12699	was	_	
75-13	12700-12708	computed	_	
75-14	12709-12711	as	_	
75-15	12712-12715	the	_	
75-16	12716-12720	peak	_	
75-17	12721-12730	amplitude	_	
75-18	12731-12733	in	_	
75-19	12734-12737	the	_	
75-20	12738-12741	0.5	_	
75-21	12742-12744	to	_	
75-22	12745-12748	4.5	_	
75-23	12749-12750	s	_	
75-24	12751-12755	time	_	
75-25	12756-12762	window	_	
75-26	12763-12772	following	_	
75-27	12773-12775	CS	_	
75-28	12776-12781	onset	_	
75-29	12782-12787	minus	_	
75-30	12788-12791	the	_	
75-31	12792-12799	average	_	
75-32	12800-12809	amplitude	_	
75-33	12810-12812	in	_	
75-34	12813-12816	the	_	
75-35	12817-12820	0.5	_	
75-36	12821-12822	s	_	
75-37	12823-12828	prior	_	
75-38	12829-12831	to	_	
75-39	12832-12834	CS	_	
75-40	12835-12840	onset	_	
75-41	12840-12841	.	_	

#Text=Thus, SCR to the CSD+, CSP+, and CS− reflected changes in skin conductance level beyond changes in this measure produced by the preceding trial or task phase.
76-1	12842-12846	Thus	_	
76-2	12846-12847	,	_	
76-3	12848-12851	SCR	_	
76-4	12852-12854	to	_	
76-5	12855-12858	the	_	
76-6	12859-12862	CSD	_	
76-7	12862-12863	+	_	
76-8	12863-12864	,	_	
76-9	12865-12868	CSP	_	
76-10	12868-12869	+	_	
76-11	12869-12870	,	_	
76-12	12871-12874	and	_	
76-13	12875-12877	CS	_	
76-14	12877-12878	−	_	
76-15	12879-12888	reflected	_	
76-16	12889-12896	changes	_	
76-17	12897-12899	in	_	
76-18	12900-12904	skin	_	
76-19	12905-12916	conductance	_	
76-20	12917-12922	level	_	
76-21	12923-12929	beyond	_	
76-22	12930-12937	changes	_	
76-23	12938-12940	in	_	
76-24	12941-12945	this	_	
76-25	12946-12953	measure	_	
76-26	12954-12962	produced	_	
76-27	12963-12965	by	_	
76-28	12966-12969	the	_	
76-29	12970-12979	preceding	_	
76-30	12980-12985	trial	_	
76-31	12986-12988	or	_	
76-32	12989-12993	task	_	
76-33	12994-12999	phase	_	
76-34	12999-13000	.	_	

#Text=After square-root transformation, the data were analyzed in a 2 (cue type: drug, pleasant) × 3 (learning phase: acquisition, day 1 extinction, day 2 extinction) × 2 (group: cocaine users, controls) mixed analysis of variance (ANOVA) on the differential SCR values (CSD+ versus CS− and CSP+ versus CS−).
77-1	13001-13006	After	_	
77-2	13007-13018	square-root	_	
77-3	13019-13033	transformation	_	
77-4	13033-13034	,	_	
77-5	13035-13038	the	_	
77-6	13039-13043	data	_	
77-7	13044-13048	were	_	
77-8	13049-13057	analyzed	_	
77-9	13058-13060	in	_	
77-10	13061-13062	a	_	
77-11	13063-13064	2	_	
77-12	13065-13066	(	_	
77-13	13066-13069	cue	_	
77-14	13070-13074	type	_	
77-15	13074-13075	:	_	
77-16	13076-13080	drug	_	
77-17	13080-13081	,	_	
77-18	13082-13090	pleasant	_	
77-19	13090-13091	)	_	
77-20	13092-13093	×	_	
77-21	13094-13095	3	_	
77-22	13096-13097	(	_	
77-23	13097-13105	learning	_	
77-24	13106-13111	phase	_	
77-25	13111-13112	:	_	
77-26	13113-13124	acquisition	_	
77-27	13124-13125	,	_	
77-28	13126-13129	day	_	
77-29	13130-13131	1	_	
77-30	13132-13142	extinction	_	
77-31	13142-13143	,	_	
77-32	13144-13147	day	_	
77-33	13148-13149	2	_	
77-34	13150-13160	extinction	_	
77-35	13160-13161	)	_	
77-36	13162-13163	×	_	
77-37	13164-13165	2	_	
77-38	13166-13167	(	_	
77-39	13167-13172	group	_	
77-40	13172-13173	:	_	
77-41	13174-13181	cocaine	_	
77-42	13182-13187	users	_	
77-43	13187-13188	,	_	
77-44	13189-13197	controls	_	
77-45	13197-13198	)	_	
77-46	13199-13204	mixed	_	
77-47	13205-13213	analysis	_	
77-48	13214-13216	of	_	
77-49	13217-13225	variance	_	
77-50	13226-13227	(	_	
77-51	13227-13232	ANOVA	_	
77-52	13232-13233	)	_	
77-53	13234-13236	on	_	
77-54	13237-13240	the	_	
77-55	13241-13253	differential	_	
77-56	13254-13257	SCR	_	
77-57	13258-13264	values	_	
77-58	13265-13266	(	_	
77-59	13266-13269	CSD	_	
77-60	13269-13270	+	_	
77-61	13271-13277	versus	_	
77-62	13278-13280	CS	_	
77-63	13280-13281	−	_	
77-64	13282-13285	and	_	
77-65	13286-13289	CSP	_	
77-66	13289-13290	+	_	
77-67	13291-13297	versus	_	
77-68	13298-13300	CS	_	
77-69	13300-13301	−	_	
77-70	13301-13302	)	_	
77-71	13302-13303	.	_	

#Text=Considering that we expected across- as well as within-session learning, the ANOVA was restricted to all unpaired trials during acquisition and the last half of all extinction trials on day 1 and day 2.
78-1	13304-13315	Considering	_	
78-2	13316-13320	that	_	
78-3	13321-13323	we	_	
78-4	13324-13332	expected	_	
78-5	13333-13339	across	_	
78-6	13339-13340	-	_	
78-7	13341-13343	as	_	
78-8	13344-13348	well	_	
78-9	13349-13351	as	_	
78-10	13352-13366	within-session	_	
78-11	13367-13375	learning	_	
78-12	13375-13376	,	_	
78-13	13377-13380	the	_	
78-14	13381-13386	ANOVA	_	
78-15	13387-13390	was	_	
78-16	13391-13401	restricted	_	
78-17	13402-13404	to	_	
78-18	13405-13408	all	_	
78-19	13409-13417	unpaired	_	
78-20	13418-13424	trials	_	
78-21	13425-13431	during	_	
78-22	13432-13443	acquisition	_	
78-23	13444-13447	and	_	
78-24	13448-13451	the	_	
78-25	13452-13456	last	_	
78-26	13457-13461	half	_	
78-27	13462-13464	of	_	
78-28	13465-13468	all	_	
78-29	13469-13479	extinction	_	
78-30	13480-13486	trials	_	
78-31	13487-13489	on	_	
78-32	13490-13493	day	_	
78-33	13494-13495	1	_	
78-34	13496-13499	and	_	
78-35	13500-13503	day	_	
78-36	13504-13505	2	_	
78-37	13505-13506	.	_	

#Text=Due to artifacts in the SCR signal, the subsample with complete SCR data for all three learning phases consisted of n=11 cocaine users and n=6 controls.
79-1	13507-13510	Due	_	
79-2	13511-13513	to	_	
79-3	13514-13523	artifacts	_	
79-4	13524-13526	in	_	
79-5	13527-13530	the	_	
79-6	13531-13534	SCR	_	
79-7	13535-13541	signal	_	
79-8	13541-13542	,	_	
79-9	13543-13546	the	_	
79-10	13547-13556	subsample	_	
79-11	13557-13561	with	_	
79-12	13562-13570	complete	_	
79-13	13571-13574	SCR	_	
79-14	13575-13579	data	_	
79-15	13580-13583	for	_	
79-16	13584-13587	all	_	
79-17	13588-13593	three	_	
79-18	13594-13602	learning	_	
79-19	13603-13609	phases	_	
79-20	13610-13619	consisted	_	
79-21	13620-13622	of	_	
79-22	13623-13624	n	_	
79-23	13624-13625	=	_	
79-24	13625-13627	11	_	
79-25	13628-13635	cocaine	_	
79-26	13636-13641	users	_	
79-27	13642-13645	and	_	
79-28	13646-13647	n	_	
79-29	13647-13648	=	_	
79-30	13648-13649	6	_	
79-31	13650-13658	controls	_	
79-32	13658-13659	.	_	

#Text=Hence, our SCR analyses comparing the diagnostic groups across the learning phases were only powered to detect large effects (specifically, d≥0.68).
80-1	13660-13665	Hence	_	
80-2	13665-13666	,	_	
80-3	13667-13670	our	_	
80-4	13671-13674	SCR	_	
80-5	13675-13683	analyses	_	
80-6	13684-13693	comparing	_	
80-7	13694-13697	the	_	
80-8	13698-13708	diagnostic	_	
80-9	13709-13715	groups	_	
80-10	13716-13722	across	_	
80-11	13723-13726	the	_	
80-12	13727-13735	learning	_	
80-13	13736-13742	phases	_	
80-14	13743-13747	were	_	
80-15	13748-13752	only	_	
80-16	13753-13760	powered	_	
80-17	13761-13763	to	_	
80-18	13764-13770	detect	_	
80-19	13771-13776	large	_	
80-20	13777-13784	effects	_	
80-21	13785-13786	(	_	
80-22	13786-13798	specifically	_	
80-23	13798-13799	,	_	
80-24	13800-13801	d	_	
80-25	13801-13802	≥	_	
80-26	13802-13806	0.68	_	
80-27	13806-13807	)	_	
80-28	13807-13808	.	_	

#Text=Image Acquisition & Analysis
#Text=Functional images were acquired with a 4T Varian/Siemens MRI scanner using a coronal T2*-weighted single shot gradient-echo EPI sequence (TE/TR=20/1600 ms, 3.125×3.125 mm2 in-plane resolution, 4 mm slice thickness, 1 mm gap, 33 coronal slices, 20 cm FOV, 64×64 matrix size, 90°-flip angle, 200 kHz bandwidth with ramp sampling).
81-1	13809-13814	Image	_	
81-2	13815-13826	Acquisition	_	
81-3	13827-13828	&	_	
81-4	13829-13837	Analysis	_	
81-5	13838-13848	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[21]	
81-6	13849-13855	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[21]	
81-7	13856-13860	were	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[21]	
81-8	13861-13869	acquired	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[21]	
81-9	13870-13874	with	_	
81-10	13875-13876	a	_	
81-11	13877-13879	4T	_	
81-12	13880-13886	Varian	_	
81-13	13886-13887	/	_	
81-14	13887-13894	Siemens	_	
81-15	13895-13898	MRI	_	
81-16	13899-13906	scanner	_	
81-17	13907-13912	using	_	
81-18	13913-13914	a	_	
81-19	13915-13922	coronal	_	
81-20	13923-13925	T2	_	
81-21	13925-13926	*	_	
81-22	13926-13927	-	_	
81-23	13927-13935	weighted	_	
81-24	13936-13942	single	_	
81-25	13943-13947	shot	_	
81-26	13948-13961	gradient-echo	_	
81-27	13962-13965	EPI	_	
81-28	13966-13974	sequence	_	
81-29	13975-13976	(	_	
81-30	13976-13978	TE	_	
81-31	13978-13979	/	_	
81-32	13979-13981	TR	_	
81-33	13981-13982	=	_	
81-34	13982-13984	20	_	
81-35	13984-13985	/	_	
81-36	13985-13989	1600	_	
81-37	13990-13992	ms	_	
81-38	13992-13993	,	_	
81-39	13994-13999	3.125	_	
81-40	13999-14000	×	_	
81-41	14000-14005	3.125	_	
81-42	14006-14009	mm2	_	
81-43	14010-14018	in-plane	_	
81-44	14019-14029	resolution	_	
81-45	14029-14030	,	_	
81-46	14031-14032	4	_	
81-47	14033-14035	mm	_	
81-48	14036-14041	slice	_	
81-49	14042-14051	thickness	_	
81-50	14051-14052	,	_	
81-51	14053-14054	1	_	
81-52	14055-14057	mm	_	
81-53	14058-14061	gap	_	
81-54	14061-14062	,	_	
81-55	14063-14065	33	_	
81-56	14066-14073	coronal	_	
81-57	14074-14080	slices	_	
81-58	14080-14081	,	_	
81-59	14082-14084	20	_	
81-60	14085-14087	cm	_	
81-61	14088-14091	FOV	_	
81-62	14091-14092	,	_	
81-63	14093-14095	64	_	
81-64	14095-14096	×	_	
81-65	14096-14098	64	_	
81-66	14099-14105	matrix	_	
81-67	14106-14110	size	_	
81-68	14110-14111	,	_	
81-69	14112-14114	90	_	
81-70	14114-14115	°	_	
81-71	14115-14116	-	_	
81-72	14116-14120	flip	_	
81-73	14121-14126	angle	_	
81-74	14126-14127	,	_	
81-75	14128-14131	200	_	
81-76	14132-14135	kHz	_	
81-77	14136-14145	bandwidth	_	
81-78	14146-14150	with	_	
81-79	14151-14155	ramp	_	
81-80	14156-14164	sampling	_	
81-81	14164-14165	)	_	
81-82	14165-14166	.	_	

#Text=Image processing and analyses were performed in SPM8 (Wellcome Trust Centre for Neuroimaging, London UK).
82-1	14167-14172	Image	_	
82-2	14173-14183	processing	_	
82-3	14184-14187	and	_	
82-4	14188-14196	analyses	_	
82-5	14197-14201	were	_	
82-6	14202-14211	performed	_	
82-7	14212-14214	in	_	
82-8	14215-14219	SPM8	_	
82-9	14220-14221	(	_	
82-10	14221-14229	Wellcome	_	
82-11	14230-14235	Trust	_	
82-12	14236-14242	Centre	_	
82-13	14243-14246	for	_	
82-14	14247-14259	Neuroimaging	_	
82-15	14259-14260	,	_	
82-16	14261-14267	London	_	
82-17	14268-14270	UK	_	
82-18	14270-14271	)	_	
82-19	14271-14272	.	_	

#Text=The data were first realigned, co-registered, and spatially normalized to a standard EPI template in the Montreal Neurological Institute (MNI) frame, resulting in a final voxel size of 3×3×3 mm.
83-1	14273-14276	The	_	
83-2	14277-14281	data	_	
83-3	14282-14286	were	_	
83-4	14287-14292	first	_	
83-5	14293-14302	realigned	_	
83-6	14302-14303	,	_	
83-7	14304-14317	co-registered	_	
83-8	14317-14318	,	_	
83-9	14319-14322	and	_	
83-10	14323-14332	spatially	_	
83-11	14333-14343	normalized	_	
83-12	14344-14346	to	_	
83-13	14347-14348	a	_	
83-14	14349-14357	standard	_	
83-15	14358-14361	EPI	_	
83-16	14362-14370	template	_	
83-17	14371-14373	in	_	
83-18	14374-14377	the	_	
83-19	14378-14386	Montreal	_	
83-20	14387-14399	Neurological	_	
83-21	14400-14409	Institute	_	
83-22	14410-14411	(	_	
83-23	14411-14414	MNI	_	
83-24	14414-14415	)	_	
83-25	14416-14421	frame	_	
83-26	14421-14422	,	_	
83-27	14423-14432	resulting	_	
83-28	14433-14435	in	_	
83-29	14436-14437	a	_	
83-30	14438-14443	final	_	
83-31	14444-14449	voxel	_	
83-32	14450-14454	size	_	
83-33	14455-14457	of	_	
83-34	14458-14459	3	_	
83-35	14459-14460	×	_	
83-36	14460-14461	3	_	
83-37	14461-14462	×	_	
83-38	14462-14463	3	_	
83-39	14464-14466	mm	_	
83-40	14466-14467	.	_	

#Text=Criteria for acceptable motion were ≤2 mm translation or ≤2 degrees rotation in any direction.
84-1	14468-14476	Criteria	_	
84-2	14477-14480	for	_	
84-3	14481-14491	acceptable	_	
84-4	14492-14498	motion	_	
84-5	14499-14503	were	_	
84-6	14504-14505	≤	_	
84-7	14505-14506	2	_	
84-8	14507-14509	mm	_	
84-9	14510-14521	translation	_	
84-10	14522-14524	or	_	
84-11	14525-14526	≤	_	
84-12	14526-14527	2	_	
84-13	14528-14535	degrees	_	
84-14	14536-14544	rotation	_	
84-15	14545-14547	in	_	
84-16	14548-14551	any	_	
84-17	14552-14561	direction	_	
84-18	14561-14562	.	_	

#Text=The data were spatially smoothed with an 8 mm full-width-at-half-maximum Gaussian kernel.
85-1	14563-14566	The	_	
85-2	14567-14571	data	_	
85-3	14572-14576	were	_	
85-4	14577-14586	spatially	_	
85-5	14587-14595	smoothed	_	
85-6	14596-14600	with	_	
85-7	14601-14603	an	_	
85-8	14604-14605	8	_	
85-9	14606-14608	mm	_	
85-10	14609-14635	full-width-at-half-maximum	_	
85-11	14636-14644	Gaussian	_	
85-12	14645-14651	kernel	_	
85-13	14651-14652	.	_	

#Text=Three random-effects general linear models (GLMs) were specified for each participant, corresponding to acquisition, day 1 extinction, and day 2 extinction, each with a session-specific intercept, the 6 motion parameters as regressors of no interest, and all task conditions convolved with a canonical HRF and high-pass filter (cut-off frequency: 1/1500 s).
86-1	14653-14658	Three	_	
86-2	14659-14673	random-effects	_	
86-3	14674-14681	general	_	
86-4	14682-14688	linear	_	
86-5	14689-14695	models	_	
86-6	14696-14697	(	_	
86-7	14697-14701	GLMs	_	
86-8	14701-14702	)	_	
86-9	14703-14707	were	_	
86-10	14708-14717	specified	_	
86-11	14718-14721	for	_	
86-12	14722-14726	each	_	
86-13	14727-14738	participant	_	
86-14	14738-14739	,	_	
86-15	14740-14753	corresponding	_	
86-16	14754-14756	to	_	
86-17	14757-14768	acquisition	_	
86-18	14768-14769	,	_	
86-19	14770-14773	day	_	
86-20	14774-14775	1	_	
86-21	14776-14786	extinction	_	
86-22	14786-14787	,	_	
86-23	14788-14791	and	_	
86-24	14792-14795	day	_	
86-25	14796-14797	2	_	
86-26	14798-14808	extinction	_	
86-27	14808-14809	,	_	
86-28	14810-14814	each	_	
86-29	14815-14819	with	_	
86-30	14820-14821	a	_	
86-31	14822-14838	session-specific	_	
86-32	14839-14848	intercept	_	
86-33	14848-14849	,	_	
86-34	14850-14853	the	_	
86-35	14854-14855	6	_	
86-36	14856-14862	motion	_	
86-37	14863-14873	parameters	_	
86-38	14874-14876	as	_	
86-39	14877-14887	regressors	_	
86-40	14888-14890	of	_	
86-41	14891-14893	no	_	
86-42	14894-14902	interest	_	
86-43	14902-14903	,	_	
86-44	14904-14907	and	_	
86-45	14908-14911	all	_	
86-46	14912-14916	task	_	
86-47	14917-14927	conditions	_	
86-48	14928-14937	convolved	_	
86-49	14938-14942	with	_	
86-50	14943-14944	a	_	
86-51	14945-14954	canonical	_	
86-52	14955-14958	HRF	_	
86-53	14959-14962	and	_	
86-54	14963-14972	high-pass	_	
86-55	14973-14979	filter	_	
86-56	14980-14981	(	_	
86-57	14981-14988	cut-off	_	
86-58	14989-14998	frequency	_	
86-59	14998-14999	:	_	
86-60	15000-15001	1	_	
86-61	15001-15002	/	_	
86-62	15002-15006	1500	_	
86-63	15007-15008	s	_	
86-64	15008-15009	)	_	
86-65	15009-15010	.	_	

#Text=The GLM for acquisition included trial onsets for each CS (CSD+, CSP+, and CS−), separately for paired and unpaired trials (6 conditions in total), modeled as epochs with duration equal to the length of CS presentation (3.5 s or 5 s; i.e., terminating when the US was presented).
87-1	15011-15014	The	_	
87-2	15015-15018	GLM	_	
87-3	15019-15022	for	_	
87-4	15023-15034	acquisition	_	
87-5	15035-15043	included	_	
87-6	15044-15049	trial	_	
87-7	15050-15056	onsets	_	
87-8	15057-15060	for	_	
87-9	15061-15065	each	_	
87-10	15066-15068	CS	_	
87-11	15069-15070	(	_	
87-12	15070-15073	CSD	_	
87-13	15073-15074	+	_	
87-14	15074-15075	,	_	
87-15	15076-15079	CSP	_	
87-16	15079-15080	+	_	
87-17	15080-15081	,	_	
87-18	15082-15085	and	_	
87-19	15086-15088	CS	_	
87-20	15088-15089	−	_	
87-21	15089-15090	)	_	
87-22	15090-15091	,	_	
87-23	15092-15102	separately	_	
87-24	15103-15106	for	_	
87-25	15107-15113	paired	_	
87-26	15114-15117	and	_	
87-27	15118-15126	unpaired	_	
87-28	15127-15133	trials	_	
87-29	15134-15135	(	_	
87-30	15135-15136	6	_	
87-31	15137-15147	conditions	_	
87-32	15148-15150	in	_	
87-33	15151-15156	total	_	
87-34	15156-15157	)	_	
87-35	15157-15158	,	_	
87-36	15159-15166	modeled	_	
87-37	15167-15169	as	_	
87-38	15170-15176	epochs	_	
87-39	15177-15181	with	_	
87-40	15182-15190	duration	_	
87-41	15191-15196	equal	_	
87-42	15197-15199	to	_	
87-43	15200-15203	the	_	
87-44	15204-15210	length	_	
87-45	15211-15213	of	_	
87-46	15214-15216	CS	_	
87-47	15217-15229	presentation	_	
87-48	15230-15231	(	_	
87-49	15231-15234	3.5	_	
87-50	15235-15236	s	_	
87-51	15237-15239	or	_	
87-52	15240-15241	5	_	
87-53	15242-15243	s	_	
87-54	15243-15244	;	_	
87-55	15245-15248	i.e	_	
87-56	15248-15249	.	_	
87-57	15249-15250	,	_	
87-58	15251-15262	terminating	_	
87-59	15263-15267	when	_	
87-60	15268-15271	the	_	
87-61	15272-15274	US	_	
87-62	15275-15278	was	_	
87-63	15279-15288	presented	_	
87-64	15288-15289	)	_	
87-65	15289-15290	.	_	

#Text=The GLMs for day 1 and day 2 extinction each included trial onsets for each CS (all unpaired trials, epoch duration=5 s).
88-1	15291-15294	The	_	
88-2	15295-15299	GLMs	_	
88-3	15300-15303	for	_	
88-4	15304-15307	day	_	
88-5	15308-15309	1	_	
88-6	15310-15313	and	_	
88-7	15314-15317	day	_	
88-8	15318-15319	2	_	
88-9	15320-15330	extinction	_	
88-10	15331-15335	each	_	
88-11	15336-15344	included	_	
88-12	15345-15350	trial	_	
88-13	15351-15357	onsets	_	
88-14	15358-15361	for	_	
88-15	15362-15366	each	_	
88-16	15367-15369	CS	_	
88-17	15370-15371	(	_	
88-18	15371-15374	all	_	
88-19	15375-15383	unpaired	_	
88-20	15384-15390	trials	_	
88-21	15390-15391	,	_	
88-22	15392-15397	epoch	_	
88-23	15398-15406	duration	_	
88-24	15406-15407	=	_	
88-25	15407-15408	5	_	
88-26	15409-15410	s	_	
88-27	15410-15411	)	_	
88-28	15411-15412	.	_	

#Text=The GLM for day 1 extinction additionally included a fourth condition for the “reminder trials”.
89-1	15413-15416	The	_	
89-2	15417-15420	GLM	_	
89-3	15421-15424	for	_	
89-4	15425-15428	day	_	
89-5	15429-15430	1	_	
89-6	15431-15441	extinction	_	
89-7	15442-15454	additionally	_	
89-8	15455-15463	included	_	
89-9	15464-15465	a	_	
89-10	15466-15472	fourth	_	
89-11	15473-15482	condition	_	
89-12	15483-15486	for	_	
89-13	15487-15490	the	_	
89-14	15491-15492	“	_	
89-15	15492-15500	reminder	_	
89-16	15501-15507	trials	_	
89-17	15507-15508	”	_	
89-18	15508-15509	.	_	

#Text=Beta maps were computed for each participant for each CS and learning phase.
90-1	15510-15514	Beta	_	
90-2	15515-15519	maps	_	
90-3	15520-15524	were	_	
90-4	15525-15533	computed	_	
90-5	15534-15537	for	_	
90-6	15538-15542	each	_	
90-7	15543-15554	participant	_	
90-8	15555-15558	for	_	
90-9	15559-15563	each	_	
90-10	15564-15566	CS	_	
90-11	15567-15570	and	_	
90-12	15571-15579	learning	_	
90-13	15580-15585	phase	_	
90-14	15585-15586	.	_	

#Text=Given that previous studies have identified a circuit centered on the VMPFC in extinction learning, and the VMPFC and striatum in the representation and updating of values including those for drug cues, we focused on these two regions, although exploratory whole-brain and targeted control region analyses were also performed (see Supporting Information).
91-1	15587-15592	Given	_	
91-2	15593-15597	that	_	
91-3	15598-15606	previous	_	
91-4	15607-15614	studies	_	
91-5	15615-15619	have	_	
91-6	15620-15630	identified	_	
91-7	15631-15632	a	_	
91-8	15633-15640	circuit	_	
91-9	15641-15649	centered	_	
91-10	15650-15652	on	_	
91-11	15653-15656	the	_	
91-12	15657-15662	VMPFC	_	
91-13	15663-15665	in	_	
91-14	15666-15676	extinction	_	
91-15	15677-15685	learning	_	
91-16	15685-15686	,	_	
91-17	15687-15690	and	_	
91-18	15691-15694	the	_	
91-19	15695-15700	VMPFC	_	
91-20	15701-15704	and	_	
91-21	15705-15713	striatum	_	
91-22	15714-15716	in	_	
91-23	15717-15720	the	_	
91-24	15721-15735	representation	_	
91-25	15736-15739	and	_	
91-26	15740-15748	updating	_	
91-27	15749-15751	of	_	
91-28	15752-15758	values	_	
91-29	15759-15768	including	_	
91-30	15769-15774	those	_	
91-31	15775-15778	for	_	
91-32	15779-15783	drug	_	
91-33	15784-15788	cues	_	
91-34	15788-15789	,	_	
91-35	15790-15792	we	_	
91-36	15793-15800	focused	_	
91-37	15801-15803	on	_	
91-38	15804-15809	these	_	
91-39	15810-15813	two	_	
91-40	15814-15821	regions	_	
91-41	15821-15822	,	_	
91-42	15823-15831	although	_	
91-43	15832-15843	exploratory	_	
91-44	15844-15855	whole-brain	_	
91-45	15856-15859	and	_	
91-46	15860-15868	targeted	_	
91-47	15869-15876	control	_	
91-48	15877-15883	region	_	
91-49	15884-15892	analyses	_	
91-50	15893-15897	were	_	
91-51	15898-15902	also	_	
91-52	15903-15912	performed	_	
91-53	15913-15914	(	_	
91-54	15914-15917	see	_	
91-55	15918-15928	Supporting	_	
91-56	15929-15940	Information	_	
91-57	15940-15941	)	_	
91-58	15941-15942	.	_	

#Text=As with SCR, we conducted 2 (cue type) × 3 (learning phase) × 2 (group) mixed ANOVAs on the differential BOLD responses (CSD+ versus CS− and CSP+ versus CS−), our neural measure of the conditioned response, extracted as average beta estimates from unbiased regions of interest (ROIs).
92-1	15943-15945	As	_	
92-2	15946-15950	with	_	
92-3	15951-15954	SCR	_	
92-4	15954-15955	,	_	
92-5	15956-15958	we	_	
92-6	15959-15968	conducted	_	
92-7	15969-15970	2	_	
92-8	15971-15972	(	_	
92-9	15972-15975	cue	_	
92-10	15976-15980	type	_	
92-11	15980-15981	)	_	
92-12	15982-15983	×	_	
92-13	15984-15985	3	_	
92-14	15986-15987	(	_	
92-15	15987-15995	learning	_	
92-16	15996-16001	phase	_	
92-17	16001-16002	)	_	
92-18	16003-16004	×	_	
92-19	16005-16006	2	_	
92-20	16007-16008	(	_	
92-21	16008-16013	group	_	
92-22	16013-16014	)	_	
92-23	16015-16020	mixed	_	
92-24	16021-16027	ANOVAs	_	
92-25	16028-16030	on	_	
92-26	16031-16034	the	_	
92-27	16035-16047	differential	_	
92-28	16048-16052	BOLD	_	
92-29	16053-16062	responses	_	
92-30	16063-16064	(	_	
92-31	16064-16067	CSD	_	
92-32	16067-16068	+	_	
92-33	16069-16075	versus	_	
92-34	16076-16078	CS	_	
92-35	16078-16079	−	_	
92-36	16080-16083	and	_	
92-37	16084-16087	CSP	_	
92-38	16087-16088	+	_	
92-39	16089-16095	versus	_	
92-40	16096-16098	CS	_	
92-41	16098-16099	−	_	
92-42	16099-16100	)	_	
92-43	16100-16101	,	_	
92-44	16102-16105	our	_	
92-45	16106-16112	neural	_	
92-46	16113-16120	measure	_	
92-47	16121-16123	of	_	
92-48	16124-16127	the	_	
92-49	16128-16139	conditioned	_	
92-50	16140-16148	response	_	
92-51	16148-16149	,	_	
92-52	16150-16159	extracted	_	
92-53	16160-16162	as	_	
92-54	16163-16170	average	_	
92-55	16171-16175	beta	_	
92-56	16176-16185	estimates	_	
92-57	16186-16190	from	_	
92-58	16191-16199	unbiased	_	
92-59	16200-16207	regions	_	
92-60	16208-16210	of	_	
92-61	16211-16219	interest	_	
92-62	16220-16221	(	_	
92-63	16221-16225	ROIs	_	
92-64	16225-16226	)	_	
92-65	16226-16227	.	_	

#Text=The full sample of N=33 participants was included in the fMRI analyses.
93-1	16228-16231	The	_	
93-2	16232-16236	full	_	
93-3	16237-16243	sample	_	
93-4	16244-16246	of	_	
93-5	16247-16248	N	_	
93-6	16248-16249	=	_	
93-7	16249-16251	33	_	
93-8	16252-16264	participants	_	
93-9	16265-16268	was	_	
93-10	16269-16277	included	_	
93-11	16278-16280	in	_	
93-12	16281-16284	the	_	
93-13	16285-16289	fMRI	_	
93-14	16290-16298	analyses	_	
93-15	16298-16299	.	_	

#Text=The striatum (entire caudate and putamen) ROI was anatomically defined in PickAtlas (ANSIR Laboratory; http://fmri.wfubmc.edu/software/PickAtlas).
94-1	16300-16303	The	_	
94-2	16304-16312	striatum	_	
94-3	16313-16314	(	_	
94-4	16314-16320	entire	_	
94-5	16321-16328	caudate	_	
94-6	16329-16332	and	_	
94-7	16333-16340	putamen	_	
94-8	16340-16341	)	_	
94-9	16342-16345	ROI	_	
94-10	16346-16349	was	_	
94-11	16350-16362	anatomically	_	
94-12	16363-16370	defined	_	
94-13	16371-16373	in	_	
94-14	16374-16383	PickAtlas	_	
94-15	16384-16385	(	_	
94-16	16385-16390	ANSIR	_	
94-17	16391-16401	Laboratory	_	
94-18	16401-16402	;	_	
94-19	16403-16407	http	_	
94-20	16407-16408	:	_	
94-21	16408-16409	/	_	
94-22	16409-16410	/	_	
94-23	16410-16425	fmri.wfubmc.edu	_	
94-24	16425-16426	/	_	
94-25	16426-16434	software	_	
94-26	16434-16435	/	_	
94-27	16435-16444	PickAtlas	_	
94-28	16444-16445	)	_	
94-29	16445-16446	.	_	

#Text=The VMPFC was defined as a 12-mm radius sphere centered on the coordinates reported in after transformation to MNI space (Talairach: x=±2, y=38, z=−3; MNI: x=±3, y=42, z=−12).
95-1	16447-16450	The	_	
95-2	16451-16456	VMPFC	_	
95-3	16457-16460	was	_	
95-4	16461-16468	defined	_	
95-5	16469-16471	as	_	
95-6	16472-16473	a	_	
95-7	16474-16476	12	_	
95-8	16476-16477	-	_	
95-9	16477-16479	mm	_	
95-10	16480-16486	radius	_	
95-11	16487-16493	sphere	_	
95-12	16494-16502	centered	_	
95-13	16503-16505	on	_	
95-14	16506-16509	the	_	
95-15	16510-16521	coordinates	_	
95-16	16522-16530	reported	_	
95-17	16531-16533	in	_	
95-18	16534-16539	after	_	
95-19	16540-16554	transformation	_	
95-20	16555-16557	to	_	
95-21	16558-16561	MNI	_	
95-22	16562-16567	space	_	
95-23	16568-16569	(	_	
95-24	16569-16578	Talairach	_	
95-25	16578-16579	:	_	
95-26	16580-16581	x	_	
95-27	16581-16582	=	_	
95-28	16582-16583	±	_	
95-29	16583-16584	2	_	
95-30	16584-16585	,	_	
95-31	16586-16587	y	_	
95-32	16587-16588	=	_	
95-33	16588-16590	38	_	
95-34	16590-16591	,	_	
95-35	16592-16593	z	_	
95-36	16593-16594	=	_	
95-37	16594-16595	−	_	
95-38	16595-16596	3	_	
95-39	16596-16597	;	_	
95-40	16598-16601	MNI	_	
95-41	16601-16602	:	_	
95-42	16603-16604	x	_	
95-43	16604-16605	=	_	
95-44	16605-16606	±	_	
95-45	16606-16607	3	_	
95-46	16607-16608	,	_	
95-47	16609-16610	y	_	
95-48	16610-16611	=	_	
95-49	16611-16613	42	_	
95-50	16613-16614	,	_	
95-51	16615-16616	z	_	
95-52	16616-16617	=	_	
95-53	16617-16618	−	_	
95-54	16618-16620	12	_	
95-55	16620-16621	)	_	
95-56	16621-16622	.	_	

#Text=The term VMPFC is used to describe a large, heterogeneous region of the medial prefrontal cortex that spans parts of the anterior cingulate cortex (anterior to the genu of the corpus callosum) and the medial orbitofrontal cortex, encompassing Brodmann areas (BAs) 25, ventral portions of 24 and 32, medial portion of 11, and ventral and medial portions of 10.
96-1	16623-16626	The	_	
96-2	16627-16631	term	_	
96-3	16632-16637	VMPFC	_	
96-4	16638-16640	is	_	
96-5	16641-16645	used	_	
96-6	16646-16648	to	_	
96-7	16649-16657	describe	_	
96-8	16658-16659	a	_	
96-9	16660-16665	large	_	
96-10	16665-16666	,	_	
96-11	16667-16680	heterogeneous	_	
96-12	16681-16687	region	_	
96-13	16688-16690	of	_	
96-14	16691-16694	the	_	
96-15	16695-16701	medial	_	
96-16	16702-16712	prefrontal	_	
96-17	16713-16719	cortex	_	
96-18	16720-16724	that	_	
96-19	16725-16730	spans	_	
96-20	16731-16736	parts	_	
96-21	16737-16739	of	_	
96-22	16740-16743	the	_	
96-23	16744-16752	anterior	_	
96-24	16753-16762	cingulate	_	
96-25	16763-16769	cortex	_	
96-26	16770-16771	(	_	
96-27	16771-16779	anterior	_	
96-28	16780-16782	to	_	
96-29	16783-16786	the	_	
96-30	16787-16791	genu	_	
96-31	16792-16794	of	_	
96-32	16795-16798	the	_	
96-33	16799-16805	corpus	_	
96-34	16806-16814	callosum	_	
96-35	16814-16815	)	_	
96-36	16816-16819	and	_	
96-37	16820-16823	the	_	
96-38	16824-16830	medial	_	
96-39	16831-16844	orbitofrontal	_	
96-40	16845-16851	cortex	_	
96-41	16851-16852	,	_	
96-42	16853-16865	encompassing	_	
96-43	16866-16874	Brodmann	_	
96-44	16875-16880	areas	_	
96-45	16881-16882	(	_	
96-46	16882-16885	BAs	_	
96-47	16885-16886	)	_	
96-48	16887-16889	25	_	
96-49	16889-16890	,	_	
96-50	16891-16898	ventral	_	
96-51	16899-16907	portions	_	
96-52	16908-16910	of	_	
96-53	16911-16913	24	_	
96-54	16914-16917	and	_	
96-55	16918-16920	32	_	
96-56	16920-16921	,	_	
96-57	16922-16928	medial	_	
96-58	16929-16936	portion	_	
96-59	16937-16939	of	_	
96-60	16940-16942	11	_	
96-61	16942-16943	,	_	
96-62	16944-16947	and	_	
96-63	16948-16955	ventral	_	
96-64	16956-16959	and	_	
96-65	16960-16966	medial	_	
96-66	16967-16975	portions	_	
96-67	16976-16978	of	_	
96-68	16979-16981	10	_	
96-69	16981-16982	.	_	

#Text=The particular aspect of the VMPFC included in our ROI is the medial portion of BA 11 and the ventral portion of BA 10 (see inset in Figure 2), which has been linked to emotion regulation including the use of extinction strategies.
97-1	16983-16986	The	_	
97-2	16987-16997	particular	_	
97-3	16998-17004	aspect	_	
97-4	17005-17007	of	_	
97-5	17008-17011	the	_	
97-6	17012-17017	VMPFC	_	
97-7	17018-17026	included	_	
97-8	17027-17029	in	_	
97-9	17030-17033	our	_	
97-10	17034-17037	ROI	_	
97-11	17038-17040	is	_	
97-12	17041-17044	the	_	
97-13	17045-17051	medial	_	
97-14	17052-17059	portion	_	
97-15	17060-17062	of	_	
97-16	17063-17065	BA	_	
97-17	17066-17068	11	_	
97-18	17069-17072	and	_	
97-19	17073-17076	the	_	
97-20	17077-17084	ventral	_	
97-21	17085-17092	portion	_	
97-22	17093-17095	of	_	
97-23	17096-17098	BA	_	
97-24	17099-17101	10	_	
97-25	17102-17103	(	_	
97-26	17103-17106	see	_	
97-27	17107-17112	inset	_	
97-28	17113-17115	in	_	
97-29	17116-17122	Figure	_	
97-30	17123-17124	2	_	
97-31	17124-17125	)	_	
97-32	17125-17126	,	_	
97-33	17127-17132	which	_	
97-34	17133-17136	has	_	
97-35	17137-17141	been	_	
97-36	17142-17148	linked	_	
97-37	17149-17151	to	_	
97-38	17152-17159	emotion	_	
97-39	17160-17170	regulation	_	
97-40	17171-17180	including	_	
97-41	17181-17184	the	_	
97-42	17185-17188	use	_	
97-43	17189-17191	of	_	
97-44	17192-17202	extinction	_	
97-45	17203-17213	strategies	_	
97-46	17213-17214	.	_	

#Text=In the anterior-posterior direction, our VMPFC ROI falls centrally, touching on posterior aspects traditionally linked to the representation of negative affect and anterior aspects representing positive affect.
98-1	17215-17217	In	_	
98-2	17218-17221	the	_	
98-3	17222-17240	anterior-posterior	_	
98-4	17241-17250	direction	_	
98-5	17250-17251	,	_	
98-6	17252-17255	our	_	
98-7	17256-17261	VMPFC	_	
98-8	17262-17265	ROI	_	
98-9	17266-17271	falls	_	
98-10	17272-17281	centrally	_	
98-11	17281-17282	,	_	
98-12	17283-17291	touching	_	
98-13	17292-17294	on	_	
98-14	17295-17304	posterior	_	
98-15	17305-17312	aspects	_	
98-16	17313-17326	traditionally	_	
98-17	17327-17333	linked	_	
98-18	17334-17336	to	_	
98-19	17337-17340	the	_	
98-20	17341-17355	representation	_	
98-21	17356-17358	of	_	
98-22	17359-17367	negative	_	
98-23	17368-17374	affect	_	
98-24	17375-17378	and	_	
98-25	17379-17387	anterior	_	
98-26	17388-17395	aspects	_	
98-27	17396-17408	representing	_	
98-28	17409-17417	positive	_	
98-29	17418-17424	affect	_	
98-30	17424-17425	.	_	

#Text=Notably, our ROI almost fully overlaps with the VMPFC locus identified in to represent value in diverse contexts.
99-1	17426-17433	Notably	_	
99-2	17433-17434	,	_	
99-3	17435-17438	our	_	
99-4	17439-17442	ROI	_	
99-5	17443-17449	almost	_	
99-6	17450-17455	fully	_	
99-7	17456-17464	overlaps	_	
99-8	17465-17469	with	_	
99-9	17470-17473	the	_	
99-10	17474-17479	VMPFC	_	
99-11	17480-17485	locus	_	
99-12	17486-17496	identified	_	
99-13	17497-17499	in	_	
99-14	17500-17502	to	_	
99-15	17503-17512	represent	_	
99-16	17513-17518	value	_	
99-17	17519-17521	in	_	
99-18	17522-17529	diverse	_	
99-19	17530-17538	contexts	_	
99-20	17538-17539	.	_	

#Text=An initial analysis that included laterality as a factor revealed differential responses in the left vs. right VMPFC ROIs.
100-1	17540-17542	An	_	
100-2	17543-17550	initial	_	
100-3	17551-17559	analysis	_	
100-4	17560-17564	that	_	
100-5	17565-17573	included	_	
100-6	17574-17584	laterality	_	
100-7	17585-17587	as	_	
100-8	17588-17589	a	_	
100-9	17590-17596	factor	_	
100-10	17597-17605	revealed	_	
100-11	17606-17618	differential	_	
100-12	17619-17628	responses	_	
100-13	17629-17631	in	_	
100-14	17632-17635	the	_	
100-15	17636-17640	left	_	
100-16	17641-17643	vs	_	
100-17	17643-17644	.	_	
100-18	17645-17650	right	_	
100-19	17651-17656	VMPFC	_	
100-20	17657-17661	ROIs	_	
100-21	17661-17662	.	_	

#Text=Therefore, the ANOVAs reported were performed on averaged left and right side activation values for the striatum but not the VMPFC.
101-1	17663-17672	Therefore	_	
101-2	17672-17673	,	_	
101-3	17674-17677	the	_	
101-4	17678-17684	ANOVAs	_	
101-5	17685-17693	reported	_	
101-6	17694-17698	were	_	
101-7	17699-17708	performed	_	
101-8	17709-17711	on	_	
101-9	17712-17720	averaged	_	
101-10	17721-17725	left	_	
101-11	17726-17729	and	_	
101-12	17730-17735	right	_	
101-13	17736-17740	side	_	
101-14	17741-17751	activation	_	
101-15	17752-17758	values	_	
101-16	17759-17762	for	_	
101-17	17763-17766	the	_	
101-18	17767-17775	striatum	_	
101-19	17776-17779	but	_	
101-20	17780-17783	not	_	
101-21	17784-17787	the	_	
101-22	17788-17793	VMPFC	_	
101-23	17793-17794	.	_	

#Text=Results
#Text=Psychophysiological and Self-Reported Measures
#Text=The 2 (cue type) × 3 (learning phase) × 2 (group) mixed ANOVA revealed a reduction in SCR (to the CSD+ and CSP+ relative to the CS−) over of the learning phases (F2, 30=2.71, P=0.08, d=0.85), an effect that reached significance for the linear contrast (acquisition>day 1 extinction>day 2 extinction: F=5.93, P=0.028, d=1.26; Figure S2), but no significant diagnostic group, cue type, or interaction effects (F<0.77, P>0.47, d<0.45).
102-1	17795-17802	Results	_	
102-2	17803-17822	Psychophysiological	_	
102-3	17823-17826	and	_	
102-4	17827-17840	Self-Reported	_	
102-5	17841-17849	Measures	_	
102-6	17850-17853	The	_	
102-7	17854-17855	2	_	
102-8	17856-17857	(	_	
102-9	17857-17860	cue	_	
102-10	17861-17865	type	_	
102-11	17865-17866	)	_	
102-12	17867-17868	×	_	
102-13	17869-17870	3	_	
102-14	17871-17872	(	_	
102-15	17872-17880	learning	_	
102-16	17881-17886	phase	_	
102-17	17886-17887	)	_	
102-18	17888-17889	×	_	
102-19	17890-17891	2	_	
102-20	17892-17893	(	_	
102-21	17893-17898	group	_	
102-22	17898-17899	)	_	
102-23	17900-17905	mixed	_	
102-24	17906-17911	ANOVA	_	
102-25	17912-17920	revealed	_	
102-26	17921-17922	a	_	
102-27	17923-17932	reduction	_	
102-28	17933-17935	in	_	
102-29	17936-17939	SCR	_	
102-30	17940-17941	(	_	
102-31	17941-17943	to	_	
102-32	17944-17947	the	_	
102-33	17948-17951	CSD	_	
102-34	17951-17952	+	_	
102-35	17953-17956	and	_	
102-36	17957-17960	CSP	_	
102-37	17960-17961	+	_	
102-38	17962-17970	relative	_	
102-39	17971-17973	to	_	
102-40	17974-17977	the	_	
102-41	17978-17980	CS	_	
102-42	17980-17981	−	_	
102-43	17981-17982	)	_	
102-44	17983-17987	over	_	
102-45	17988-17990	of	_	
102-46	17991-17994	the	_	
102-47	17995-18003	learning	_	
102-48	18004-18010	phases	_	
102-49	18011-18012	(	_	
102-50	18012-18014	F2	_	
102-51	18014-18015	,	_	
102-52	18016-18018	30	_	
102-53	18018-18019	=	_	
102-54	18019-18023	2.71	_	
102-55	18023-18024	,	_	
102-56	18025-18026	P	_	
102-57	18026-18027	=	_	
102-58	18027-18031	0.08	_	
102-59	18031-18032	,	_	
102-60	18033-18034	d	_	
102-61	18034-18035	=	_	
102-62	18035-18039	0.85	_	
102-63	18039-18040	)	_	
102-64	18040-18041	,	_	
102-65	18042-18044	an	_	
102-66	18045-18051	effect	_	
102-67	18052-18056	that	_	
102-68	18057-18064	reached	_	
102-69	18065-18077	significance	_	
102-70	18078-18081	for	_	
102-71	18082-18085	the	_	
102-72	18086-18092	linear	_	
102-73	18093-18101	contrast	_	
102-74	18102-18103	(	_	
102-75	18103-18114	acquisition	_	
102-76	18114-18115	>	_	
102-77	18115-18118	day	_	
102-78	18119-18120	1	_	
102-79	18121-18131	extinction	_	
102-80	18131-18132	>	_	
102-81	18132-18135	day	_	
102-82	18136-18137	2	_	
102-83	18138-18148	extinction	_	
102-84	18148-18149	:	_	
102-85	18150-18151	F	_	
102-86	18151-18152	=	_	
102-87	18152-18156	5.93	_	
102-88	18156-18157	,	_	
102-89	18158-18159	P	_	
102-90	18159-18160	=	_	
102-91	18160-18165	0.028	_	
102-92	18165-18166	,	_	
102-93	18167-18168	d	_	
102-94	18168-18169	=	_	
102-95	18169-18173	1.26	_	
102-96	18173-18174	;	_	
102-97	18175-18181	Figure	_	
102-98	18182-18184	S2	_	
102-99	18184-18185	)	_	
102-100	18185-18186	,	_	
102-101	18187-18190	but	_	
102-102	18191-18193	no	_	
102-103	18194-18205	significant	_	
102-104	18206-18216	diagnostic	_	
102-105	18217-18222	group	_	
102-106	18222-18223	,	_	
102-107	18224-18227	cue	_	
102-108	18228-18232	type	_	
102-109	18232-18233	,	_	
102-110	18234-18236	or	_	
102-111	18237-18248	interaction	_	
102-112	18249-18256	effects	_	
102-113	18257-18258	(	_	
102-114	18258-18259	F	_	
102-115	18259-18260	<	_	
102-116	18260-18264	0.77	_	
102-117	18264-18265	,	_	
102-118	18266-18267	P	_	
102-119	18267-18268	>	_	
102-120	18268-18272	0.47	_	
102-121	18272-18273	,	_	
102-122	18274-18275	d	_	
102-123	18275-18276	<	_	
102-124	18276-18280	0.45	_	
102-125	18280-18281	)	_	
102-126	18281-18282	.	_	

#Text=In addition, there were no differences between the groups in attention or subjective ratings/choice for the CSs (see Supporting Information and Figure S1C–D).
103-1	18283-18285	In	_	
103-2	18286-18294	addition	_	
103-3	18294-18295	,	_	
103-4	18296-18301	there	_	
103-5	18302-18306	were	_	
103-6	18307-18309	no	_	
103-7	18310-18321	differences	_	
103-8	18322-18329	between	_	
103-9	18330-18333	the	_	
103-10	18334-18340	groups	_	
103-11	18341-18343	in	_	
103-12	18344-18353	attention	_	
103-13	18354-18356	or	_	
103-14	18357-18367	subjective	_	
103-15	18368-18375	ratings	_	
103-16	18375-18376	/	_	
103-17	18376-18382	choice	_	
103-18	18383-18386	for	_	
103-19	18387-18390	the	_	
103-20	18391-18394	CSs	_	
103-21	18395-18396	(	_	
103-22	18396-18399	see	_	
103-23	18400-18410	Supporting	_	
103-24	18411-18422	Information	_	
103-25	18423-18426	and	_	
103-26	18427-18433	Figure	_	
103-27	18434-18439	S1C–D	_	
103-28	18439-18440	)	_	
103-29	18440-18441	.	_	

#Text=Neural Correlates of Extinction Learning for Drug and Pleasant Cue Associations
#Text=We hypothesized that, paralleling the SCR data, the striatum and VMPFC would show similar progressive increased or decreased activation over the learning phases as tested with 2×3×2 mixed ANOVAs on the differential BOLD responses (CSD+ and CSP+, both relative to the CS−) in each ROI, followed by linear contrasts specifically testing for this progression.
104-1	18442-18448	Neural	_	
104-2	18449-18459	Correlates	_	
104-3	18460-18462	of	_	
104-4	18463-18473	Extinction	_	
104-5	18474-18482	Learning	_	
104-6	18483-18486	for	_	
104-7	18487-18491	Drug	_	
104-8	18492-18495	and	_	
104-9	18496-18504	Pleasant	_	
104-10	18505-18508	Cue	_	
104-11	18509-18521	Associations	_	
104-12	18522-18524	We	_	
104-13	18525-18537	hypothesized	_	
104-14	18538-18542	that	_	
104-15	18542-18543	,	_	
104-16	18544-18555	paralleling	_	
104-17	18556-18559	the	_	
104-18	18560-18563	SCR	_	
104-19	18564-18568	data	_	
104-20	18568-18569	,	_	
104-21	18570-18573	the	_	
104-22	18574-18582	striatum	_	
104-23	18583-18586	and	_	
104-24	18587-18592	VMPFC	_	
104-25	18593-18598	would	_	
104-26	18599-18603	show	_	
104-27	18604-18611	similar	_	
104-28	18612-18623	progressive	_	
104-29	18624-18633	increased	_	
104-30	18634-18636	or	_	
104-31	18637-18646	decreased	_	
104-32	18647-18657	activation	_	
104-33	18658-18662	over	_	
104-34	18663-18666	the	_	
104-35	18667-18675	learning	_	
104-36	18676-18682	phases	_	
104-37	18683-18685	as	_	
104-38	18686-18692	tested	_	
104-39	18693-18697	with	_	
104-40	18698-18699	2	_	
104-41	18699-18700	×	_	
104-42	18700-18701	3	_	
104-43	18701-18702	×	_	
104-44	18702-18703	2	_	
104-45	18704-18709	mixed	_	
104-46	18710-18716	ANOVAs	_	
104-47	18717-18719	on	_	
104-48	18720-18723	the	_	
104-49	18724-18736	differential	_	
104-50	18737-18741	BOLD	_	
104-51	18742-18751	responses	_	
104-52	18752-18753	(	_	
104-53	18753-18756	CSD	_	
104-54	18756-18757	+	_	
104-55	18758-18761	and	_	
104-56	18762-18765	CSP	_	
104-57	18765-18766	+	_	
104-58	18766-18767	,	_	
104-59	18768-18772	both	_	
104-60	18773-18781	relative	_	
104-61	18782-18784	to	_	
104-62	18785-18788	the	_	
104-63	18789-18791	CS	_	
104-64	18791-18792	−	_	
104-65	18792-18793	)	_	
104-66	18794-18796	in	_	
104-67	18797-18801	each	_	
104-68	18802-18805	ROI	_	
104-69	18805-18806	,	_	
104-70	18807-18815	followed	_	
104-71	18816-18818	by	_	
104-72	18819-18825	linear	_	
104-73	18826-18835	contrasts	_	
104-74	18836-18848	specifically	_	
104-75	18849-18856	testing	_	
104-76	18857-18860	for	_	
104-77	18861-18865	this	_	
104-78	18866-18877	progression	_	
104-79	18877-18878	.	_	

#Text=The main finding we observed was a diagnostic group main effect (F1, 31=5.44, P=0.026, d=0.84) and a cue type × learning phase interaction in the left VMPFC (F1.37, 42.44=4.05, P=0.039, d=0.72), which were both qualified by a significant cue type × learning phase × group interaction (F2, 62=4.21, P=0.019, d=0.74; all other effects, P>0.31, d<0.37).
105-1	18879-18882	The	_	
105-2	18883-18887	main	_	
105-3	18888-18895	finding	_	
105-4	18896-18898	we	_	
105-5	18899-18907	observed	_	
105-6	18908-18911	was	_	
105-7	18912-18913	a	_	
105-8	18914-18924	diagnostic	_	
105-9	18925-18930	group	_	
105-10	18931-18935	main	_	
105-11	18936-18942	effect	_	
105-12	18943-18944	(	_	
105-13	18944-18946	F1	_	
105-14	18946-18947	,	_	
105-15	18948-18950	31	_	
105-16	18950-18951	=	_	
105-17	18951-18955	5.44	_	
105-18	18955-18956	,	_	
105-19	18957-18958	P	_	
105-20	18958-18959	=	_	
105-21	18959-18964	0.026	_	
105-22	18964-18965	,	_	
105-23	18966-18967	d	_	
105-24	18967-18968	=	_	
105-25	18968-18972	0.84	_	
105-26	18972-18973	)	_	
105-27	18974-18977	and	_	
105-28	18978-18979	a	_	
105-29	18980-18983	cue	_	
105-30	18984-18988	type	_	
105-31	18989-18990	×	_	
105-32	18991-18999	learning	_	
105-33	19000-19005	phase	_	
105-34	19006-19017	interaction	_	
105-35	19018-19020	in	_	
105-36	19021-19024	the	_	
105-37	19025-19029	left	_	
105-38	19030-19035	VMPFC	_	
105-39	19036-19037	(	_	
105-40	19037-19042	F1.37	_	
105-41	19042-19043	,	_	
105-42	19044-19049	42.44	_	
105-43	19049-19050	=	_	
105-44	19050-19054	4.05	_	
105-45	19054-19055	,	_	
105-46	19056-19057	P	_	
105-47	19057-19058	=	_	
105-48	19058-19063	0.039	_	
105-49	19063-19064	,	_	
105-50	19065-19066	d	_	
105-51	19066-19067	=	_	
105-52	19067-19071	0.72	_	
105-53	19071-19072	)	_	
105-54	19072-19073	,	_	
105-55	19074-19079	which	_	
105-56	19080-19084	were	_	
105-57	19085-19089	both	_	
105-58	19090-19099	qualified	_	
105-59	19100-19102	by	_	
105-60	19103-19104	a	_	
105-61	19105-19116	significant	_	
105-62	19117-19120	cue	_	
105-63	19121-19125	type	_	
105-64	19126-19127	×	_	
105-65	19128-19136	learning	_	
105-66	19137-19142	phase	_	
105-67	19143-19144	×	_	
105-68	19145-19150	group	_	
105-69	19151-19162	interaction	_	
105-70	19163-19164	(	_	
105-71	19164-19166	F2	_	
105-72	19166-19167	,	_	
105-73	19168-19170	62	_	
105-74	19170-19171	=	_	
105-75	19171-19175	4.21	_	
105-76	19175-19176	,	_	
105-77	19177-19178	P	_	
105-78	19178-19179	=	_	
105-79	19179-19184	0.019	_	
105-80	19184-19185	,	_	
105-81	19186-19187	d	_	
105-82	19187-19188	=	_	
105-83	19188-19192	0.74	_	
105-84	19192-19193	;	_	
105-85	19194-19197	all	_	
105-86	19198-19203	other	_	
105-87	19204-19211	effects	_	
105-88	19211-19212	,	_	
105-89	19213-19214	P	_	
105-90	19214-19215	>	_	
105-91	19215-19219	0.31	_	
105-92	19219-19220	,	_	
105-93	19221-19222	d	_	
105-94	19222-19223	<	_	
105-95	19223-19227	0.37	_	
105-96	19227-19228	)	_	
105-97	19228-19229	.	_	

#Text=A similar albeit statistically weaker pattern was observed in the right VMPFC (group main effect: F1, 31=4.47, P=0.043, d=0.76; cue type × learning phase interaction: F1.27, 39.47=3.07, P=0.054, d=0.63; cue type × learning phase × group interaction: F2, 62=1.94, P=0.15, d=0.50).
106-1	19230-19231	A	_	
106-2	19232-19239	similar	_	
106-3	19240-19246	albeit	_	
106-4	19247-19260	statistically	_	
106-5	19261-19267	weaker	_	
106-6	19268-19275	pattern	_	
106-7	19276-19279	was	_	
106-8	19280-19288	observed	_	
106-9	19289-19291	in	_	
106-10	19292-19295	the	_	
106-11	19296-19301	right	_	
106-12	19302-19307	VMPFC	_	
106-13	19308-19309	(	_	
106-14	19309-19314	group	_	
106-15	19315-19319	main	_	
106-16	19320-19326	effect	_	
106-17	19326-19327	:	_	
106-18	19328-19330	F1	_	
106-19	19330-19331	,	_	
106-20	19332-19334	31	_	
106-21	19334-19335	=	_	
106-22	19335-19339	4.47	_	
106-23	19339-19340	,	_	
106-24	19341-19342	P	_	
106-25	19342-19343	=	_	
106-26	19343-19348	0.043	_	
106-27	19348-19349	,	_	
106-28	19350-19351	d	_	
106-29	19351-19352	=	_	
106-30	19352-19356	0.76	_	
106-31	19356-19357	;	_	
106-32	19358-19361	cue	_	
106-33	19362-19366	type	_	
106-34	19367-19368	×	_	
106-35	19369-19377	learning	_	
106-36	19378-19383	phase	_	
106-37	19384-19395	interaction	_	
106-38	19395-19396	:	_	
106-39	19397-19402	F1.27	_	
106-40	19402-19403	,	_	
106-41	19404-19409	39.47	_	
106-42	19409-19410	=	_	
106-43	19410-19414	3.07	_	
106-44	19414-19415	,	_	
106-45	19416-19417	P	_	
106-46	19417-19418	=	_	
106-47	19418-19423	0.054	_	
106-48	19423-19424	,	_	
106-49	19425-19426	d	_	
106-50	19426-19427	=	_	
106-51	19427-19431	0.63	_	
106-52	19431-19432	;	_	
106-53	19433-19436	cue	_	
106-54	19437-19441	type	_	
106-55	19442-19443	×	_	
106-56	19444-19452	learning	_	
106-57	19453-19458	phase	_	
106-58	19459-19460	×	_	
106-59	19461-19466	group	_	
106-60	19467-19478	interaction	_	
106-61	19478-19479	:	_	
106-62	19480-19482	F2	_	
106-63	19482-19483	,	_	
106-64	19484-19486	62	_	
106-65	19486-19487	=	_	
106-66	19487-19491	1.94	_	
106-67	19491-19492	,	_	
106-68	19493-19494	P	_	
106-69	19494-19495	=	_	
106-70	19495-19499	0.15	_	
106-71	19499-19500	,	_	
106-72	19501-19502	d	_	
106-73	19502-19503	=	_	
106-74	19503-19507	0.50	_	
106-75	19507-19508	)	_	
106-76	19508-19509	.	_	

#Text=All other effects in the right VMPFC were non-significant (P>0.32, d<0.38).
107-1	19510-19513	All	_	
107-2	19514-19519	other	_	
107-3	19520-19527	effects	_	
107-4	19528-19530	in	_	
107-5	19531-19534	the	_	
107-6	19535-19540	right	_	
107-7	19541-19546	VMPFC	_	
107-8	19547-19551	were	_	
107-9	19552-19567	non-significant	_	
107-10	19568-19569	(	_	
107-11	19569-19570	P	_	
107-12	19570-19571	>	_	
107-13	19571-19575	0.32	_	
107-14	19575-19576	,	_	
107-15	19577-19578	d	_	
107-16	19578-19579	<	_	
107-17	19579-19583	0.38	_	
107-18	19583-19584	)	_	
107-19	19584-19585	.	_	

#Text=The three-way interaction in the left VMPFC was explained by differences over the learning phases in response to the CSD+ versus CSP+ in controls but not cocaine users (Figure 2A).
108-1	19586-19589	The	_	
108-2	19590-19599	three-way	_	
108-3	19600-19611	interaction	_	
108-4	19612-19614	in	_	
108-5	19615-19618	the	_	
108-6	19619-19623	left	_	
108-7	19624-19629	VMPFC	_	
108-8	19630-19633	was	_	
108-9	19634-19643	explained	_	
108-10	19644-19646	by	_	
108-11	19647-19658	differences	_	
108-12	19659-19663	over	_	
108-13	19664-19667	the	_	
108-14	19668-19676	learning	_	
108-15	19677-19683	phases	_	
108-16	19684-19686	in	_	
108-17	19687-19695	response	_	
108-18	19696-19698	to	_	
108-19	19699-19702	the	_	
108-20	19703-19706	CSD	_	
108-21	19706-19707	+	_	
108-22	19708-19714	versus	_	
108-23	19715-19718	CSP	_	
108-24	19718-19719	+	_	
108-25	19720-19722	in	_	
108-26	19723-19731	controls	_	
108-27	19732-19735	but	_	
108-28	19736-19739	not	_	
108-29	19740-19747	cocaine	_	
108-30	19748-19753	users	_	
108-31	19754-19755	(	_	
108-32	19755-19761	Figure	_	
108-33	19762-19764	2A	_	
108-34	19764-19765	)	_	
108-35	19765-19766	.	_	

#Text=As in fear extinction studies, in controls, VMPFC activation was higher during extinction for the CSD+ (which was rated as unpleasant).
109-1	19767-19769	As	_	
109-2	19770-19772	in	_	
109-3	19773-19777	fear	_	
109-4	19778-19788	extinction	_	
109-5	19789-19796	studies	_	
109-6	19796-19797	,	_	
109-7	19798-19800	in	_	
109-8	19801-19809	controls	_	
109-9	19809-19810	,	_	
109-10	19811-19816	VMPFC	_	
109-11	19817-19827	activation	_	
109-12	19828-19831	was	_	
109-13	19832-19838	higher	_	
109-14	19839-19845	during	_	
109-15	19846-19856	extinction	_	
109-16	19857-19860	for	_	
109-17	19861-19864	the	_	
109-18	19865-19868	CSD	_	
109-19	19868-19869	+	_	
109-20	19870-19871	(	_	
109-21	19871-19876	which	_	
109-22	19877-19880	was	_	
109-23	19881-19886	rated	_	
109-24	19887-19889	as	_	
109-25	19890-19900	unpleasant	_	
109-26	19900-19901	)	_	
109-27	19901-19902	.	_	

#Text=However, it was lower during extinction for the CSP+ (which was rated as pleasant; cue × learning phase interaction in controls: F1.32, 18.48=5.00, P=0.029, cue × learning phase linear effect: P=0.021).
110-1	19903-19910	However	_	
110-2	19910-19911	,	_	
110-3	19912-19914	it	_	
110-4	19915-19918	was	_	
110-5	19919-19924	lower	_	
110-6	19925-19931	during	_	
110-7	19932-19942	extinction	_	
110-8	19943-19946	for	_	
110-9	19947-19950	the	_	
110-10	19951-19954	CSP	_	
110-11	19954-19955	+	_	
110-12	19956-19957	(	_	
110-13	19957-19962	which	_	
110-14	19963-19966	was	_	
110-15	19967-19972	rated	_	
110-16	19973-19975	as	_	
110-17	19976-19984	pleasant	_	
110-18	19984-19985	;	_	
110-19	19986-19989	cue	_	
110-20	19990-19991	×	_	
110-21	19992-20000	learning	_	
110-22	20001-20006	phase	_	
110-23	20007-20018	interaction	_	
110-24	20019-20021	in	_	
110-25	20022-20030	controls	_	
110-26	20030-20031	:	_	
110-27	20032-20037	F1.32	_	
110-28	20037-20038	,	_	
110-29	20039-20044	18.48	_	
110-30	20044-20045	=	_	
110-31	20045-20049	5.00	_	
110-32	20049-20050	,	_	
110-33	20051-20052	P	_	
110-34	20052-20053	=	_	
110-35	20053-20058	0.029	_	
110-36	20058-20059	,	_	
110-37	20060-20063	cue	_	
110-38	20064-20065	×	_	
110-39	20066-20074	learning	_	
110-40	20075-20080	phase	_	
110-41	20081-20087	linear	_	
110-42	20088-20094	effect	_	
110-43	20094-20095	:	_	
110-44	20096-20097	P	_	
110-45	20097-20098	=	_	
110-46	20098-20103	0.021	_	
110-47	20103-20104	)	_	
110-48	20104-20105	.	_	

#Text=In contrast, in cocaine users, there was no such shift as extinction progressed (cue × learning phase interaction in the cocaine group: F1.44, 24.45=0.72, P=0.49).
111-1	20106-20108	In	_	
111-2	20109-20117	contrast	_	
111-3	20117-20118	,	_	
111-4	20119-20121	in	_	
111-5	20122-20129	cocaine	_	
111-6	20130-20135	users	_	
111-7	20135-20136	,	_	
111-8	20137-20142	there	_	
111-9	20143-20146	was	_	
111-10	20147-20149	no	_	
111-11	20150-20154	such	_	
111-12	20155-20160	shift	_	
111-13	20161-20163	as	_	
111-14	20164-20174	extinction	_	
111-15	20175-20185	progressed	_	
111-16	20186-20187	(	_	
111-17	20187-20190	cue	_	
111-18	20191-20192	×	_	
111-19	20193-20201	learning	_	
111-20	20202-20207	phase	_	
111-21	20208-20219	interaction	_	
111-22	20220-20222	in	_	
111-23	20223-20226	the	_	
111-24	20227-20234	cocaine	_	
111-25	20235-20240	group	_	
111-26	20240-20241	:	_	
111-27	20242-20247	F1.44	_	
111-28	20247-20248	,	_	
111-29	20249-20254	24.45	_	
111-30	20254-20255	=	_	
111-31	20255-20259	0.72	_	
111-32	20259-20260	,	_	
111-33	20261-20262	P	_	
111-34	20262-20263	=	_	
111-35	20263-20267	0.49	_	
111-36	20267-20268	)	_	
111-37	20268-20269	.	_	

#Text=See the Supporting Information for preliminary data showing that these VMPFC findings do not appear to be specific to the abstract image cues used in the present study but rather extend to alternate USs (i.e., gain of real money).
112-1	20270-20273	See	_	
112-2	20274-20277	the	_	
112-3	20278-20288	Supporting	_	
112-4	20289-20300	Information	_	
112-5	20301-20304	for	_	
112-6	20305-20316	preliminary	_	
112-7	20317-20321	data	_	
112-8	20322-20329	showing	_	
112-9	20330-20334	that	_	
112-10	20335-20340	these	_	
112-11	20341-20346	VMPFC	_	
112-12	20347-20355	findings	_	
112-13	20356-20358	do	_	
112-14	20359-20362	not	_	
112-15	20363-20369	appear	_	
112-16	20370-20372	to	_	
112-17	20373-20375	be	_	
112-18	20376-20384	specific	_	
112-19	20385-20387	to	_	
112-20	20388-20391	the	_	
112-21	20392-20400	abstract	_	
112-22	20401-20406	image	_	
112-23	20407-20411	cues	_	
112-24	20412-20416	used	_	
112-25	20417-20419	in	_	
112-26	20420-20423	the	_	
112-27	20424-20431	present	_	
112-28	20432-20437	study	_	
112-29	20438-20441	but	_	
112-30	20442-20448	rather	_	
112-31	20449-20455	extend	_	
112-32	20456-20458	to	_	
112-33	20459-20468	alternate	_	
112-34	20469-20472	USs	_	
112-35	20473-20474	(	_	
112-36	20474-20477	i.e	_	
112-37	20477-20478	.	_	
112-38	20478-20479	,	_	
112-39	20480-20484	gain	_	
112-40	20485-20487	of	_	
112-41	20488-20492	real	_	
112-42	20493-20498	money	_	
112-43	20498-20499	)	_	
112-44	20499-20500	.	_	

#Text=As in, we also tested the cross-day association between SCR and VMPFC activity.
113-1	20501-20503	As	_	
113-2	20504-20506	in	_	
113-3	20506-20507	,	_	
113-4	20508-20510	we	_	
113-5	20511-20515	also	_	
113-6	20516-20522	tested	_	
113-7	20523-20526	the	_	
113-8	20527-20536	cross-day	_	
113-9	20537-20548	association	_	
113-10	20549-20556	between	_	
113-11	20557-20560	SCR	_	
113-12	20561-20564	and	_	
113-13	20565-20570	VMPFC	_	
113-14	20571-20579	activity	_	
113-15	20579-20580	.	_	

#Text=The success of extinction learning on day 1, as indexed by a reduction in SCR (average SCR over the last half of day 1 extinction) to the CSD+ versus CS−, correlated with the magnitude of left VMPFC activation to the CSD+ versus CS− during day 2 extinction (n=25, RS=−0.45, P=0.025; Figure 2B) and neither group alone drove this effect.
114-1	20581-20584	The	_	
114-2	20585-20592	success	_	
114-3	20593-20595	of	_	
114-4	20596-20606	extinction	_	
114-5	20607-20615	learning	_	
114-6	20616-20618	on	_	
114-7	20619-20622	day	_	
114-8	20623-20624	1	_	
114-9	20624-20625	,	_	
114-10	20626-20628	as	_	
114-11	20629-20636	indexed	_	
114-12	20637-20639	by	_	
114-13	20640-20641	a	_	
114-14	20642-20651	reduction	_	
114-15	20652-20654	in	_	
114-16	20655-20658	SCR	_	
114-17	20659-20660	(	_	
114-18	20660-20667	average	_	
114-19	20668-20671	SCR	_	
114-20	20672-20676	over	_	
114-21	20677-20680	the	_	
114-22	20681-20685	last	_	
114-23	20686-20690	half	_	
114-24	20691-20693	of	_	
114-25	20694-20697	day	_	
114-26	20698-20699	1	_	
114-27	20700-20710	extinction	_	
114-28	20710-20711	)	_	
114-29	20712-20714	to	_	
114-30	20715-20718	the	_	
114-31	20719-20722	CSD	_	
114-32	20722-20723	+	_	
114-33	20724-20730	versus	_	
114-34	20731-20733	CS	_	
114-35	20733-20734	−	_	
114-36	20734-20735	,	_	
114-37	20736-20746	correlated	_	
114-38	20747-20751	with	_	
114-39	20752-20755	the	_	
114-40	20756-20765	magnitude	_	
114-41	20766-20768	of	_	
114-42	20769-20773	left	_	
114-43	20774-20779	VMPFC	_	
114-44	20780-20790	activation	_	
114-45	20791-20793	to	_	
114-46	20794-20797	the	_	
114-47	20798-20801	CSD	_	
114-48	20801-20802	+	_	
114-49	20803-20809	versus	_	
114-50	20810-20812	CS	_	
114-51	20812-20813	−	_	
114-52	20814-20820	during	_	
114-53	20821-20824	day	_	
114-54	20825-20826	2	_	
114-55	20827-20837	extinction	_	
114-56	20838-20839	(	_	
114-57	20839-20840	n	_	
114-58	20840-20841	=	_	
114-59	20841-20843	25	_	
114-60	20843-20844	,	_	
114-61	20845-20847	RS	_	
114-62	20847-20848	=	_	
114-63	20848-20849	−	_	
114-64	20849-20853	0.45	_	
114-65	20853-20854	,	_	
114-66	20855-20856	P	_	
114-67	20856-20857	=	_	
114-68	20857-20862	0.025	_	
114-69	20862-20863	;	_	
114-70	20864-20870	Figure	_	
114-71	20871-20873	2B	_	
114-72	20873-20874	)	_	
114-73	20875-20878	and	_	
114-74	20879-20886	neither	_	
114-75	20887-20892	group	_	
114-76	20893-20898	alone	_	
114-77	20899-20904	drove	_	
114-78	20905-20909	this	_	
114-79	20910-20916	effect	_	
114-80	20916-20917	.	_	

#Text=In cocaine users (n=14), this relationship was RS=−0.66, while in controls (n=11) it was RS=−0.44.
115-1	20918-20920	In	_	
115-2	20921-20928	cocaine	_	
115-3	20929-20934	users	_	
115-4	20935-20936	(	_	
115-5	20936-20937	n	_	
115-6	20937-20938	=	_	
115-7	20938-20940	14	_	
115-8	20940-20941	)	_	
115-9	20941-20942	,	_	
115-10	20943-20947	this	_	
115-11	20948-20960	relationship	_	
115-12	20961-20964	was	_	
115-13	20965-20967	RS	_	
115-14	20967-20968	=	_	
115-15	20968-20969	−	_	
115-16	20969-20973	0.66	_	
115-17	20973-20974	,	_	
115-18	20975-20980	while	_	
115-19	20981-20983	in	_	
115-20	20984-20992	controls	_	
115-21	20993-20994	(	_	
115-22	20994-20995	n	_	
115-23	20995-20996	=	_	
115-24	20996-20998	11	_	
115-25	20998-20999	)	_	
115-26	21000-21002	it	_	
115-27	21003-21006	was	_	
115-28	21007-21009	RS	_	
115-29	21009-21010	=	_	
115-30	21010-21011	−	_	
115-31	21011-21015	0.44	_	
115-32	21015-21016	.	_	

#Text=The relationship between SCR and right VMPFC activation was similar (RS=−0.39, P=0.053; cocaine users: RS=−0.57, controls: RS=−0.41), altogether showing the VMPFC might have a specific role in the retrieval of extinction learning for drug cues as previously found for fear.
116-1	21017-21020	The	_	
116-2	21021-21033	relationship	_	
116-3	21034-21041	between	_	
116-4	21042-21045	SCR	_	
116-5	21046-21049	and	_	
116-6	21050-21055	right	_	
116-7	21056-21061	VMPFC	_	
116-8	21062-21072	activation	_	
116-9	21073-21076	was	_	
116-10	21077-21084	similar	_	
116-11	21085-21086	(	_	
116-12	21086-21088	RS	_	
116-13	21088-21089	=	_	
116-14	21089-21090	−	_	
116-15	21090-21094	0.39	_	
116-16	21094-21095	,	_	
116-17	21096-21097	P	_	
116-18	21097-21098	=	_	
116-19	21098-21103	0.053	_	
116-20	21103-21104	;	_	
116-21	21105-21112	cocaine	_	
116-22	21113-21118	users	_	
116-23	21118-21119	:	_	
116-24	21120-21122	RS	_	
116-25	21122-21123	=	_	
116-26	21123-21124	−	_	
116-27	21124-21128	0.57	_	
116-28	21128-21129	,	_	
116-29	21130-21138	controls	_	
116-30	21138-21139	:	_	
116-31	21140-21142	RS	_	
116-32	21142-21143	=	_	
116-33	21143-21144	−	_	
116-34	21144-21148	0.41	_	
116-35	21148-21149	)	_	
116-36	21149-21150	,	_	
116-37	21151-21161	altogether	_	
116-38	21162-21169	showing	_	
116-39	21170-21173	the	_	
116-40	21174-21179	VMPFC	_	
116-41	21180-21185	might	_	
116-42	21186-21190	have	_	
116-43	21191-21192	a	_	
116-44	21193-21201	specific	_	
116-45	21202-21206	role	_	
116-46	21207-21209	in	_	
116-47	21210-21213	the	_	
116-48	21214-21223	retrieval	_	
116-49	21224-21226	of	_	
116-50	21227-21237	extinction	_	
116-51	21238-21246	learning	_	
116-52	21247-21250	for	_	
116-53	21251-21255	drug	_	
116-54	21256-21260	cues	_	
116-55	21261-21263	as	_	
116-56	21264-21274	previously	_	
116-57	21275-21280	found	_	
116-58	21281-21284	for	_	
116-59	21285-21289	fear	_	
116-60	21289-21290	.	_	

#Text=Finally, supporting a role for the striatum in extinction learning, but not supporting our hypothesis of group differences, we observed a significant cue × learning phase interaction in this region (F2, 62=7.97, P=0.001, d=1.01) and no significant diagnostic group or additional interaction effects (all F<0.61, P>0.54, d<0.28).
117-1	21291-21298	Finally	_	
117-2	21298-21299	,	_	
117-3	21300-21310	supporting	_	
117-4	21311-21312	a	_	
117-5	21313-21317	role	_	
117-6	21318-21321	for	_	
117-7	21322-21325	the	_	
117-8	21326-21334	striatum	_	
117-9	21335-21337	in	_	
117-10	21338-21348	extinction	_	
117-11	21349-21357	learning	_	
117-12	21357-21358	,	_	
117-13	21359-21362	but	_	
117-14	21363-21366	not	_	
117-15	21367-21377	supporting	_	
117-16	21378-21381	our	_	
117-17	21382-21392	hypothesis	_	
117-18	21393-21395	of	_	
117-19	21396-21401	group	_	
117-20	21402-21413	differences	_	
117-21	21413-21414	,	_	
117-22	21415-21417	we	_	
117-23	21418-21426	observed	_	
117-24	21427-21428	a	_	
117-25	21429-21440	significant	_	
117-26	21441-21444	cue	_	
117-27	21445-21446	×	_	
117-28	21447-21455	learning	_	
117-29	21456-21461	phase	_	
117-30	21462-21473	interaction	_	
117-31	21474-21476	in	_	
117-32	21477-21481	this	_	
117-33	21482-21488	region	_	
117-34	21489-21490	(	_	
117-35	21490-21492	F2	_	
117-36	21492-21493	,	_	
117-37	21494-21496	62	_	
117-38	21496-21497	=	_	
117-39	21497-21501	7.97	_	
117-40	21501-21502	,	_	
117-41	21503-21504	P	_	
117-42	21504-21505	=	_	
117-43	21505-21510	0.001	_	
117-44	21510-21511	,	_	
117-45	21512-21513	d	_	
117-46	21513-21514	=	_	
117-47	21514-21518	1.01	_	
117-48	21518-21519	)	_	
117-49	21520-21523	and	_	
117-50	21524-21526	no	_	
117-51	21527-21538	significant	_	
117-52	21539-21549	diagnostic	_	
117-53	21550-21555	group	_	
117-54	21556-21558	or	_	
117-55	21559-21569	additional	_	
117-56	21570-21581	interaction	_	
117-57	21582-21589	effects	_	
117-58	21590-21591	(	_	
117-59	21591-21594	all	_	
117-60	21595-21596	F	_	
117-61	21596-21597	<	_	
117-62	21597-21601	0.61	_	
117-63	21601-21602	,	_	
117-64	21603-21604	P	_	
117-65	21604-21605	>	_	
117-66	21605-21609	0.54	_	
117-67	21609-21610	,	_	
117-68	21611-21612	d	_	
117-69	21612-21613	<	_	
117-70	21613-21617	0.28	_	
117-71	21617-21618	)	_	
117-72	21618-21619	.	_	

#Text=Similar to findings in the VMPFC, the two-way interaction was explained by higher striatum activation to the CSD+ but lower activation to the CSP+ during extinction relative to acquisition (cue × learning phase linear effect: P=0.003; Figure 3).
118-1	21620-21627	Similar	_	
118-2	21628-21630	to	_	
118-3	21631-21639	findings	_	
118-4	21640-21642	in	_	
118-5	21643-21646	the	_	
118-6	21647-21652	VMPFC	_	
118-7	21652-21653	,	_	
118-8	21654-21657	the	_	
118-9	21658-21665	two-way	_	
118-10	21666-21677	interaction	_	
118-11	21678-21681	was	_	
118-12	21682-21691	explained	_	
118-13	21692-21694	by	_	
118-14	21695-21701	higher	_	
118-15	21702-21710	striatum	_	
118-16	21711-21721	activation	_	
118-17	21722-21724	to	_	
118-18	21725-21728	the	_	
118-19	21729-21732	CSD	_	
118-20	21732-21733	+	_	
118-21	21734-21737	but	_	
118-22	21738-21743	lower	_	
118-23	21744-21754	activation	_	
118-24	21755-21757	to	_	
118-25	21758-21761	the	_	
118-26	21762-21765	CSP	_	
118-27	21765-21766	+	_	
118-28	21767-21773	during	_	
118-29	21774-21784	extinction	_	
118-30	21785-21793	relative	_	
118-31	21794-21796	to	_	
118-32	21797-21808	acquisition	_	
118-33	21809-21810	(	_	
118-34	21810-21813	cue	_	
118-35	21814-21815	×	_	
118-36	21816-21824	learning	_	
118-37	21825-21830	phase	_	
118-38	21831-21837	linear	_	
118-39	21838-21844	effect	_	
118-40	21844-21845	:	_	
118-41	21846-21847	P	_	
118-42	21847-21848	=	_	
118-43	21848-21853	0.003	_	
118-44	21853-21854	;	_	
118-45	21855-21861	Figure	_	
118-46	21862-21863	3	_	
118-47	21863-21864	)	_	
118-48	21864-21865	.	_	

#Text=There was no significant correlation with SCR for either day 1 or day 2 extinction (RS<0.22, P>0.31).
119-1	21866-21871	There	_	
119-2	21872-21875	was	_	
119-3	21876-21878	no	_	
119-4	21879-21890	significant	_	
119-5	21891-21902	correlation	_	
119-6	21903-21907	with	_	
119-7	21908-21911	SCR	_	
119-8	21912-21915	for	_	
119-9	21916-21922	either	_	
119-10	21923-21926	day	_	
119-11	21927-21928	1	_	
119-12	21929-21931	or	_	
119-13	21932-21935	day	_	
119-14	21936-21937	2	_	
119-15	21938-21948	extinction	_	
119-16	21949-21950	(	_	
119-17	21950-21952	RS	_	
119-18	21952-21953	<	_	
119-19	21953-21957	0.22	_	
119-20	21957-21958	,	_	
119-21	21959-21960	P	_	
119-22	21960-21961	>	_	
119-23	21961-21965	0.31	_	
119-24	21965-21966	)	_	
119-25	21966-21967	.	_	

#Text=See Tables S1–S2 and Figures S3–S4 for results of whole-brain analyses and the Supporting Information for control region analyses.
120-1	21968-21971	See	_	
120-2	21972-21978	Tables	_	
120-3	21979-21981	S1	_	
120-4	21981-21982	–	_	
120-5	21982-21984	S2	_	
120-6	21985-21988	and	_	
120-7	21989-21996	Figures	_	
120-8	21997-21999	S3	_	
120-9	21999-22000	–	_	
120-10	22000-22002	S4	_	
120-11	22003-22006	for	_	
120-12	22007-22014	results	_	
120-13	22015-22017	of	_	
120-14	22018-22029	whole-brain	_	
120-15	22030-22038	analyses	_	
120-16	22039-22042	and	_	
120-17	22043-22046	the	_	
120-18	22047-22057	Supporting	_	
120-19	22058-22069	Information	_	
120-20	22070-22073	for	_	
120-21	22074-22081	control	_	
120-22	22082-22088	region	_	
120-23	22089-22097	analyses	_	
120-24	22097-22098	.	_	

#Text=In addition to providing independent support for our ROI findings, the whole-brain analyses showed additional involvement of the amygdala and parahippocampal gyrus, among other regions such as the inferior frontal gyrus and sensory cortices, during extinction learning, and as expected, no significant differential task modulation or task condition by diagnostic group interactions in our negative control (auditory cortex) region.
121-1	22099-22101	In	_	
121-2	22102-22110	addition	_	
121-3	22111-22113	to	_	
121-4	22114-22123	providing	_	
121-5	22124-22135	independent	_	
121-6	22136-22143	support	_	
121-7	22144-22147	for	_	
121-8	22148-22151	our	_	
121-9	22152-22155	ROI	_	
121-10	22156-22164	findings	_	
121-11	22164-22165	,	_	
121-12	22166-22169	the	_	
121-13	22170-22181	whole-brain	_	
121-14	22182-22190	analyses	_	
121-15	22191-22197	showed	_	
121-16	22198-22208	additional	_	
121-17	22209-22220	involvement	_	
121-18	22221-22223	of	_	
121-19	22224-22227	the	_	
121-20	22228-22236	amygdala	_	
121-21	22237-22240	and	_	
121-22	22241-22256	parahippocampal	_	
121-23	22257-22262	gyrus	_	
121-24	22262-22263	,	_	
121-25	22264-22269	among	_	
121-26	22270-22275	other	_	
121-27	22276-22283	regions	_	
121-28	22284-22288	such	_	
121-29	22289-22291	as	_	
121-30	22292-22295	the	_	
121-31	22296-22304	inferior	_	
121-32	22305-22312	frontal	_	
121-33	22313-22318	gyrus	_	
121-34	22319-22322	and	_	
121-35	22323-22330	sensory	_	
121-36	22331-22339	cortices	_	
121-37	22339-22340	,	_	
121-38	22341-22347	during	_	
121-39	22348-22358	extinction	_	
121-40	22359-22367	learning	_	
121-41	22367-22368	,	_	
121-42	22369-22372	and	_	
121-43	22373-22375	as	_	
121-44	22376-22384	expected	_	
121-45	22384-22385	,	_	
121-46	22386-22388	no	_	
121-47	22389-22400	significant	_	
121-48	22401-22413	differential	_	
121-49	22414-22418	task	_	
121-50	22419-22429	modulation	_	
121-51	22430-22432	or	_	
121-52	22433-22437	task	_	
121-53	22438-22447	condition	_	
121-54	22448-22450	by	_	
121-55	22451-22461	diagnostic	_	
121-56	22462-22467	group	_	
121-57	22468-22480	interactions	_	
121-58	22481-22483	in	_	
121-59	22484-22487	our	_	
121-60	22488-22496	negative	_	
121-61	22497-22504	control	_	
121-62	22505-22506	(	_	
121-63	22506-22514	auditory	_	
121-64	22515-22521	cortex	_	
121-65	22521-22522	)	_	
121-66	22523-22529	region	_	
121-67	22529-22530	.	_	

#Text=Finally, because a subset (n=6 on day 1 and n=4 on day 2) of participants tested positive for cocaine, indicating recent (≤72 h) exposure to the drug, we also tested whether cocaine urine status had any bearing on our main results.
122-1	22531-22538	Finally	_	
122-2	22538-22539	,	_	
122-3	22540-22547	because	_	
122-4	22548-22549	a	_	
122-5	22550-22556	subset	_	
122-6	22557-22558	(	_	
122-7	22558-22559	n	_	
122-8	22559-22560	=	_	
122-9	22560-22561	6	_	
122-10	22562-22564	on	_	
122-11	22565-22568	day	_	
122-12	22569-22570	1	_	
122-13	22571-22574	and	_	
122-14	22575-22576	n	_	
122-15	22576-22577	=	_	
122-16	22577-22578	4	_	
122-17	22579-22581	on	_	
122-18	22582-22585	day	_	
122-19	22586-22587	2	_	
122-20	22587-22588	)	_	
122-21	22589-22591	of	_	
122-22	22592-22604	participants	_	
122-23	22605-22611	tested	_	
122-24	22612-22620	positive	_	
122-25	22621-22624	for	_	
122-26	22625-22632	cocaine	_	
122-27	22632-22633	,	_	
122-28	22634-22644	indicating	_	
122-29	22645-22651	recent	_	
122-30	22652-22653	(	_	
122-31	22653-22654	≤	_	
122-32	22654-22656	72	_	
122-33	22657-22658	h	_	
122-34	22658-22659	)	_	
122-35	22660-22668	exposure	_	
122-36	22669-22671	to	_	
122-37	22672-22675	the	_	
122-38	22676-22680	drug	_	
122-39	22680-22681	,	_	
122-40	22682-22684	we	_	
122-41	22685-22689	also	_	
122-42	22690-22696	tested	_	
122-43	22697-22704	whether	_	
122-44	22705-22712	cocaine	_	
122-45	22713-22718	urine	_	
122-46	22719-22725	status	_	
122-47	22726-22729	had	_	
122-48	22730-22733	any	_	
122-49	22734-22741	bearing	_	
122-50	22742-22744	on	_	
122-51	22745-22748	our	_	
122-52	22749-22753	main	_	
122-53	22754-22761	results	_	
122-54	22761-22762	.	_	

#Text=The linear learning phase main effect on SCR, the cue type × learning phase × group interaction in the left VMPFC, and the cue type × learning phase interaction in the striatum all remained significant when we excluded the n=4 participants who were cocaine positive on both study days (P<0.038).
123-1	22763-22766	The	_	
123-2	22767-22773	linear	_	
123-3	22774-22782	learning	_	
123-4	22783-22788	phase	_	
123-5	22789-22793	main	_	
123-6	22794-22800	effect	_	
123-7	22801-22803	on	_	
123-8	22804-22807	SCR	_	
123-9	22807-22808	,	_	
123-10	22809-22812	the	_	
123-11	22813-22816	cue	_	
123-12	22817-22821	type	_	
123-13	22822-22823	×	_	
123-14	22824-22832	learning	_	
123-15	22833-22838	phase	_	
123-16	22839-22840	×	_	
123-17	22841-22846	group	_	
123-18	22847-22858	interaction	_	
123-19	22859-22861	in	_	
123-20	22862-22865	the	_	
123-21	22866-22870	left	_	
123-22	22871-22876	VMPFC	_	
123-23	22876-22877	,	_	
123-24	22878-22881	and	_	
123-25	22882-22885	the	_	
123-26	22886-22889	cue	_	
123-27	22890-22894	type	_	
123-28	22895-22896	×	_	
123-29	22897-22905	learning	_	
123-30	22906-22911	phase	_	
123-31	22912-22923	interaction	_	
123-32	22924-22926	in	_	
123-33	22927-22930	the	_	
123-34	22931-22939	striatum	_	
123-35	22940-22943	all	_	
123-36	22944-22952	remained	_	
123-37	22953-22964	significant	_	
123-38	22965-22969	when	_	
123-39	22970-22972	we	_	
123-40	22973-22981	excluded	_	
123-41	22982-22985	the	_	
123-42	22986-22987	n	_	
123-43	22987-22988	=	_	
123-44	22988-22989	4	_	
123-45	22990-23002	participants	_	
123-46	23003-23006	who	_	
123-47	23007-23011	were	_	
123-48	23012-23019	cocaine	_	
123-49	23020-23028	positive	_	
123-50	23029-23031	on	_	
123-51	23032-23036	both	_	
123-52	23037-23042	study	_	
123-53	23043-23047	days	_	
123-54	23048-23049	(	_	
123-55	23049-23050	P	_	
123-56	23050-23051	<	_	
123-57	23051-23056	0.038	_	
123-58	23056-23057	)	_	
123-59	23057-23058	.	_	

#Text=SCR and activation in the two ROIs also did not differ by cocaine urine status (positive/negative) at acquisition and day 1 extinction (n=6 vs. n=12, respectively; P>0.066) or day 2 extinction (n=4 vs. n=14, respectively; P>0.084).
124-1	23059-23062	SCR	_	
124-2	23063-23066	and	_	
124-3	23067-23077	activation	_	
124-4	23078-23080	in	_	
124-5	23081-23084	the	_	
124-6	23085-23088	two	_	
124-7	23089-23093	ROIs	_	
124-8	23094-23098	also	_	
124-9	23099-23102	did	_	
124-10	23103-23106	not	_	
124-11	23107-23113	differ	_	
124-12	23114-23116	by	_	
124-13	23117-23124	cocaine	_	
124-14	23125-23130	urine	_	
124-15	23131-23137	status	_	
124-16	23138-23139	(	_	
124-17	23139-23147	positive	_	
124-18	23147-23148	/	_	
124-19	23148-23156	negative	_	
124-20	23156-23157	)	_	
124-21	23158-23160	at	_	
124-22	23161-23172	acquisition	_	
124-23	23173-23176	and	_	
124-24	23177-23180	day	_	
124-25	23181-23182	1	_	
124-26	23183-23193	extinction	_	
124-27	23194-23195	(	_	
124-28	23195-23196	n	_	
124-29	23196-23197	=	_	
124-30	23197-23198	6	_	
124-31	23199-23201	vs	_	
124-32	23201-23202	.	_	
124-33	23203-23204	n	_	
124-34	23204-23205	=	_	
124-35	23205-23207	12	_	
124-36	23207-23208	,	_	
124-37	23209-23221	respectively	_	
124-38	23221-23222	;	_	
124-39	23223-23224	P	_	
124-40	23224-23225	>	_	
124-41	23225-23230	0.066	_	
124-42	23230-23231	)	_	
124-43	23232-23234	or	_	
124-44	23235-23238	day	_	
124-45	23239-23240	2	_	
124-46	23241-23251	extinction	_	
124-47	23252-23253	(	_	
124-48	23253-23254	n	_	
124-49	23254-23255	=	_	
124-50	23255-23256	4	_	
124-51	23257-23259	vs	_	
124-52	23259-23260	.	_	
124-53	23261-23262	n	_	
124-54	23262-23263	=	_	
124-55	23263-23265	14	_	
124-56	23265-23266	,	_	
124-57	23267-23279	respectively	_	
124-58	23279-23280	;	_	
124-59	23281-23282	P	_	
124-60	23282-23283	>	_	
124-61	23283-23288	0.084	_	
124-62	23288-23289	)	_	
124-63	23289-23290	.	_	

#Text=These control analyses suggest that the effects of recent cocaine use are not likely to have confounded those of diagnosis.
125-1	23291-23296	These	_	
125-2	23297-23304	control	_	
125-3	23305-23313	analyses	_	
125-4	23314-23321	suggest	_	
125-5	23322-23326	that	_	
125-6	23327-23330	the	_	
125-7	23331-23338	effects	_	
125-8	23339-23341	of	_	
125-9	23342-23348	recent	_	
125-10	23349-23356	cocaine	_	
125-11	23357-23360	use	_	
125-12	23361-23364	are	_	
125-13	23365-23368	not	_	
125-14	23369-23375	likely	_	
125-15	23376-23378	to	_	
125-16	23379-23383	have	_	
125-17	23384-23394	confounded	_	
125-18	23395-23400	those	_	
125-19	23401-23403	of	_	
125-20	23404-23413	diagnosis	_	
125-21	23413-23414	.	_	

#Text=Relationship to Craving
#Text=Given its role in cue-induced craving, we tested whether VMPFC activation during extinction correlated with participants’ current and past 24 h desire for cocaine, including that triggered by drug-related cues (total craving score; Table 1).
126-1	23415-23427	Relationship	_	
126-2	23428-23430	to	_	
126-3	23431-23438	Craving	_	
126-4	23439-23444	Given	_	
126-5	23445-23448	its	_	
126-6	23449-23453	role	_	
126-7	23454-23456	in	_	
126-8	23457-23468	cue-induced	_	
126-9	23469-23476	craving	_	
126-10	23476-23477	,	_	
126-11	23478-23480	we	_	
126-12	23481-23487	tested	_	
126-13	23488-23495	whether	_	
126-14	23496-23501	VMPFC	_	
126-15	23502-23512	activation	_	
126-16	23513-23519	during	_	
126-17	23520-23530	extinction	_	
126-18	23531-23541	correlated	_	
126-19	23542-23546	with	_	
126-20	23547-23559	participants	_	
126-21	23559-23560	’	_	
126-22	23561-23568	current	_	
126-23	23569-23572	and	_	
126-24	23573-23577	past	_	
126-25	23578-23580	24	_	
126-26	23581-23582	h	_	
126-27	23583-23589	desire	_	
126-28	23590-23593	for	_	
126-29	23594-23601	cocaine	_	
126-30	23601-23602	,	_	
126-31	23603-23612	including	_	
126-32	23613-23617	that	_	
126-33	23618-23627	triggered	_	
126-34	23628-23630	by	_	
126-35	23631-23643	drug-related	_	
126-36	23644-23648	cues	_	
126-37	23649-23650	(	_	
126-38	23650-23655	total	_	
126-39	23656-23663	craving	_	
126-40	23664-23669	score	_	
126-41	23669-23670	;	_	
126-42	23671-23676	Table	_	
126-43	23677-23678	1	_	
126-44	23678-23679	)	_	
126-45	23679-23680	.	_	

#Text=Those cocaine users with higher VMPFC activation to the CSD+ versus CS− during day 1 extinction (i.e., who looked more like controls) reported a greater reduction in craving on day 2 relative to day 1 (R=−0.49, P=0.04; Figure 4), as driven by the relationship to day 2 craving (R=−0.53, P=0.02; day 1 craving: R=−0.26, P=0.29).
127-1	23681-23686	Those	_	
127-2	23687-23694	cocaine	_	
127-3	23695-23700	users	_	
127-4	23701-23705	with	_	
127-5	23706-23712	higher	_	
127-6	23713-23718	VMPFC	_	
127-7	23719-23729	activation	_	
127-8	23730-23732	to	_	
127-9	23733-23736	the	_	
127-10	23737-23740	CSD	_	
127-11	23740-23741	+	_	
127-12	23742-23748	versus	_	
127-13	23749-23751	CS	_	
127-14	23751-23752	−	_	
127-15	23753-23759	during	_	
127-16	23760-23763	day	_	
127-17	23764-23765	1	_	
127-18	23766-23776	extinction	_	
127-19	23777-23778	(	_	
127-20	23778-23781	i.e	_	
127-21	23781-23782	.	_	
127-22	23782-23783	,	_	
127-23	23784-23787	who	_	
127-24	23788-23794	looked	_	
127-25	23795-23799	more	_	
127-26	23800-23804	like	_	
127-27	23805-23813	controls	_	
127-28	23813-23814	)	_	
127-29	23815-23823	reported	_	
127-30	23824-23825	a	_	
127-31	23826-23833	greater	_	
127-32	23834-23843	reduction	_	
127-33	23844-23846	in	_	
127-34	23847-23854	craving	_	
127-35	23855-23857	on	_	
127-36	23858-23861	day	_	
127-37	23862-23863	2	_	
127-38	23864-23872	relative	_	
127-39	23873-23875	to	_	
127-40	23876-23879	day	_	
127-41	23880-23881	1	_	
127-42	23882-23883	(	_	
127-43	23883-23884	R	_	
127-44	23884-23885	=	_	
127-45	23885-23886	−	_	
127-46	23886-23890	0.49	_	
127-47	23890-23891	,	_	
127-48	23892-23893	P	_	
127-49	23893-23894	=	_	
127-50	23894-23898	0.04	_	
127-51	23898-23899	;	_	
127-52	23900-23906	Figure	_	
127-53	23907-23908	4	_	
127-54	23908-23909	)	_	
127-55	23909-23910	,	_	
127-56	23911-23913	as	_	
127-57	23914-23920	driven	_	
127-58	23921-23923	by	_	
127-59	23924-23927	the	_	
127-60	23928-23940	relationship	_	
127-61	23941-23943	to	_	
127-62	23944-23947	day	_	
127-63	23948-23949	2	_	
127-64	23950-23957	craving	_	
127-65	23958-23959	(	_	
127-66	23959-23960	R	_	
127-67	23960-23961	=	_	
127-68	23961-23962	−	_	
127-69	23962-23966	0.53	_	
127-70	23966-23967	,	_	
127-71	23968-23969	P	_	
127-72	23969-23970	=	_	
127-73	23970-23974	0.02	_	
127-74	23974-23975	;	_	
127-75	23976-23979	day	_	
127-76	23980-23981	1	_	
127-77	23982-23989	craving	_	
127-78	23989-23990	:	_	
127-79	23991-23992	R	_	
127-80	23992-23993	=	_	
127-81	23993-23994	−	_	
127-82	23994-23998	0.26	_	
127-83	23998-23999	,	_	
127-84	24000-24001	P	_	
127-85	24001-24002	=	_	
127-86	24002-24006	0.29	_	
127-87	24006-24007	)	_	
127-88	24007-24008	.	_	

#Text=Discussion
#Text=Extinction of fear critically depends on the VMPFC.
128-1	24009-24019	Discussion	_	
128-2	24020-24030	Extinction	_	
128-3	24031-24033	of	_	
128-4	24034-24038	fear	_	
128-5	24039-24049	critically	_	
128-6	24050-24057	depends	_	
128-7	24058-24060	on	_	
128-8	24061-24064	the	_	
128-9	24065-24070	VMPFC	_	
128-10	24070-24071	.	_	

#Text=Here we show that this same region plays a role also in extinction of drug cue associations.
129-1	24072-24076	Here	_	
129-2	24077-24079	we	_	
129-3	24080-24084	show	_	
129-4	24085-24089	that	_	
129-5	24090-24094	this	_	
129-6	24095-24099	same	_	
129-7	24100-24106	region	_	
129-8	24107-24112	plays	_	
129-9	24113-24114	a	_	
129-10	24115-24119	role	_	
129-11	24120-24124	also	_	
129-12	24125-24127	in	_	
129-13	24128-24138	extinction	_	
129-14	24139-24141	of	_	
129-15	24142-24146	drug	_	
129-16	24147-24150	cue	_	
129-17	24151-24163	associations	_	
129-18	24163-24164	.	_	

#Text=During extinction learning, VMPFC response to the CSD+ (cue associated with the drug-related image) increased, while psychophysiological arousal decreased.
130-1	24165-24171	During	_	
130-2	24172-24182	extinction	_	
130-3	24183-24191	learning	_	
130-4	24191-24192	,	_	
130-5	24193-24198	VMPFC	_	
130-6	24199-24207	response	_	
130-7	24208-24210	to	_	
130-8	24211-24214	the	_	
130-9	24215-24218	CSD	_	
130-10	24218-24219	+	_	
130-11	24220-24221	(	_	
130-12	24221-24224	cue	_	
130-13	24225-24235	associated	_	
130-14	24236-24240	with	_	
130-15	24241-24244	the	_	
130-16	24245-24257	drug-related	_	
130-17	24258-24263	image	_	
130-18	24263-24264	)	_	
130-19	24265-24274	increased	_	
130-20	24274-24275	,	_	
130-21	24276-24281	while	_	
130-22	24282-24301	psychophysiological	_	
130-23	24302-24309	arousal	_	
130-24	24310-24319	decreased	_	
130-25	24319-24320	.	_	

#Text=These two measures were correlated such that participants who showed the most success in extinguishing arousal responses to the CSD+ on day 1 also showed the greatest VMPFC increases to the CSD+ on day 2, presumably when extinction learning from day 1 is recalled.
131-1	24321-24326	These	_	
131-2	24327-24330	two	_	
131-3	24331-24339	measures	_	
131-4	24340-24344	were	_	
131-5	24345-24355	correlated	_	
131-6	24356-24360	such	_	
131-7	24361-24365	that	_	
131-8	24366-24378	participants	_	
131-9	24379-24382	who	_	
131-10	24383-24389	showed	_	
131-11	24390-24393	the	_	
131-12	24394-24398	most	_	
131-13	24399-24406	success	_	
131-14	24407-24409	in	_	
131-15	24410-24423	extinguishing	_	
131-16	24424-24431	arousal	_	
131-17	24432-24441	responses	_	
131-18	24442-24444	to	_	
131-19	24445-24448	the	_	
131-20	24449-24452	CSD	_	
131-21	24452-24453	+	_	
131-22	24454-24456	on	_	
131-23	24457-24460	day	_	
131-24	24461-24462	1	_	
131-25	24463-24467	also	_	
131-26	24468-24474	showed	_	
131-27	24475-24478	the	_	
131-28	24479-24487	greatest	_	
131-29	24488-24493	VMPFC	_	
131-30	24494-24503	increases	_	
131-31	24504-24506	to	_	
131-32	24507-24510	the	_	
131-33	24511-24514	CSD	_	
131-34	24514-24515	+	_	
131-35	24516-24518	on	_	
131-36	24519-24522	day	_	
131-37	24523-24524	2	_	
131-38	24524-24525	,	_	
131-39	24526-24536	presumably	_	
131-40	24537-24541	when	_	
131-41	24542-24552	extinction	_	
131-42	24553-24561	learning	_	
131-43	24562-24566	from	_	
131-44	24567-24570	day	_	
131-45	24571-24572	1	_	
131-46	24573-24575	is	_	
131-47	24576-24584	recalled	_	
131-48	24584-24585	.	_	

#Text=While a similar (increased) VMPFC activation is observed in fear extinction studies, VMPFC response to the CSP+ (cue associated with the affectively pleasant image) and an alternate appetitive CS (cue associated with monetary gain; see Supporting Information) instead decreased during extinction learning, consistent with a value updating process.
132-1	24586-24591	While	_	
132-2	24592-24593	a	_	
132-3	24594-24601	similar	_	
132-4	24602-24603	(	_	
132-5	24603-24612	increased	_	
132-6	24612-24613	)	_	
132-7	24614-24619	VMPFC	_	
132-8	24620-24630	activation	_	
132-9	24631-24633	is	_	
132-10	24634-24642	observed	_	
132-11	24643-24645	in	_	
132-12	24646-24650	fear	_	
132-13	24651-24661	extinction	_	
132-14	24662-24669	studies	_	
132-15	24669-24670	,	_	
132-16	24671-24676	VMPFC	_	
132-17	24677-24685	response	_	
132-18	24686-24688	to	_	
132-19	24689-24692	the	_	
132-20	24693-24696	CSP	_	
132-21	24696-24697	+	_	
132-22	24698-24699	(	_	
132-23	24699-24702	cue	_	
132-24	24703-24713	associated	_	
132-25	24714-24718	with	_	
132-26	24719-24722	the	_	
132-27	24723-24734	affectively	_	
132-28	24735-24743	pleasant	_	
132-29	24744-24749	image	_	
132-30	24749-24750	)	_	
132-31	24751-24754	and	_	
132-32	24755-24757	an	_	
132-33	24758-24767	alternate	_	
132-34	24768-24778	appetitive	_	
132-35	24779-24781	CS	_	
132-36	24782-24783	(	_	
132-37	24783-24786	cue	_	
132-38	24787-24797	associated	_	
132-39	24798-24802	with	_	
132-40	24803-24811	monetary	_	
132-41	24812-24816	gain	_	
132-42	24816-24817	;	_	
132-43	24818-24821	see	_	
132-44	24822-24832	Supporting	_	
132-45	24833-24844	Information	_	
132-46	24844-24845	)	_	
132-47	24846-24853	instead	_	
132-48	24854-24863	decreased	_	
132-49	24864-24870	during	_	
132-50	24871-24881	extinction	_	
132-51	24882-24890	learning	_	
132-52	24890-24891	,	_	
132-53	24892-24902	consistent	_	
132-54	24903-24907	with	_	
132-55	24908-24909	a	_	
132-56	24910-24915	value	_	
132-57	24916-24924	updating	_	
132-58	24925-24932	process	_	
132-59	24932-24933	.	_	

#Text=Finally, while controls showed these distinct VMPFC response profiles, cocaine-addicted individuals, who manifest deficits in the VMPFC, did not, suggesting that the VMPFC, when intact, supports extinction learning in diverse contexts including of drug cue and pleasant associations.
133-1	24934-24941	Finally	_	
133-2	24941-24942	,	_	
133-3	24943-24948	while	_	
133-4	24949-24957	controls	_	
133-5	24958-24964	showed	_	
133-6	24965-24970	these	_	
133-7	24971-24979	distinct	_	
133-8	24980-24985	VMPFC	_	
133-9	24986-24994	response	_	
133-10	24995-25003	profiles	_	
133-11	25003-25004	,	_	
133-12	25005-25021	cocaine-addicted	_	
133-13	25022-25033	individuals	_	
133-14	25033-25034	,	_	
133-15	25035-25038	who	_	
133-16	25039-25047	manifest	_	
133-17	25048-25056	deficits	_	
133-18	25057-25059	in	_	
133-19	25060-25063	the	_	
133-20	25064-25069	VMPFC	_	
133-21	25069-25070	,	_	
133-22	25071-25074	did	_	
133-23	25075-25078	not	_	
133-24	25078-25079	,	_	
133-25	25080-25090	suggesting	_	
133-26	25091-25095	that	_	
133-27	25096-25099	the	_	
133-28	25100-25105	VMPFC	_	
133-29	25105-25106	,	_	
133-30	25107-25111	when	_	
133-31	25112-25118	intact	_	
133-32	25118-25119	,	_	
133-33	25120-25128	supports	_	
133-34	25129-25139	extinction	_	
133-35	25140-25148	learning	_	
133-36	25149-25151	in	_	
133-37	25152-25159	diverse	_	
133-38	25160-25168	contexts	_	
133-39	25169-25178	including	_	
133-40	25179-25181	of	_	
133-41	25182-25186	drug	_	
133-42	25187-25190	cue	_	
133-43	25191-25194	and	_	
133-44	25195-25203	pleasant	_	
133-45	25204-25216	associations	_	
133-46	25216-25217	.	_	

#Text=That activation in the VMPFC might reflect a shift from a more valenced state (unpleasant as for the CSD+, or pleasant as for the CSP+) to a less valenced or neutral state follows from a large body of work showing that the VMPFC represents the value of a wide range of (appetitive and aversive) stimuli to guide behavior.
134-1	25218-25222	That	_	
134-2	25223-25233	activation	_	
134-3	25234-25236	in	_	
134-4	25237-25240	the	_	
134-5	25241-25246	VMPFC	_	
134-6	25247-25252	might	_	
134-7	25253-25260	reflect	_	
134-8	25261-25262	a	_	
134-9	25263-25268	shift	_	
134-10	25269-25273	from	_	
134-11	25274-25275	a	_	
134-12	25276-25280	more	_	
134-13	25281-25289	valenced	_	
134-14	25290-25295	state	_	
134-15	25296-25297	(	_	
134-16	25297-25307	unpleasant	_	
134-17	25308-25310	as	_	
134-18	25311-25314	for	_	
134-19	25315-25318	the	_	
134-20	25319-25322	CSD	_	
134-21	25322-25323	+	_	
134-22	25323-25324	,	_	
134-23	25325-25327	or	_	
134-24	25328-25336	pleasant	_	
134-25	25337-25339	as	_	
134-26	25340-25343	for	_	
134-27	25344-25347	the	_	
134-28	25348-25351	CSP	_	
134-29	25351-25352	+	_	
134-30	25352-25353	)	_	
134-31	25354-25356	to	_	
134-32	25357-25358	a	_	
134-33	25359-25363	less	_	
134-34	25364-25372	valenced	_	
134-35	25373-25375	or	_	
134-36	25376-25383	neutral	_	
134-37	25384-25389	state	_	
134-38	25390-25397	follows	_	
134-39	25398-25402	from	_	
134-40	25403-25404	a	_	
134-41	25405-25410	large	_	
134-42	25411-25415	body	_	
134-43	25416-25418	of	_	
134-44	25419-25423	work	_	
134-45	25424-25431	showing	_	
134-46	25432-25436	that	_	
134-47	25437-25440	the	_	
134-48	25441-25446	VMPFC	_	
134-49	25447-25457	represents	_	
134-50	25458-25461	the	_	
134-51	25462-25467	value	_	
134-52	25468-25470	of	_	
134-53	25471-25472	a	_	
134-54	25473-25477	wide	_	
134-55	25478-25483	range	_	
134-56	25484-25486	of	_	
134-57	25487-25488	(	_	
134-58	25488-25498	appetitive	_	
134-59	25499-25502	and	_	
134-60	25503-25511	aversive	_	
134-61	25511-25512	)	_	
134-62	25513-25520	stimuli	_	
134-63	25521-25523	to	_	
134-64	25524-25529	guide	_	
134-65	25530-25538	behavior	_	
134-66	25538-25539	.	_	

#Text=While this more general role of the VMPFC in extinction has been previously hypothesized, direct empirical support has been limited as neuroimaging studies have almost exclusively focused on fear extinction.
135-1	25540-25545	While	_	
135-2	25546-25550	this	_	
135-3	25551-25555	more	_	
135-4	25556-25563	general	_	
135-5	25564-25568	role	_	
135-6	25569-25571	of	_	
135-7	25572-25575	the	_	
135-8	25576-25581	VMPFC	_	
135-9	25582-25584	in	_	
135-10	25585-25595	extinction	_	
135-11	25596-25599	has	_	
135-12	25600-25604	been	_	
135-13	25605-25615	previously	_	
135-14	25616-25628	hypothesized	_	
135-15	25628-25629	,	_	
135-16	25630-25636	direct	_	
135-17	25637-25646	empirical	_	
135-18	25647-25654	support	_	
135-19	25655-25658	has	_	
135-20	25659-25663	been	_	
135-21	25664-25671	limited	_	
135-22	25672-25674	as	_	
135-23	25675-25687	neuroimaging	_	
135-24	25688-25695	studies	_	
135-25	25696-25700	have	_	
135-26	25701-25707	almost	_	
135-27	25708-25719	exclusively	_	
135-28	25720-25727	focused	_	
135-29	25728-25730	on	_	
135-30	25731-25735	fear	_	
135-31	25736-25746	extinction	_	
135-32	25746-25747	.	_	

#Text=Animal work shows that the infralimbic cortex (the rodent homologue of the VMPFC) is involved in extinction of both appetitive and aversive CSs.
136-1	25748-25754	Animal	_	
136-2	25755-25759	work	_	
136-3	25760-25765	shows	_	
136-4	25766-25770	that	_	
136-5	25771-25774	the	_	
136-6	25775-25786	infralimbic	_	
136-7	25787-25793	cortex	_	
136-8	25794-25795	(	_	
136-9	25795-25798	the	_	
136-10	25799-25805	rodent	_	
136-11	25806-25815	homologue	_	
136-12	25816-25818	of	_	
136-13	25819-25822	the	_	
136-14	25823-25828	VMPFC	_	
136-15	25828-25829	)	_	
136-16	25830-25832	is	_	
136-17	25833-25841	involved	_	
136-18	25842-25844	in	_	
136-19	25845-25855	extinction	_	
136-20	25856-25858	of	_	
136-21	25859-25863	both	_	
136-22	25864-25874	appetitive	_	
136-23	25875-25878	and	_	
136-24	25879-25887	aversive	_	
136-25	25888-25891	CSs	_	
136-26	25891-25892	.	_	

#Text=In these studies inactivation of the infralimbic cortex impairs extinction as well as extinction recall for CSs that during acquisition predicted shocks [e.g., ], but seems to facilitate extinction for CSs that during acquisition predicted appetitive reinforcers [e.g., sugar ].
137-1	25893-25895	In	_	
137-2	25896-25901	these	_	
137-3	25902-25909	studies	_	
137-4	25910-25922	inactivation	_	
137-5	25923-25925	of	_	
137-6	25926-25929	the	_	
137-7	25930-25941	infralimbic	_	
137-8	25942-25948	cortex	_	
137-9	25949-25956	impairs	_	
137-10	25957-25967	extinction	_	
137-11	25968-25970	as	_	
137-12	25971-25975	well	_	
137-13	25976-25978	as	_	
137-14	25979-25989	extinction	_	
137-15	25990-25996	recall	_	
137-16	25997-26000	for	_	
137-17	26001-26004	CSs	_	
137-18	26005-26009	that	_	
137-19	26010-26016	during	_	
137-20	26017-26028	acquisition	_	
137-21	26029-26038	predicted	_	
137-22	26039-26045	shocks	_	
137-23	26046-26047	[	_	
137-24	26047-26050	e.g	_	
137-25	26050-26051	.	_	
137-26	26051-26052	,	_	
137-27	26053-26054	]	_	
137-28	26054-26055	,	_	
137-29	26056-26059	but	_	
137-30	26060-26065	seems	_	
137-31	26066-26068	to	_	
137-32	26069-26079	facilitate	_	
137-33	26080-26090	extinction	_	
137-34	26091-26094	for	_	
137-35	26095-26098	CSs	_	
137-36	26099-26103	that	_	
137-37	26104-26110	during	_	
137-38	26111-26122	acquisition	_	
137-39	26123-26132	predicted	_	
137-40	26133-26143	appetitive	_	
137-41	26144-26155	reinforcers	_	
137-42	26156-26157	[	_	
137-43	26157-26160	e.g	_	
137-44	26160-26161	.	_	
137-45	26161-26162	,	_	
137-46	26163-26168	sugar	_	
137-47	26169-26170	]	_	
137-48	26170-26171	.	_	

#Text=While additional studies are clearly needed to determine if the same VMPFC-mediated mechanism underlies extinction for all types of CSs, we speculate that the VMPFC stores the current value of the CS, likely in concert with other regions which themselves represent specific features of the CS (e.g., the amygdala in the case of aversive CSs, the striatum in the case of appetitive CSs).
138-1	26172-26177	While	_	
138-2	26178-26188	additional	_	
138-3	26189-26196	studies	_	
138-4	26197-26200	are	_	
138-5	26201-26208	clearly	_	
138-6	26209-26215	needed	_	
138-7	26216-26218	to	_	
138-8	26219-26228	determine	_	
138-9	26229-26231	if	_	
138-10	26232-26235	the	_	
138-11	26236-26240	same	_	
138-12	26241-26255	VMPFC-mediated	_	
138-13	26256-26265	mechanism	_	
138-14	26266-26275	underlies	_	
138-15	26276-26286	extinction	_	
138-16	26287-26290	for	_	
138-17	26291-26294	all	_	
138-18	26295-26300	types	_	
138-19	26301-26303	of	_	
138-20	26304-26307	CSs	_	
138-21	26307-26308	,	_	
138-22	26309-26311	we	_	
138-23	26312-26321	speculate	_	
138-24	26322-26326	that	_	
138-25	26327-26330	the	_	
138-26	26331-26336	VMPFC	_	
138-27	26337-26343	stores	_	
138-28	26344-26347	the	_	
138-29	26348-26355	current	_	
138-30	26356-26361	value	_	
138-31	26362-26364	of	_	
138-32	26365-26368	the	_	
138-33	26369-26371	CS	_	
138-34	26371-26372	,	_	
138-35	26373-26379	likely	_	
138-36	26380-26382	in	_	
138-37	26383-26390	concert	_	
138-38	26391-26395	with	_	
138-39	26396-26401	other	_	
138-40	26402-26409	regions	_	
138-41	26410-26415	which	_	
138-42	26416-26426	themselves	_	
138-43	26427-26436	represent	_	
138-44	26437-26445	specific	_	
138-45	26446-26454	features	_	
138-46	26455-26457	of	_	
138-47	26458-26461	the	_	
138-48	26462-26464	CS	_	
138-49	26465-26466	(	_	
138-50	26466-26469	e.g	_	
138-51	26469-26470	.	_	
138-52	26470-26471	,	_	
138-53	26472-26475	the	_	
138-54	26476-26484	amygdala	_	
138-55	26485-26487	in	_	
138-56	26488-26491	the	_	
138-57	26492-26496	case	_	
138-58	26497-26499	of	_	
138-59	26500-26508	aversive	_	
138-60	26509-26512	CSs	_	
138-61	26512-26513	,	_	
138-62	26514-26517	the	_	
138-63	26518-26526	striatum	_	
138-64	26527-26529	in	_	
138-65	26530-26533	the	_	
138-66	26534-26538	case	_	
138-67	26539-26541	of	_	
138-68	26542-26552	appetitive	_	
138-69	26553-26556	CSs	_	
138-70	26556-26557	)	_	
138-71	26557-26558	.	_	

#Text=In a previous fear extinction study, reduction in SCR during extinction correlated with VMPFC activation a day later, suggesting the VMPFC is specifically involved in the retrieval of extinction learning.
139-1	26559-26561	In	_	
139-2	26562-26563	a	_	
139-3	26564-26572	previous	_	
139-4	26573-26577	fear	_	
139-5	26578-26588	extinction	_	
139-6	26589-26594	study	_	
139-7	26594-26595	,	_	
139-8	26596-26605	reduction	_	
139-9	26606-26608	in	_	
139-10	26609-26612	SCR	_	
139-11	26613-26619	during	_	
139-12	26620-26630	extinction	_	
139-13	26631-26641	correlated	_	
139-14	26642-26646	with	_	
139-15	26647-26652	VMPFC	_	
139-16	26653-26663	activation	_	
139-17	26664-26665	a	_	
139-18	26666-26669	day	_	
139-19	26670-26675	later	_	
139-20	26675-26676	,	_	
139-21	26677-26687	suggesting	_	
139-22	26688-26691	the	_	
139-23	26692-26697	VMPFC	_	
139-24	26698-26700	is	_	
139-25	26701-26713	specifically	_	
139-26	26714-26722	involved	_	
139-27	26723-26725	in	_	
139-28	26726-26729	the	_	
139-29	26730-26739	retrieval	_	
139-30	26740-26742	of	_	
139-31	26743-26753	extinction	_	
139-32	26754-26762	learning	_	
139-33	26762-26763	.	_	

#Text=We saw this same relationship here: lower SCR during day 1 extinction correlated with higher VMPFC activation during day 2 extinction.
140-1	26764-26766	We	_	
140-2	26767-26770	saw	_	
140-3	26771-26775	this	_	
140-4	26776-26780	same	_	
140-5	26781-26793	relationship	_	
140-6	26794-26798	here	_	
140-7	26798-26799	:	_	
140-8	26800-26805	lower	_	
140-9	26806-26809	SCR	_	
140-10	26810-26816	during	_	
140-11	26817-26820	day	_	
140-12	26821-26822	1	_	
140-13	26823-26833	extinction	_	
140-14	26834-26844	correlated	_	
140-15	26845-26849	with	_	
140-16	26850-26856	higher	_	
140-17	26857-26862	VMPFC	_	
140-18	26863-26873	activation	_	
140-19	26874-26880	during	_	
140-20	26881-26884	day	_	
140-21	26885-26886	2	_	
140-22	26887-26897	extinction	_	
140-23	26897-26898	.	_	

#Text=This relationship to SCR is supported by evidence that the VMPFC, unlike a more dorsal medial region of the prefrontal cortex typically implicated in the expression of conditioned associations (namely the dorsal anterior cingulate), granger causally drives changes in skin conductance.
141-1	26899-26903	This	_	
141-2	26904-26916	relationship	_	
141-3	26917-26919	to	_	
141-4	26920-26923	SCR	_	
141-5	26924-26926	is	_	
141-6	26927-26936	supported	_	
141-7	26937-26939	by	_	
141-8	26940-26948	evidence	_	
141-9	26949-26953	that	_	
141-10	26954-26957	the	_	
141-11	26958-26963	VMPFC	_	
141-12	26963-26964	,	_	
141-13	26965-26971	unlike	_	
141-14	26972-26973	a	_	
141-15	26974-26978	more	_	
141-16	26979-26985	dorsal	_	
141-17	26986-26992	medial	_	
141-18	26993-26999	region	_	
141-19	27000-27002	of	_	
141-20	27003-27006	the	_	
141-21	27007-27017	prefrontal	_	
141-22	27018-27024	cortex	_	
141-23	27025-27034	typically	_	
141-24	27035-27045	implicated	_	
141-25	27046-27048	in	_	
141-26	27049-27052	the	_	
141-27	27053-27063	expression	_	
141-28	27064-27066	of	_	
141-29	27067-27078	conditioned	_	
141-30	27079-27091	associations	_	
141-31	27092-27093	(	_	
141-32	27093-27099	namely	_	
141-33	27100-27103	the	_	
141-34	27104-27110	dorsal	_	
141-35	27111-27119	anterior	_	
141-36	27120-27129	cingulate	_	
141-37	27129-27130	)	_	
141-38	27130-27131	,	_	
141-39	27132-27139	granger	_	
141-40	27140-27148	causally	_	
141-41	27149-27155	drives	_	
141-42	27156-27163	changes	_	
141-43	27164-27166	in	_	
141-44	27167-27171	skin	_	
141-45	27172-27183	conductance	_	
141-46	27183-27184	.	_	

#Text=Despite differences in the activity profiles of the VMPFC for the CSD+ versus the CSP+, however, for both CSs, SCR decreased during extinction relative to acquisition.
142-1	27185-27192	Despite	_	
142-2	27193-27204	differences	_	
142-3	27205-27207	in	_	
142-4	27208-27211	the	_	
142-5	27212-27220	activity	_	
142-6	27221-27229	profiles	_	
142-7	27230-27232	of	_	
142-8	27233-27236	the	_	
142-9	27237-27242	VMPFC	_	
142-10	27243-27246	for	_	
142-11	27247-27250	the	_	
142-12	27251-27254	CSD	_	
142-13	27254-27255	+	_	
142-14	27256-27262	versus	_	
142-15	27263-27266	the	_	
142-16	27267-27270	CSP	_	
142-17	27270-27271	+	_	
142-18	27271-27272	,	_	
142-19	27273-27280	however	_	
142-20	27280-27281	,	_	
142-21	27282-27285	for	_	
142-22	27286-27290	both	_	
142-23	27291-27294	CSs	_	
142-24	27294-27295	,	_	
142-25	27296-27299	SCR	_	
142-26	27300-27309	decreased	_	
142-27	27310-27316	during	_	
142-28	27317-27327	extinction	_	
142-29	27328-27336	relative	_	
142-30	27337-27339	to	_	
142-31	27340-27351	acquisition	_	
142-32	27351-27352	.	_	

#Text=This cue-insensitive SCR pattern is not surprising given that SCR indexes arousal, and is consistent with that observed in extinction learning studies of food- and shock-paired CSs.
143-1	27353-27357	This	_	
143-2	27358-27373	cue-insensitive	_	
143-3	27374-27377	SCR	_	
143-4	27378-27385	pattern	_	
143-5	27386-27388	is	_	
143-6	27389-27392	not	_	
143-7	27393-27403	surprising	_	
143-8	27404-27409	given	_	
143-9	27410-27414	that	_	
143-10	27415-27418	SCR	_	
143-11	27419-27426	indexes	_	
143-12	27427-27434	arousal	_	
143-13	27434-27435	,	_	
143-14	27436-27439	and	_	
143-15	27440-27442	is	_	
143-16	27443-27453	consistent	_	
143-17	27454-27458	with	_	
143-18	27459-27463	that	_	
143-19	27464-27472	observed	_	
143-20	27473-27475	in	_	
143-21	27476-27486	extinction	_	
143-22	27487-27495	learning	_	
143-23	27496-27503	studies	_	
143-24	27504-27506	of	_	
143-25	27507-27511	food	_	
143-26	27511-27512	-	_	
143-27	27513-27516	and	_	
143-28	27517-27529	shock-paired	_	
143-29	27530-27533	CSs	_	
143-30	27533-27534	.	_	

#Text=Importantly, despite eliciting similar SCRs, valence ratings clearly differentiated the CSs as appetitive or aversive in this prior study.
144-1	27535-27546	Importantly	_	
144-2	27546-27547	,	_	
144-3	27548-27555	despite	_	
144-4	27556-27565	eliciting	_	
144-5	27566-27573	similar	_	
144-6	27574-27578	SCRs	_	
144-7	27578-27579	,	_	
144-8	27580-27587	valence	_	
144-9	27588-27595	ratings	_	
144-10	27596-27603	clearly	_	
144-11	27604-27618	differentiated	_	
144-12	27619-27622	the	_	
144-13	27623-27626	CSs	_	
144-14	27627-27629	as	_	
144-15	27630-27640	appetitive	_	
144-16	27641-27643	or	_	
144-17	27644-27652	aversive	_	
144-18	27653-27655	in	_	
144-19	27656-27660	this	_	
144-20	27661-27666	prior	_	
144-21	27667-27672	study	_	
144-22	27672-27673	.	_	

#Text=Thus, as indices of the conditioned response, VMPFC BOLD and SCR might represent partly distinct aspects of the CS (valence versus arousal).
145-1	27674-27678	Thus	_	
145-2	27678-27679	,	_	
145-3	27680-27682	as	_	
145-4	27683-27690	indices	_	
145-5	27691-27693	of	_	
145-6	27694-27697	the	_	
145-7	27698-27709	conditioned	_	
145-8	27710-27718	response	_	
145-9	27718-27719	,	_	
145-10	27720-27725	VMPFC	_	
145-11	27726-27730	BOLD	_	
145-12	27731-27734	and	_	
145-13	27735-27738	SCR	_	
145-14	27739-27744	might	_	
145-15	27745-27754	represent	_	
145-16	27755-27761	partly	_	
145-17	27762-27770	distinct	_	
145-18	27771-27778	aspects	_	
145-19	27779-27781	of	_	
145-20	27782-27785	the	_	
145-21	27786-27788	CS	_	
145-22	27789-27790	(	_	
145-23	27790-27797	valence	_	
145-24	27798-27804	versus	_	
145-25	27805-27812	arousal	_	
145-26	27812-27813	)	_	
145-27	27813-27814	.	_	

#Text=Perhaps most strikingly, while controls showed parametric VMPFC changes over the learning phases, which were modulated by CS type, chronic cocaine users did not.
146-1	27815-27822	Perhaps	_	
146-2	27823-27827	most	_	
146-3	27828-27838	strikingly	_	
146-4	27838-27839	,	_	
146-5	27840-27845	while	_	
146-6	27846-27854	controls	_	
146-7	27855-27861	showed	_	
146-8	27862-27872	parametric	_	
146-9	27873-27878	VMPFC	_	
146-10	27879-27886	changes	_	
146-11	27887-27891	over	_	
146-12	27892-27895	the	_	
146-13	27896-27904	learning	_	
146-14	27905-27911	phases	_	
146-15	27911-27912	,	_	
146-16	27913-27918	which	_	
146-17	27919-27923	were	_	
146-18	27924-27933	modulated	_	
146-19	27934-27936	by	_	
146-20	27937-27939	CS	_	
146-21	27940-27944	type	_	
146-22	27944-27945	,	_	
146-23	27946-27953	chronic	_	
146-24	27954-27961	cocaine	_	
146-25	27962-27967	users	_	
146-26	27968-27971	did	_	
146-27	27972-27975	not	_	
146-28	27975-27976	.	_	

#Text=This was the case for both CSs, pointing to a generalized VMPFC abnormality in this group.
147-1	27977-27981	This	_	
147-2	27982-27985	was	_	
147-3	27986-27989	the	_	
147-4	27990-27994	case	_	
147-5	27995-27998	for	_	
147-6	27999-28003	both	_	
147-7	28004-28007	CSs	_	
147-8	28007-28008	,	_	
147-9	28009-28017	pointing	_	
147-10	28018-28020	to	_	
147-11	28021-28022	a	_	
147-12	28023-28034	generalized	_	
147-13	28035-28040	VMPFC	_	
147-14	28041-28052	abnormality	_	
147-15	28053-28055	in	_	
147-16	28056-28060	this	_	
147-17	28061-28066	group	_	
147-18	28066-28067	.	_	

#Text=Speaking to the clinical relevance of this finding, cocaine users who were more successful at modulating their VMPFC response to the CSD+ during day 1 extinction (i.e., who looked more like controls) reported greater reductions in craving 24 h later.
148-1	28068-28076	Speaking	_	
148-2	28077-28079	to	_	
148-3	28080-28083	the	_	
148-4	28084-28092	clinical	_	
148-5	28093-28102	relevance	_	
148-6	28103-28105	of	_	
148-7	28106-28110	this	_	
148-8	28111-28118	finding	_	
148-9	28118-28119	,	_	
148-10	28120-28127	cocaine	_	
148-11	28128-28133	users	_	
148-12	28134-28137	who	_	
148-13	28138-28142	were	_	
148-14	28143-28147	more	_	
148-15	28148-28158	successful	_	
148-16	28159-28161	at	_	
148-17	28162-28172	modulating	_	
148-18	28173-28178	their	_	
148-19	28179-28184	VMPFC	_	
148-20	28185-28193	response	_	
148-21	28194-28196	to	_	
148-22	28197-28200	the	_	
148-23	28201-28204	CSD	_	
148-24	28204-28205	+	_	
148-25	28206-28212	during	_	
148-26	28213-28216	day	_	
148-27	28217-28218	1	_	
148-28	28219-28229	extinction	_	
148-29	28230-28231	(	_	
148-30	28231-28234	i.e	_	
148-31	28234-28235	.	_	
148-32	28235-28236	,	_	
148-33	28237-28240	who	_	
148-34	28241-28247	looked	_	
148-35	28248-28252	more	_	
148-36	28253-28257	like	_	
148-37	28258-28266	controls	_	
148-38	28266-28267	)	_	
148-39	28268-28276	reported	_	
148-40	28277-28284	greater	_	
148-41	28285-28295	reductions	_	
148-42	28296-28298	in	_	
148-43	28299-28306	craving	_	
148-44	28307-28309	24	_	
148-45	28310-28311	h	_	
148-46	28312-28317	later	_	
148-47	28317-28318	.	_	

#Text=While these data predict that cocaine-addicted individuals with greater VMPFC impairments may be particularly vulnerable in real-world situations involving drug cues, the SCR data did not reveal differences from controls.
149-1	28319-28324	While	_	
149-2	28325-28330	these	_	
149-3	28331-28335	data	_	
149-4	28336-28343	predict	_	
149-5	28344-28348	that	_	
149-6	28349-28365	cocaine-addicted	_	
149-7	28366-28377	individuals	_	
149-8	28378-28382	with	_	
149-9	28383-28390	greater	_	
149-10	28391-28396	VMPFC	_	
149-11	28397-28408	impairments	_	
149-12	28409-28412	may	_	
149-13	28413-28415	be	_	
149-14	28416-28428	particularly	_	
149-15	28429-28439	vulnerable	_	
149-16	28440-28442	in	_	
149-17	28443-28453	real-world	_	
149-18	28454-28464	situations	_	
149-19	28465-28474	involving	_	
149-20	28475-28479	drug	_	
149-21	28480-28484	cues	_	
149-22	28484-28485	,	_	
149-23	28486-28489	the	_	
149-24	28490-28493	SCR	_	
149-25	28494-28498	data	_	
149-26	28499-28502	did	_	
149-27	28503-28506	not	_	
149-28	28507-28513	reveal	_	
149-29	28514-28525	differences	_	
149-30	28526-28530	from	_	
149-31	28531-28539	controls	_	
149-32	28539-28540	.	_	

#Text=We used SCR as a passive measure of the conditioned response consistent with a large body of literature.
150-1	28541-28543	We	_	
150-2	28544-28548	used	_	
150-3	28549-28552	SCR	_	
150-4	28553-28555	as	_	
150-5	28556-28557	a	_	
150-6	28558-28565	passive	_	
150-7	28566-28573	measure	_	
150-8	28574-28576	of	_	
150-9	28577-28580	the	_	
150-10	28581-28592	conditioned	_	
150-11	28593-28601	response	_	
150-12	28602-28612	consistent	_	
150-13	28613-28617	with	_	
150-14	28618-28619	a	_	
150-15	28620-28625	large	_	
150-16	28626-28630	body	_	
150-17	28631-28633	of	_	
150-18	28634-28644	literature	_	
150-19	28644-28645	.	_	

#Text=However, SCR is a noisy measurement in the MRI environment (indeed, there was substantial data loss that may have reduced our power to detect group differences in SCR if these differences existed).
151-1	28646-28653	However	_	
151-2	28653-28654	,	_	
151-3	28655-28658	SCR	_	
151-4	28659-28661	is	_	
151-5	28662-28663	a	_	
151-6	28664-28669	noisy	_	
151-7	28670-28681	measurement	_	
151-8	28682-28684	in	_	
151-9	28685-28688	the	_	
151-10	28689-28692	MRI	_	
151-11	28693-28704	environment	_	
151-12	28705-28706	(	_	
151-13	28706-28712	indeed	_	
151-14	28712-28713	,	_	
151-15	28714-28719	there	_	
151-16	28720-28723	was	_	
151-17	28724-28735	substantial	_	
151-18	28736-28740	data	_	
151-19	28741-28745	loss	_	
151-20	28746-28750	that	_	
151-21	28751-28754	may	_	
151-22	28755-28759	have	_	
151-23	28760-28767	reduced	_	
151-24	28768-28771	our	_	
151-25	28772-28777	power	_	
151-26	28778-28780	to	_	
151-27	28781-28787	detect	_	
151-28	28788-28793	group	_	
151-29	28794-28805	differences	_	
151-30	28806-28808	in	_	
151-31	28809-28812	SCR	_	
151-32	28813-28815	if	_	
151-33	28816-28821	these	_	
151-34	28822-28833	differences	_	
151-35	28834-28841	existed	_	
151-36	28841-28842	)	_	
151-37	28842-28843	.	_	

#Text=Alternatively, however, these neural differences might exist outside overt SCR differences.
152-1	28844-28857	Alternatively	_	
152-2	28857-28858	,	_	
152-3	28859-28866	however	_	
152-4	28866-28867	,	_	
152-5	28868-28873	these	_	
152-6	28874-28880	neural	_	
152-7	28881-28892	differences	_	
152-8	28893-28898	might	_	
152-9	28899-28904	exist	_	
152-10	28905-28912	outside	_	
152-11	28913-28918	overt	_	
152-12	28919-28922	SCR	_	
152-13	28923-28934	differences	_	
152-14	28934-28935	.	_	

#Text=In studies of anxiety disorders, for example, reproducible VMPFC impairments during fear extinction and its later retrieval are observed in the absence of abnormalities in SCR.
153-1	28936-28938	In	_	
153-2	28939-28946	studies	_	
153-3	28947-28949	of	_	
153-4	28950-28957	anxiety	_	
153-5	28958-28967	disorders	_	
153-6	28967-28968	,	_	
153-7	28969-28972	for	_	
153-8	28973-28980	example	_	
153-9	28980-28981	,	_	
153-10	28982-28994	reproducible	_	
153-11	28995-29000	VMPFC	_	
153-12	29001-29012	impairments	_	
153-13	29013-29019	during	_	
153-14	29020-29024	fear	_	
153-15	29025-29035	extinction	_	
153-16	29036-29039	and	_	
153-17	29040-29043	its	_	
153-18	29044-29049	later	_	
153-19	29050-29059	retrieval	_	
153-20	29060-29063	are	_	
153-21	29064-29072	observed	_	
153-22	29073-29075	in	_	
153-23	29076-29079	the	_	
153-24	29080-29087	absence	_	
153-25	29088-29090	of	_	
153-26	29091-29104	abnormalities	_	
153-27	29105-29107	in	_	
153-28	29108-29111	SCR	_	
153-29	29111-29112	.	_	

#Text=That is, VMPFC activation might be more sensitive in detecting differences from health, although this possibility remains an open empirical question.
154-1	29113-29117	That	_	
154-2	29118-29120	is	_	
154-3	29120-29121	,	_	
154-4	29122-29127	VMPFC	_	
154-5	29128-29138	activation	_	
154-6	29139-29144	might	_	
154-7	29145-29147	be	_	
154-8	29148-29152	more	_	
154-9	29153-29162	sensitive	_	
154-10	29163-29165	in	_	
154-11	29166-29175	detecting	_	
154-12	29176-29187	differences	_	
154-13	29188-29192	from	_	
154-14	29193-29199	health	_	
154-15	29199-29200	,	_	
154-16	29201-29209	although	_	
154-17	29210-29214	this	_	
154-18	29215-29226	possibility	_	
154-19	29227-29234	remains	_	
154-20	29235-29237	an	_	
154-21	29238-29242	open	_	
154-22	29243-29252	empirical	_	
154-23	29253-29261	question	_	
154-24	29261-29262	.	_	

#Text=To directly test this possibility, future studies could incorporate trial-by-trial expectancy ratings as explicit measures of learning and additional physiological indices of arousal (e.g., pupil dilation) and valence [e.g., startle potentiation/attenuation ].
155-1	29263-29265	To	_	
155-2	29266-29274	directly	_	
155-3	29275-29279	test	_	
155-4	29280-29284	this	_	
155-5	29285-29296	possibility	_	
155-6	29296-29297	,	_	
155-7	29298-29304	future	_	
155-8	29305-29312	studies	_	
155-9	29313-29318	could	_	
155-10	29319-29330	incorporate	_	
155-11	29331-29345	trial-by-trial	_	
155-12	29346-29356	expectancy	_	
155-13	29357-29364	ratings	_	
155-14	29365-29367	as	_	
155-15	29368-29376	explicit	_	
155-16	29377-29385	measures	_	
155-17	29386-29388	of	_	
155-18	29389-29397	learning	_	
155-19	29398-29401	and	_	
155-20	29402-29412	additional	_	
155-21	29413-29426	physiological	_	
155-22	29427-29434	indices	_	
155-23	29435-29437	of	_	
155-24	29438-29445	arousal	_	
155-25	29446-29447	(	_	
155-26	29447-29450	e.g	_	
155-27	29450-29451	.	_	
155-28	29451-29452	,	_	
155-29	29453-29458	pupil	_	
155-30	29459-29467	dilation	_	
155-31	29467-29468	)	_	
155-32	29469-29472	and	_	
155-33	29473-29480	valence	_	
155-34	29481-29482	[	_	
155-35	29482-29485	e.g	_	
155-36	29485-29486	.	_	
155-37	29486-29487	,	_	
155-38	29488-29495	startle	_	
155-39	29496-29508	potentiation	_	
155-40	29508-29509	/	_	
155-41	29509-29520	attenuation	_	
155-42	29521-29522	]	_	
155-43	29522-29523	.	_	

#Text=Contrary to expectations, the groups differed only in the VMPFC.
156-1	29524-29532	Contrary	_	
156-2	29533-29535	to	_	
156-3	29536-29548	expectations	_	
156-4	29548-29549	,	_	
156-5	29550-29553	the	_	
156-6	29554-29560	groups	_	
156-7	29561-29569	differed	_	
156-8	29570-29574	only	_	
156-9	29575-29577	in	_	
156-10	29578-29581	the	_	
156-11	29582-29587	VMPFC	_	
156-12	29587-29588	.	_	

#Text=Activation in the striatum mirrored that of the VMPFC, increasing in response to the CSD+ and decreasing in response to the CSP+ as extinction progressed, but there were no differences between cocaine users and controls.
157-1	29589-29599	Activation	_	
157-2	29600-29602	in	_	
157-3	29603-29606	the	_	
157-4	29607-29615	striatum	_	
157-5	29616-29624	mirrored	_	
157-6	29625-29629	that	_	
157-7	29630-29632	of	_	
157-8	29633-29636	the	_	
157-9	29637-29642	VMPFC	_	
157-10	29642-29643	,	_	
157-11	29644-29654	increasing	_	
157-12	29655-29657	in	_	
157-13	29658-29666	response	_	
157-14	29667-29669	to	_	
157-15	29670-29673	the	_	
157-16	29674-29677	CSD	_	
157-17	29677-29678	+	_	
157-18	29679-29682	and	_	
157-19	29683-29693	decreasing	_	
157-20	29694-29696	in	_	
157-21	29697-29705	response	_	
157-22	29706-29708	to	_	
157-23	29709-29712	the	_	
157-24	29713-29716	CSP	_	
157-25	29716-29717	+	_	
157-26	29718-29720	as	_	
157-27	29721-29731	extinction	_	
157-28	29732-29742	progressed	_	
157-29	29742-29743	,	_	
157-30	29744-29747	but	_	
157-31	29748-29753	there	_	
157-32	29754-29758	were	_	
157-33	29759-29761	no	_	
157-34	29762-29773	differences	_	
157-35	29774-29781	between	_	
157-36	29782-29789	cocaine	_	
157-37	29790-29795	users	_	
157-38	29796-29799	and	_	
157-39	29800-29808	controls	_	
157-40	29808-29809	.	_	

#Text=This coordinated pattern of activation in the VMPFC and striatum, another central node within the valuation system, further supports a value-sensitive account of extinction learning.
158-1	29810-29814	This	_	
158-2	29815-29826	coordinated	_	
158-3	29827-29834	pattern	_	
158-4	29835-29837	of	_	
158-5	29838-29848	activation	_	
158-6	29849-29851	in	_	
158-7	29852-29855	the	_	
158-8	29856-29861	VMPFC	_	
158-9	29862-29865	and	_	
158-10	29866-29874	striatum	_	
158-11	29874-29875	,	_	
158-12	29876-29883	another	_	
158-13	29884-29891	central	_	
158-14	29892-29896	node	_	
158-15	29897-29903	within	_	
158-16	29904-29907	the	_	
158-17	29908-29917	valuation	_	
158-18	29918-29924	system	_	
158-19	29924-29925	,	_	
158-20	29926-29933	further	_	
158-21	29934-29942	supports	_	
158-22	29943-29944	a	_	
158-23	29945-29960	value-sensitive	_	
158-24	29961-29968	account	_	
158-25	29969-29971	of	_	
158-26	29972-29982	extinction	_	
158-27	29983-29991	learning	_	
158-28	29991-29992	.	_	

#Text=But while we and others consistently find structural and functional impairments in stimulant users in the VMPFC, that in some cases persist long after drug use ceases, a similar consensus finding regarding the striatum has been difficult to ascertain from the human neuroimaging literature, with a bulk of studies showing intact or even enhanced striatum function [see for a detailed discussion on this topic].
159-1	29993-29996	But	_	
159-2	29997-30002	while	_	
159-3	30003-30005	we	_	
159-4	30006-30009	and	_	
159-5	30010-30016	others	_	
159-6	30017-30029	consistently	_	
159-7	30030-30034	find	_	
159-8	30035-30045	structural	_	
159-9	30046-30049	and	_	
159-10	30050-30060	functional	_	
159-11	30061-30072	impairments	_	
159-12	30073-30075	in	_	
159-13	30076-30085	stimulant	_	
159-14	30086-30091	users	_	
159-15	30092-30094	in	_	
159-16	30095-30098	the	_	
159-17	30099-30104	VMPFC	_	
159-18	30104-30105	,	_	
159-19	30106-30110	that	_	
159-20	30111-30113	in	_	
159-21	30114-30118	some	_	
159-22	30119-30124	cases	_	
159-23	30125-30132	persist	_	
159-24	30133-30137	long	_	
159-25	30138-30143	after	_	
159-26	30144-30148	drug	_	
159-27	30149-30152	use	_	
159-28	30153-30159	ceases	_	
159-29	30159-30160	,	_	
159-30	30161-30162	a	_	
159-31	30163-30170	similar	_	
159-32	30171-30180	consensus	_	
159-33	30181-30188	finding	_	
159-34	30189-30198	regarding	_	
159-35	30199-30202	the	_	
159-36	30203-30211	striatum	_	
159-37	30212-30215	has	_	
159-38	30216-30220	been	_	
159-39	30221-30230	difficult	_	
159-40	30231-30233	to	_	
159-41	30234-30243	ascertain	_	
159-42	30244-30248	from	_	
159-43	30249-30252	the	_	
159-44	30253-30258	human	_	
159-45	30259-30271	neuroimaging	_	
159-46	30272-30282	literature	_	
159-47	30282-30283	,	_	
159-48	30284-30288	with	_	
159-49	30289-30290	a	_	
159-50	30291-30295	bulk	_	
159-51	30296-30298	of	_	
159-52	30299-30306	studies	_	
159-53	30307-30314	showing	_	
159-54	30315-30321	intact	_	
159-55	30322-30324	or	_	
159-56	30325-30329	even	_	
159-57	30330-30338	enhanced	_	
159-58	30339-30347	striatum	_	
159-59	30348-30356	function	_	
159-60	30357-30358	[	_	
159-61	30358-30361	see	_	
159-62	30362-30365	for	_	
159-63	30366-30367	a	_	
159-64	30368-30376	detailed	_	
159-65	30377-30387	discussion	_	
159-66	30388-30390	on	_	
159-67	30391-30395	this	_	
159-68	30396-30401	topic	_	
159-69	30401-30402	]	_	
159-70	30402-30403	.	_	

#Text=Thus, the specific contribution of the striatum to extinction learning in drug addiction requires further study.
160-1	30404-30408	Thus	_	
160-2	30408-30409	,	_	
160-3	30410-30413	the	_	
160-4	30414-30422	specific	_	
160-5	30423-30435	contribution	_	
160-6	30436-30438	of	_	
160-7	30439-30442	the	_	
160-8	30443-30451	striatum	_	
160-9	30452-30454	to	_	
160-10	30455-30465	extinction	_	
160-11	30466-30474	learning	_	
160-12	30475-30477	in	_	
160-13	30478-30482	drug	_	
160-14	30483-30492	addiction	_	
160-15	30493-30501	requires	_	
160-16	30502-30509	further	_	
160-17	30510-30515	study	_	
160-18	30515-30516	.	_	

#Text=Given the theoretical impetus for extinction-based therapy in addiction, it is important to consider how our VMPFC findings might inform treatment development, considering at least two potentially meaningful aims: enhancing VMPFC function or “bypassing” it.
161-1	30517-30522	Given	_	
161-2	30523-30526	the	_	
161-3	30527-30538	theoretical	_	
161-4	30539-30546	impetus	_	
161-5	30547-30550	for	_	
161-6	30551-30567	extinction-based	_	
161-7	30568-30575	therapy	_	
161-8	30576-30578	in	_	
161-9	30579-30588	addiction	_	
161-10	30588-30589	,	_	
161-11	30590-30592	it	_	
161-12	30593-30595	is	_	
161-13	30596-30605	important	_	
161-14	30606-30608	to	_	
161-15	30609-30617	consider	_	
161-16	30618-30621	how	_	
161-17	30622-30625	our	_	
161-18	30626-30631	VMPFC	_	
161-19	30632-30640	findings	_	
161-20	30641-30646	might	_	
161-21	30647-30653	inform	_	
161-22	30654-30663	treatment	_	
161-23	30664-30675	development	_	
161-24	30675-30676	,	_	
161-25	30677-30688	considering	_	
161-26	30689-30691	at	_	
161-27	30692-30697	least	_	
161-28	30698-30701	two	_	
161-29	30702-30713	potentially	_	
161-30	30714-30724	meaningful	_	
161-31	30725-30729	aims	_	
161-32	30729-30730	:	_	
161-33	30731-30740	enhancing	_	
161-34	30741-30746	VMPFC	_	
161-35	30747-30755	function	_	
161-36	30756-30758	or	_	
161-37	30759-30760	“	_	
161-38	30760-30769	bypassing	_	
161-39	30769-30770	”	_	
161-40	30771-30773	it	_	
161-41	30773-30774	.	_	

#Text=For the former, the indirect dopamine agonist methylphenidate has been shown to enhance extinction and its retention, possibly via local effects in the infralimbic cortex.
162-1	30775-30778	For	_	
162-2	30779-30782	the	_	
162-3	30783-30789	former	_	
162-4	30789-30790	,	_	
162-5	30791-30794	the	_	
162-6	30795-30803	indirect	_	
162-7	30804-30812	dopamine	_	
162-8	30813-30820	agonist	_	
162-9	30821-30836	methylphenidate	_	
162-10	30837-30840	has	_	
162-11	30841-30845	been	_	
162-12	30846-30851	shown	_	
162-13	30852-30854	to	_	
162-14	30855-30862	enhance	_	
162-15	30863-30873	extinction	_	
162-16	30874-30877	and	_	
162-17	30878-30881	its	_	
162-18	30882-30891	retention	_	
162-19	30891-30892	,	_	
162-20	30893-30901	possibly	_	
162-21	30902-30905	via	_	
162-22	30906-30911	local	_	
162-23	30912-30919	effects	_	
162-24	30920-30922	in	_	
162-25	30923-30926	the	_	
162-26	30927-30938	infralimbic	_	
162-27	30939-30945	cortex	_	
162-28	30945-30946	.	_	

#Text=This pharmacological approach may be particularly well-suited for cocaine-addicted individuals as prior studies in this population show that methylphenidate bolsters VMPFC function on both emotionally salient and emotionally neutral tasks.
163-1	30947-30951	This	_	
163-2	30952-30967	pharmacological	_	
163-3	30968-30976	approach	_	
163-4	30977-30980	may	_	
163-5	30981-30983	be	_	
163-6	30984-30996	particularly	_	
163-7	30997-31008	well-suited	_	
163-8	31009-31012	for	_	
163-9	31013-31029	cocaine-addicted	_	
163-10	31030-31041	individuals	_	
163-11	31042-31044	as	_	
163-12	31045-31050	prior	_	
163-13	31051-31058	studies	_	
163-14	31059-31061	in	_	
163-15	31062-31066	this	_	
163-16	31067-31077	population	_	
163-17	31078-31082	show	_	
163-18	31083-31087	that	_	
163-19	31088-31103	methylphenidate	_	
163-20	31104-31112	bolsters	_	
163-21	31113-31118	VMPFC	_	
163-22	31119-31127	function	_	
163-23	31128-31130	on	_	
163-24	31131-31135	both	_	
163-25	31136-31147	emotionally	_	
163-26	31148-31155	salient	_	
163-27	31156-31159	and	_	
163-28	31160-31171	emotionally	_	
163-29	31172-31179	neutral	_	
163-30	31180-31185	tasks	_	
163-31	31185-31186	.	_	

#Text=Methylphenidate is also shown to modulate resting functional connectivity with the VMPFC.
164-1	31187-31202	Methylphenidate	_	
164-2	31203-31205	is	_	
164-3	31206-31210	also	_	
164-4	31211-31216	shown	_	
164-5	31217-31219	to	_	
164-6	31220-31228	modulate	_	
164-7	31229-31236	resting	_	
164-8	31237-31247	functional	_	
164-9	31248-31260	connectivity	_	
164-10	31261-31265	with	_	
164-11	31266-31269	the	_	
164-12	31270-31275	VMPFC	_	
164-13	31275-31276	.	_	

#Text=For the latter aim (decreasing reliance on the VMPFC), post-retrieval extinction, which interferes with memory reconsolidation, may offer a more efficacious method for targeting drug-related associations.
165-1	31277-31280	For	_	
165-2	31281-31284	the	_	
165-3	31285-31291	latter	_	
165-4	31292-31295	aim	_	
165-5	31296-31297	(	_	
165-6	31297-31307	decreasing	_	
165-7	31308-31316	reliance	_	
165-8	31317-31319	on	_	
165-9	31320-31323	the	_	
165-10	31324-31329	VMPFC	_	
165-11	31329-31330	)	_	
165-12	31330-31331	,	_	
165-13	31332-31346	post-retrieval	_	
165-14	31347-31357	extinction	_	
165-15	31357-31358	,	_	
165-16	31359-31364	which	_	
165-17	31365-31375	interferes	_	
165-18	31376-31380	with	_	
165-19	31381-31387	memory	_	
165-20	31388-31403	reconsolidation	_	
165-21	31403-31404	,	_	
165-22	31405-31408	may	_	
165-23	31409-31414	offer	_	
165-24	31415-31416	a	_	
165-25	31417-31421	more	_	
165-26	31422-31433	efficacious	_	
165-27	31434-31440	method	_	
165-28	31441-31444	for	_	
165-29	31445-31454	targeting	_	
165-30	31455-31467	drug-related	_	
165-31	31468-31480	associations	_	
165-32	31480-31481	.	_	

#Text=Indeed, post-retrieval extinction is shown to be effective at reducing reinstatement and/or renewal of drug-, sugar-, and fear-related associations in rodents and humans.
166-1	31482-31488	Indeed	_	
166-2	31488-31489	,	_	
166-3	31490-31504	post-retrieval	_	
166-4	31505-31515	extinction	_	
166-5	31516-31518	is	_	
166-6	31519-31524	shown	_	
166-7	31525-31527	to	_	
166-8	31528-31530	be	_	
166-9	31531-31540	effective	_	
166-10	31541-31543	at	_	
166-11	31544-31552	reducing	_	
166-12	31553-31566	reinstatement	_	
166-13	31567-31570	and	_	
166-14	31570-31571	/	_	
166-15	31571-31573	or	_	
166-16	31574-31581	renewal	_	
166-17	31582-31584	of	_	
166-18	31585-31589	drug	_	
166-19	31589-31590	-	_	
166-20	31590-31591	,	_	
166-21	31592-31597	sugar	_	
166-22	31597-31598	-	_	
166-23	31598-31599	,	_	
166-24	31600-31603	and	_	
166-25	31604-31616	fear-related	_	
166-26	31617-31629	associations	_	
166-27	31630-31632	in	_	
166-28	31633-31640	rodents	_	
166-29	31641-31644	and	_	
166-30	31645-31651	humans	_	
166-31	31651-31652	.	_	

#Text=Some of this procedure’s success is attributed to its relative independence of the VMPFC, and may therefore represent a viable alternative for disorders with compromises in this region such as addiction.
167-1	31653-31657	Some	_	
167-2	31658-31660	of	_	
167-3	31661-31665	this	_	
167-4	31666-31675	procedure	_	
167-5	31675-31676	’	_	
167-6	31676-31677	s	_	
167-7	31678-31685	success	_	
167-8	31686-31688	is	_	
167-9	31689-31699	attributed	_	
167-10	31700-31702	to	_	
167-11	31703-31706	its	_	
167-12	31707-31715	relative	_	
167-13	31716-31728	independence	_	
167-14	31729-31731	of	_	
167-15	31732-31735	the	_	
167-16	31736-31741	VMPFC	_	
167-17	31741-31742	,	_	
167-18	31743-31746	and	_	
167-19	31747-31750	may	_	
167-20	31751-31760	therefore	_	
167-21	31761-31770	represent	_	
167-22	31771-31772	a	_	
167-23	31773-31779	viable	_	
167-24	31780-31791	alternative	_	
167-25	31792-31795	for	_	
167-26	31796-31805	disorders	_	
167-27	31806-31810	with	_	
167-28	31811-31822	compromises	_	
167-29	31823-31825	in	_	
167-30	31826-31830	this	_	
167-31	31831-31837	region	_	
167-32	31838-31842	such	_	
167-33	31843-31845	as	_	
167-34	31846-31855	addiction	_	
167-35	31855-31856	.	_	

#Text=In summary, a hallmark feature of drug addiction is an inability to discontinue drug seeking and use despite reduced pleasure derived from the drug and a range of negative consequences including the foregoing of other potentially rewarding outcomes.
168-1	31857-31859	In	_	
168-2	31860-31867	summary	_	
168-3	31867-31868	,	_	
168-4	31869-31870	a	_	
168-5	31871-31879	hallmark	_	
168-6	31880-31887	feature	_	
168-7	31888-31890	of	_	
168-8	31891-31895	drug	_	
168-9	31896-31905	addiction	_	
168-10	31906-31908	is	_	
168-11	31909-31911	an	_	
168-12	31912-31921	inability	_	
168-13	31922-31924	to	_	
168-14	31925-31936	discontinue	_	
168-15	31937-31941	drug	_	
168-16	31942-31949	seeking	_	
168-17	31950-31953	and	_	
168-18	31954-31957	use	_	
168-19	31958-31965	despite	_	
168-20	31966-31973	reduced	_	
168-21	31974-31982	pleasure	_	
168-22	31983-31990	derived	_	
168-23	31991-31995	from	_	
168-24	31996-31999	the	_	
168-25	32000-32004	drug	_	
168-26	32005-32008	and	_	
168-27	32009-32010	a	_	
168-28	32011-32016	range	_	
168-29	32017-32019	of	_	
168-30	32020-32028	negative	_	
168-31	32029-32041	consequences	_	
168-32	32042-32051	including	_	
168-33	32052-32055	the	_	
168-34	32056-32065	foregoing	_	
168-35	32066-32068	of	_	
168-36	32069-32074	other	_	
168-37	32075-32086	potentially	_	
168-38	32087-32096	rewarding	_	
168-39	32097-32105	outcomes	_	
168-40	32105-32106	.	_	

#Text=Here we show that this inability may stem from a VMPFC-mediated impairment in forming and maintaining new associations for stimuli that were previously, although no longer, predictive of both drug and non-drug related outcomes.
169-1	32107-32111	Here	_	
169-2	32112-32114	we	_	
169-3	32115-32119	show	_	
169-4	32120-32124	that	_	
169-5	32125-32129	this	_	
169-6	32130-32139	inability	_	
169-7	32140-32143	may	_	
169-8	32144-32148	stem	_	
169-9	32149-32153	from	_	
169-10	32154-32155	a	_	
169-11	32156-32170	VMPFC-mediated	_	
169-12	32171-32181	impairment	_	
169-13	32182-32184	in	_	
169-14	32185-32192	forming	_	
169-15	32193-32196	and	_	
169-16	32197-32208	maintaining	_	
169-17	32209-32212	new	_	
169-18	32213-32225	associations	_	
169-19	32226-32229	for	_	
169-20	32230-32237	stimuli	_	
169-21	32238-32242	that	_	
169-22	32243-32247	were	_	
169-23	32248-32258	previously	_	
169-24	32258-32259	,	_	
169-25	32260-32268	although	_	
169-26	32269-32271	no	_	
169-27	32272-32278	longer	_	
169-28	32278-32279	,	_	
169-29	32280-32290	predictive	_	
169-30	32291-32293	of	_	
169-31	32294-32298	both	_	
169-32	32299-32303	drug	_	
169-33	32304-32307	and	_	
169-34	32308-32316	non-drug	_	
169-35	32317-32324	related	_	
169-36	32325-32333	outcomes	_	
169-37	32333-32334	.	_	

#Text=As this impairment may hinder the success of extinction-based therapies for addiction, future work could aim to concomitantly bolster VMPFC function and/or develop treatments that minimize reliance on this region.
170-1	32335-32337	As	_	
170-2	32338-32342	this	_	
170-3	32343-32353	impairment	_	
170-4	32354-32357	may	_	
170-5	32358-32364	hinder	_	
170-6	32365-32368	the	_	
170-7	32369-32376	success	_	
170-8	32377-32379	of	_	
170-9	32380-32396	extinction-based	_	
170-10	32397-32406	therapies	_	
170-11	32407-32410	for	_	
170-12	32411-32420	addiction	_	
170-13	32420-32421	,	_	
170-14	32422-32428	future	_	
170-15	32429-32433	work	_	
170-16	32434-32439	could	_	
170-17	32440-32443	aim	_	
170-18	32444-32446	to	_	
170-19	32447-32460	concomitantly	_	
170-20	32461-32468	bolster	_	
170-21	32469-32474	VMPFC	_	
170-22	32475-32483	function	_	
170-23	32484-32487	and	_	
170-24	32487-32488	/	_	
170-25	32488-32490	or	_	
170-26	32491-32498	develop	_	
170-27	32499-32509	treatments	_	
170-28	32510-32514	that	_	
170-29	32515-32523	minimize	_	
170-30	32524-32532	reliance	_	
170-31	32533-32535	on	_	
170-32	32536-32540	this	_	
170-33	32541-32547	region	_	
170-34	32547-32548	.	_	

#Text=Supplementary Material
#Text=           Author contributions         
#Text=MAP, MRD, NA-K, and RZG were responsible for the study concept and design.
171-1	32549-32562	Supplementary	_	
171-2	32563-32571	Material	_	
171-3	32583-32589	Author	_	
171-4	32590-32603	contributions	_	
171-5	32613-32616	MAP	_	
171-6	32616-32617	,	_	
171-7	32618-32621	MRD	_	
171-8	32621-32622	,	_	
171-9	32623-32627	NA-K	_	
171-10	32627-32628	,	_	
171-11	32629-32632	and	_	
171-12	32633-32636	RZG	_	
171-13	32637-32641	were	_	
171-14	32642-32653	responsible	_	
171-15	32654-32657	for	_	
171-16	32658-32661	the	_	
171-17	32662-32667	study	_	
171-18	32668-32675	concept	_	
171-19	32676-32679	and	_	
171-20	32680-32686	design	_	
171-21	32686-32687	.	_	

#Text=ABK and MAP contributed to the acquisition of behavioral and imaging data.
172-1	32688-32691	ABK	_	
172-2	32692-32695	and	_	
172-3	32696-32699	MAP	_	
172-4	32700-32711	contributed	_	
172-5	32712-32714	to	_	
172-6	32715-32718	the	_	
172-7	32719-32730	acquisition	_	
172-8	32731-32733	of	_	
172-9	32734-32744	behavioral	_	
172-10	32745-32748	and	_	
172-11	32749-32756	imaging	_	
172-12	32757-32761	data	_	
172-13	32761-32762	.	_	

#Text=ABK, MAP, and VB performed statistical and imaging data analyses.
173-1	32763-32766	ABK	_	
173-2	32766-32767	,	_	
173-3	32768-32771	MAP	_	
173-4	32771-32772	,	_	
173-5	32773-32776	and	_	
173-6	32777-32779	VB	_	
173-7	32780-32789	performed	_	
173-8	32790-32801	statistical	_	
173-9	32802-32805	and	_	
173-10	32806-32813	imaging	_	
173-11	32814-32818	data	_	
173-12	32819-32827	analyses	_	
173-13	32827-32828	.	_	

#Text=ABK drafted the manuscript.
174-1	32829-32832	ABK	_	
174-2	32833-32840	drafted	_	
174-3	32841-32844	the	_	
174-4	32845-32855	manuscript	_	
174-5	32855-32856	.	_	

#Text=MAP, AZ, SJM, MRD and RZG provided critical revision of the manuscript for important intellectual content.
175-1	32857-32860	MAP	_	
175-2	32860-32861	,	_	
175-3	32862-32864	AZ	_	
175-4	32864-32865	,	_	
175-5	32866-32869	SJM	_	
175-6	32869-32870	,	_	
175-7	32871-32874	MRD	_	
175-8	32875-32878	and	_	
175-9	32879-32882	RZG	_	
175-10	32883-32891	provided	_	
175-11	32892-32900	critical	_	
175-12	32901-32909	revision	_	
175-13	32910-32912	of	_	
175-14	32913-32916	the	_	
175-15	32917-32927	manuscript	_	
175-16	32928-32931	for	_	
175-17	32932-32941	important	_	
175-18	32942-32954	intellectual	_	
175-19	32955-32962	content	_	
175-20	32962-32963	.	_	

#Text=All authors critically reviewed content and approved final version for journal submission.
176-1	32964-32967	All	_	
176-2	32968-32975	authors	_	
176-3	32976-32986	critically	_	
176-4	32987-32995	reviewed	_	
176-5	32996-33003	content	_	
176-6	33004-33007	and	_	
176-7	33008-33016	approved	_	
176-8	33017-33022	final	_	
176-9	33023-33030	version	_	
176-10	33031-33034	for	_	
176-11	33035-33042	journal	_	
176-12	33043-33053	submission	_	
176-13	33053-33054	.	_	

#Text=Disclosure/Conflict of Interest         
#Text=The authors declare no conflict of interest.
177-1	33066-33076	Disclosure	_	
177-2	33076-33077	/	_	
177-3	33077-33085	Conflict	_	
177-4	33086-33088	of	_	
177-5	33089-33097	Interest	_	
177-6	33107-33110	The	_	
177-7	33111-33118	authors	_	
177-8	33119-33126	declare	_	
177-9	33127-33129	no	_	
177-10	33130-33138	conflict	_	
177-11	33139-33141	of	_	
177-12	33142-33150	interest	_	
177-13	33150-33151	.	_	

#Text=Methylphenidate enhances extinction of contextual fear
#Text=Gene x disease interaction on orbitofrontal gray matter in cocaine addiction
#Text=Appetitive vs.
178-1	33152-33167	Methylphenidate	_	
178-2	33168-33176	enhances	_	
178-3	33177-33187	extinction	_	
178-4	33188-33190	of	_	
178-5	33191-33201	contextual	_	
178-6	33202-33206	fear	_	
178-7	33207-33211	Gene	_	
178-8	33212-33213	x	_	
178-9	33214-33221	disease	_	
178-10	33222-33233	interaction	_	
178-11	33234-33236	on	_	
178-12	33237-33250	orbitofrontal	_	
178-13	33251-33255	gray	_	
178-14	33256-33262	matter	_	
178-15	33263-33265	in	_	
178-16	33266-33273	cocaine	_	
178-17	33274-33283	addiction	_	
178-18	33284-33294	Appetitive	_	
178-19	33295-33297	vs	_	
178-20	33297-33298	.	_	

#Text=Aversive conditioning in humans
#Text=Post-retrieval extinction as reconsolidation interference: methodological issues or boundary conditions?
179-1	33299-33307	Aversive	_	
179-2	33308-33320	conditioning	_	
179-3	33321-33323	in	_	
179-4	33324-33330	humans	_	
179-5	33331-33345	Post-retrieval	_	
179-6	33346-33356	extinction	_	
179-7	33357-33359	as	_	
179-8	33360-33375	reconsolidation	_	
179-9	33376-33388	interference	_	
179-10	33388-33389	:	_	
179-11	33390-33404	methodological	_	
179-12	33405-33411	issues	_	
179-13	33412-33414	or	_	
179-14	33415-33423	boundary	_	
179-15	33424-33434	conditions	_	
179-16	33434-33435	?	_	

#Text=Attending to striatal ups and downs in addictions
#Text=The valuation system: a coordinate-based meta-analysis of BOLD fMRI experiments examining neural correlates of subjective value
#Text=Context and behavioral processes in extinction
#Text=Calcium-permeable AMPA receptor dynamics mediate fear memory erasure
#Text=Fear is only as deep as the mind allows: a coordinate-based meta-analysis of neuroimaging studies on the regulation of negative affect
#Text=Meta-analysis of structural brain abnormalities associated with stimulant drug dependence and neuroimaging of addiction vulnerability and resilience
#Text=Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses
#Text=
#Text=Behavioural memory reconsolidation of food and fear memories
#Text=Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications
#Text=Oral methylphenidate normalizes cingulate activity in cocaine addiction during a salient cognitive task
#Text=Value, pleasure and choice in the ventral prefrontal cortex
#Text=Brain structure correlates of individual differences in the acquisition and inhibition of conditioned fear
#Text=The promises and pitfalls of retrieval-extinction procedures in preventing relapse to drug seeking
#Text=Context-dependent human extinction memory is mediated by a ventromedial prefrontal and hippocampal network
#Text=Brain Activity During Cocaine Craving and Gambling Urges: An fMRI Study
#Text=Addiction and Addiction Treatment
#Text=Structural and behavioral correlates of abnormal encoding of money value in the sensorimotor striatum in cocaine addiction
#Text=Effects of methylphenidate on resting-state functional connectivity of the mesocorticolimbic dopamine pathways in cocaine addiction
#Text=Common biology of craving across legal and illegal drugs - a quantitative meta-analysis of cue-reactivity brain response
#Text=Biological markers of the effects of intravenous methylphenidate on improving inhibitory control in cocaine-dependent patients
#Text=A novel UCS memory retrieval-extinction procedure to inhibit relapse to drug seeking
#Text=Architecture and morphology of the human ventromedial prefrontal cortex
#Text=Persistent cocaine-induced reversal learning deficits are associated with altered limbic cortico-striatal local field potential synchronization
#Text=The Fifth Edition of the Addiction Severity Index
#Text=Inactivating the infralimbic but not prelimbic medial prefrontal cortex facilitates the extinction of appetitive Pavlovian conditioning in Long-Evans rats
#Text=Deficits in conditioned fear extinction in obsessive-compulsive disorder and neurobiological changes in the fear circuit
#Text=Presence and acquired origin of reduced recall for fear extinction in PTSD: results of a twin study
#Text=Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder
#Text=Thickness of ventromedial prefrontal cortex in humans is correlated with extinction memory
#Text=Fear extinction as a model for translational neuroscience: ten years of progress
#Text=Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert
#Text=Methylphenidate enhances executive function and optimizes prefrontal function in both health and cocaine addiction
#Text=Impaired insight in cocaine addiction: laboratory evidence and effects on cocaine-seeking behaviour
#Text=Enhanced choice for viewing cocaine pictures in cocaine addiction
#Text=Gene x abstinence effects on drug cue reactivity in addiction: multimodal evidence
#Text=Extinction-reconsolidation boundaries: key to persistent attenuation of fear memories
#Text=Functional anatomy of ventromedial prefrontal cortex: implications for mood and anxiety disorders
#Text=The use of an unpleasant sound as an unconditional stimulus in a human aversive Pavlovian conditioning procedure
#Text=Structural integrity of the prefrontal cortex modulates electrocortical sensitivity to reward
#Text=Extinction circuits for fear and addiction overlap in prefrontal cortex
#Text=Extinction learning in humans: role of the amygdala and vmPFC
#Text=Impact of DCS-facilitated cue exposure therapy on brain activation to cocaine cues in cocaine dependence
#Text=Neural mechanisms of extinction learning and retrieval
#Text=Retrieval-specific endocytosis of GluA2-AMPARs underlies adaptive reconsolidation of contextual fear
#Text=Post-Retrieval Extinction Attenuates Cocaine Memories
#Text=Overlapping neural systems mediating extinction, reversal and regulation of fear
#Text=Extinction during reconsolidation of threat memory diminishes prefrontal cortex involvement
#Text=From fear to safety and back: reversal of fear in the human brain
#Text=Preventing the return of fear in humans using reconsolidation update mechanisms
#Text=Not so bad: avoidance and aversive discounting modulate threat appraisal in anterior cingulate and medial prefrontal cortex
#Text=Cocaine-experienced rats exhibit learning deficits in a task sensitive to orbitofrontal cortex lesions
#Text=Dissociable roles of prelimbic and infralimbic cortices, ventral hippocampus, and basolateral amygdala in the expression and extinction of conditioned fear
#Text=Acute effects of cocaine and cannabis on reversal learning as a function of COMT and DRD2 genotype
#Text=Medial Orbitofrontal Cortex Gray Matter Is Reduced in Abstinent Substance-Dependent Individuals
#Text=Targeting extinction and reconsolidation mechanisms to combat the impact of drug cues on addiction
#Text=Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P)
#Text=Methylphenidate attenuates limbic brain inhibition after cocaine-cues exposure in cocaine abusers
#Text=Effects of cue-exposure treatment on neural cue reactivity in alcohol dependence: a randomized trial
#Text=A memory retrieval-extinction procedure to prevent drug craving and relapse
#Text=Ventromedial prefrontal cortex and the regulation of physiological arousal
#Text=Study overview and conditioning paradigm.
180-1	33436-33445	Attending	_	
180-2	33446-33448	to	_	
180-3	33449-33457	striatal	_	
180-4	33458-33461	ups	_	
180-5	33462-33465	and	_	
180-6	33466-33471	downs	_	
180-7	33472-33474	in	_	
180-8	33475-33485	addictions	_	
180-9	33486-33489	The	_	
180-10	33490-33499	valuation	_	
180-11	33500-33506	system	_	
180-12	33506-33507	:	_	
180-13	33508-33509	a	_	
180-14	33510-33526	coordinate-based	_	
180-15	33527-33540	meta-analysis	_	
180-16	33541-33543	of	_	
180-17	33544-33548	BOLD	_	
180-18	33549-33553	fMRI	_	
180-19	33554-33565	experiments	_	
180-20	33566-33575	examining	_	
180-21	33576-33582	neural	_	
180-22	33583-33593	correlates	_	
180-23	33594-33596	of	_	
180-24	33597-33607	subjective	_	
180-25	33608-33613	value	_	
180-26	33614-33621	Context	_	
180-27	33622-33625	and	_	
180-28	33626-33636	behavioral	_	
180-29	33637-33646	processes	_	
180-30	33647-33649	in	_	
180-31	33650-33660	extinction	_	
180-32	33661-33678	Calcium-permeable	_	
180-33	33679-33683	AMPA	_	
180-34	33684-33692	receptor	_	
180-35	33693-33701	dynamics	_	
180-36	33702-33709	mediate	_	
180-37	33710-33714	fear	_	
180-38	33715-33721	memory	_	
180-39	33722-33729	erasure	_	
180-40	33730-33734	Fear	_	
180-41	33735-33737	is	_	
180-42	33738-33742	only	_	
180-43	33743-33745	as	_	
180-44	33746-33750	deep	_	
180-45	33751-33753	as	_	
180-46	33754-33757	the	_	
180-47	33758-33762	mind	_	
180-48	33763-33769	allows	_	
180-49	33769-33770	:	_	
180-50	33771-33772	a	_	
180-51	33773-33789	coordinate-based	_	
180-52	33790-33803	meta-analysis	_	
180-53	33804-33806	of	_	
180-54	33807-33819	neuroimaging	_	
180-55	33820-33827	studies	_	
180-56	33828-33830	on	_	
180-57	33831-33834	the	_	
180-58	33835-33845	regulation	_	
180-59	33846-33848	of	_	
180-60	33849-33857	negative	_	
180-61	33858-33864	affect	_	
180-62	33865-33878	Meta-analysis	_	
180-63	33879-33881	of	_	
180-64	33882-33892	structural	_	
180-65	33893-33898	brain	_	
180-66	33899-33912	abnormalities	_	
180-67	33913-33923	associated	_	
180-68	33924-33928	with	_	
180-69	33929-33938	stimulant	_	
180-70	33939-33943	drug	_	
180-71	33944-33954	dependence	_	
180-72	33955-33958	and	_	
180-73	33959-33971	neuroimaging	_	
180-74	33972-33974	of	_	
180-75	33975-33984	addiction	_	
180-76	33985-33998	vulnerability	_	
180-77	33999-34002	and	_	
180-78	34003-34013	resilience	_	
180-79	34014-34025	Statistical	_	
180-80	34026-34031	power	_	
180-81	34032-34040	analyses	_	
180-82	34041-34046	using	_	
180-83	34047-34048	G	_	
180-84	34048-34049	*	_	
180-85	34049-34054	Power	_	
180-86	34055-34058	3.1	_	
180-87	34058-34059	:	_	
180-88	34060-34065	tests	_	
180-89	34066-34069	for	_	
180-90	34070-34081	correlation	_	
180-91	34082-34085	and	_	
180-92	34086-34096	regression	_	
180-93	34097-34105	analyses	_	
180-94	34107-34118	Behavioural	_	
180-95	34119-34125	memory	_	
180-96	34126-34141	reconsolidation	_	
180-97	34142-34144	of	_	
180-98	34145-34149	food	_	
180-99	34150-34153	and	_	
180-100	34154-34158	fear	_	
180-101	34159-34167	memories	_	
180-102	34168-34179	Dysfunction	_	
180-103	34180-34182	of	_	
180-104	34183-34186	the	_	
180-105	34187-34197	prefrontal	_	
180-106	34198-34204	cortex	_	
180-107	34205-34207	in	_	
180-108	34208-34217	addiction	_	
180-109	34217-34218	:	_	
180-110	34219-34231	neuroimaging	_	
180-111	34232-34240	findings	_	
180-112	34241-34244	and	_	
180-113	34245-34253	clinical	_	
180-114	34254-34266	implications	_	
180-115	34267-34271	Oral	_	
180-116	34272-34287	methylphenidate	_	
180-117	34288-34298	normalizes	_	
180-118	34299-34308	cingulate	_	
180-119	34309-34317	activity	_	
180-120	34318-34320	in	_	
180-121	34321-34328	cocaine	_	
180-122	34329-34338	addiction	_	
180-123	34339-34345	during	_	
180-124	34346-34347	a	_	
180-125	34348-34355	salient	_	
180-126	34356-34365	cognitive	_	
180-127	34366-34370	task	_	
180-128	34371-34376	Value	_	
180-129	34376-34377	,	_	
180-130	34378-34386	pleasure	_	
180-131	34387-34390	and	_	
180-132	34391-34397	choice	_	
180-133	34398-34400	in	_	
180-134	34401-34404	the	_	
180-135	34405-34412	ventral	_	
180-136	34413-34423	prefrontal	_	
180-137	34424-34430	cortex	_	
180-138	34431-34436	Brain	_	
180-139	34437-34446	structure	_	
180-140	34447-34457	correlates	_	
180-141	34458-34460	of	_	
180-142	34461-34471	individual	_	
180-143	34472-34483	differences	_	
180-144	34484-34486	in	_	
180-145	34487-34490	the	_	
180-146	34491-34502	acquisition	_	
180-147	34503-34506	and	_	
180-148	34507-34517	inhibition	_	
180-149	34518-34520	of	_	
180-150	34521-34532	conditioned	_	
180-151	34533-34537	fear	_	
180-152	34538-34541	The	_	
180-153	34542-34550	promises	_	
180-154	34551-34554	and	_	
180-155	34555-34563	pitfalls	_	
180-156	34564-34566	of	_	
180-157	34567-34587	retrieval-extinction	_	
180-158	34588-34598	procedures	_	
180-159	34599-34601	in	_	
180-160	34602-34612	preventing	_	
180-161	34613-34620	relapse	_	
180-162	34621-34623	to	_	
180-163	34624-34628	drug	_	
180-164	34629-34636	seeking	_	
180-165	34637-34654	Context-dependent	_	
180-166	34655-34660	human	_	
180-167	34661-34671	extinction	_	
180-168	34672-34678	memory	_	
180-169	34679-34681	is	_	
180-170	34682-34690	mediated	_	
180-171	34691-34693	by	_	
180-172	34694-34695	a	_	
180-173	34696-34708	ventromedial	_	
180-174	34709-34719	prefrontal	_	
180-175	34720-34723	and	_	
180-176	34724-34735	hippocampal	_	
180-177	34736-34743	network	_	
180-178	34744-34749	Brain	_	
180-179	34750-34758	Activity	_	
180-180	34759-34765	During	_	
180-181	34766-34773	Cocaine	_	
180-182	34774-34781	Craving	_	
180-183	34782-34785	and	_	
180-184	34786-34794	Gambling	_	
180-185	34795-34800	Urges	_	
180-186	34800-34801	:	_	
180-187	34802-34804	An	_	
180-188	34805-34809	fMRI	_	
180-189	34810-34815	Study	_	
180-190	34816-34825	Addiction	_	
180-191	34826-34829	and	_	
180-192	34830-34839	Addiction	_	
180-193	34840-34849	Treatment	_	
180-194	34850-34860	Structural	_	
180-195	34861-34864	and	_	
180-196	34865-34875	behavioral	_	
180-197	34876-34886	correlates	_	
180-198	34887-34889	of	_	
180-199	34890-34898	abnormal	_	
180-200	34899-34907	encoding	_	
180-201	34908-34910	of	_	
180-202	34911-34916	money	_	
180-203	34917-34922	value	_	
180-204	34923-34925	in	_	
180-205	34926-34929	the	_	
180-206	34930-34942	sensorimotor	_	
180-207	34943-34951	striatum	_	
180-208	34952-34954	in	_	
180-209	34955-34962	cocaine	_	
180-210	34963-34972	addiction	_	
180-211	34973-34980	Effects	_	
180-212	34981-34983	of	_	
180-213	34984-34999	methylphenidate	_	
180-214	35000-35002	on	_	
180-215	35003-35016	resting-state	_	
180-216	35017-35027	functional	_	
180-217	35028-35040	connectivity	_	
180-218	35041-35043	of	_	
180-219	35044-35047	the	_	
180-220	35048-35065	mesocorticolimbic	_	
180-221	35066-35074	dopamine	_	
180-222	35075-35083	pathways	_	
180-223	35084-35086	in	_	
180-224	35087-35094	cocaine	_	
180-225	35095-35104	addiction	_	
180-226	35105-35111	Common	_	
180-227	35112-35119	biology	_	
180-228	35120-35122	of	_	
180-229	35123-35130	craving	_	
180-230	35131-35137	across	_	
180-231	35138-35143	legal	_	
180-232	35144-35147	and	_	
180-233	35148-35155	illegal	_	
180-234	35156-35161	drugs	_	
180-235	35162-35163	-	_	
180-236	35164-35165	a	_	
180-237	35166-35178	quantitative	_	
180-238	35179-35192	meta-analysis	_	
180-239	35193-35195	of	_	
180-240	35196-35210	cue-reactivity	_	
180-241	35211-35216	brain	_	
180-242	35217-35225	response	_	
180-243	35226-35236	Biological	_	
180-244	35237-35244	markers	_	
180-245	35245-35247	of	_	
180-246	35248-35251	the	_	
180-247	35252-35259	effects	_	
180-248	35260-35262	of	_	
180-249	35263-35274	intravenous	_	
180-250	35275-35290	methylphenidate	_	
180-251	35291-35293	on	_	
180-252	35294-35303	improving	_	
180-253	35304-35314	inhibitory	_	
180-254	35315-35322	control	_	
180-255	35323-35325	in	_	
180-256	35326-35343	cocaine-dependent	_	
180-257	35344-35352	patients	_	
180-258	35353-35354	A	_	
180-259	35355-35360	novel	_	
180-260	35361-35364	UCS	_	
180-261	35365-35371	memory	_	
180-262	35372-35392	retrieval-extinction	_	
180-263	35393-35402	procedure	_	
180-264	35403-35405	to	_	
180-265	35406-35413	inhibit	_	
180-266	35414-35421	relapse	_	
180-267	35422-35424	to	_	
180-268	35425-35429	drug	_	
180-269	35430-35437	seeking	_	
180-270	35438-35450	Architecture	_	
180-271	35451-35454	and	_	
180-272	35455-35465	morphology	_	
180-273	35466-35468	of	_	
180-274	35469-35472	the	_	
180-275	35473-35478	human	_	
180-276	35479-35491	ventromedial	_	
180-277	35492-35502	prefrontal	_	
180-278	35503-35509	cortex	_	
180-279	35510-35520	Persistent	_	
180-280	35521-35536	cocaine-induced	_	
180-281	35537-35545	reversal	_	
180-282	35546-35554	learning	_	
180-283	35555-35563	deficits	_	
180-284	35564-35567	are	_	
180-285	35568-35578	associated	_	
180-286	35579-35583	with	_	
180-287	35584-35591	altered	_	
180-288	35592-35598	limbic	_	
180-289	35599-35615	cortico-striatal	_	
180-290	35616-35621	local	_	
180-291	35622-35627	field	_	
180-292	35628-35637	potential	_	
180-293	35638-35653	synchronization	_	
180-294	35654-35657	The	_	
180-295	35658-35663	Fifth	_	
180-296	35664-35671	Edition	_	
180-297	35672-35674	of	_	
180-298	35675-35678	the	_	
180-299	35679-35688	Addiction	_	
180-300	35689-35697	Severity	_	
180-301	35698-35703	Index	_	
180-302	35704-35716	Inactivating	_	
180-303	35717-35720	the	_	
180-304	35721-35732	infralimbic	_	
180-305	35733-35736	but	_	
180-306	35737-35740	not	_	
180-307	35741-35750	prelimbic	_	
180-308	35751-35757	medial	_	
180-309	35758-35768	prefrontal	_	
180-310	35769-35775	cortex	_	
180-311	35776-35787	facilitates	_	
180-312	35788-35791	the	_	
180-313	35792-35802	extinction	_	
180-314	35803-35805	of	_	
180-315	35806-35816	appetitive	_	
180-316	35817-35826	Pavlovian	_	
180-317	35827-35839	conditioning	_	
180-318	35840-35842	in	_	
180-319	35843-35853	Long-Evans	_	
180-320	35854-35858	rats	_	
180-321	35859-35867	Deficits	_	
180-322	35868-35870	in	_	
180-323	35871-35882	conditioned	_	
180-324	35883-35887	fear	_	
180-325	35888-35898	extinction	_	
180-326	35899-35901	in	_	
180-327	35902-35922	obsessive-compulsive	_	
180-328	35923-35931	disorder	_	
180-329	35932-35935	and	_	
180-330	35936-35951	neurobiological	_	
180-331	35952-35959	changes	_	
180-332	35960-35962	in	_	
180-333	35963-35966	the	_	
180-334	35967-35971	fear	_	
180-335	35972-35979	circuit	_	
180-336	35980-35988	Presence	_	
180-337	35989-35992	and	_	
180-338	35993-36001	acquired	_	
180-339	36002-36008	origin	_	
180-340	36009-36011	of	_	
180-341	36012-36019	reduced	_	
180-342	36020-36026	recall	_	
180-343	36027-36030	for	_	
180-344	36031-36035	fear	_	
180-345	36036-36046	extinction	_	
180-346	36047-36049	in	_	
180-347	36050-36054	PTSD	_	
180-348	36054-36055	:	_	
180-349	36056-36063	results	_	
180-350	36064-36066	of	_	
180-351	36067-36068	a	_	
180-352	36069-36073	twin	_	
180-353	36074-36079	study	_	
180-354	36080-36095	Neurobiological	_	
180-355	36096-36101	basis	_	
180-356	36102-36104	of	_	
180-357	36105-36112	failure	_	
180-358	36113-36115	to	_	
180-359	36116-36122	recall	_	
180-360	36123-36133	extinction	_	
180-361	36134-36140	memory	_	
180-362	36141-36143	in	_	
180-363	36144-36157	posttraumatic	_	
180-364	36158-36164	stress	_	
180-365	36165-36173	disorder	_	
180-366	36174-36183	Thickness	_	
180-367	36184-36186	of	_	
180-368	36187-36199	ventromedial	_	
180-369	36200-36210	prefrontal	_	
180-370	36211-36217	cortex	_	
180-371	36218-36220	in	_	
180-372	36221-36227	humans	_	
180-373	36228-36230	is	_	
180-374	36231-36241	correlated	_	
180-375	36242-36246	with	_	
180-376	36247-36257	extinction	_	
180-377	36258-36264	memory	_	
180-378	36265-36269	Fear	_	
180-379	36270-36280	extinction	_	
180-380	36281-36283	as	_	
180-381	36284-36285	a	_	
180-382	36286-36291	model	_	
180-383	36292-36295	for	_	
180-384	36296-36309	translational	_	
180-385	36310-36322	neuroscience	_	
180-386	36322-36323	:	_	
180-387	36324-36327	ten	_	
180-388	36328-36333	years	_	
180-389	36334-36336	of	_	
180-390	36337-36345	progress	_	
180-391	36346-36352	Recall	_	
180-392	36353-36355	of	_	
180-393	36356-36360	fear	_	
180-394	36361-36371	extinction	_	
180-395	36372-36374	in	_	
180-396	36375-36381	humans	_	
180-397	36382-36391	activates	_	
180-398	36392-36395	the	_	
180-399	36396-36408	ventromedial	_	
180-400	36409-36419	prefrontal	_	
180-401	36420-36426	cortex	_	
180-402	36427-36430	and	_	
180-403	36431-36442	hippocampus	_	
180-404	36443-36445	in	_	
180-405	36446-36453	concert	_	
180-406	36454-36469	Methylphenidate	_	
180-407	36470-36478	enhances	_	
180-408	36479-36488	executive	_	
180-409	36489-36497	function	_	
180-410	36498-36501	and	_	
180-411	36502-36511	optimizes	_	
180-412	36512-36522	prefrontal	_	
180-413	36523-36531	function	_	
180-414	36532-36534	in	_	
180-415	36535-36539	both	_	
180-416	36540-36546	health	_	
180-417	36547-36550	and	_	
180-418	36551-36558	cocaine	_	
180-419	36559-36568	addiction	_	
180-420	36569-36577	Impaired	_	
180-421	36578-36585	insight	_	
180-422	36586-36588	in	_	
180-423	36589-36596	cocaine	_	
180-424	36597-36606	addiction	_	
180-425	36606-36607	:	_	
180-426	36608-36618	laboratory	_	
180-427	36619-36627	evidence	_	
180-428	36628-36631	and	_	
180-429	36632-36639	effects	_	
180-430	36640-36642	on	_	
180-431	36643-36658	cocaine-seeking	_	
180-432	36659-36668	behaviour	_	
180-433	36669-36677	Enhanced	_	
180-434	36678-36684	choice	_	
180-435	36685-36688	for	_	
180-436	36689-36696	viewing	_	
180-437	36697-36704	cocaine	_	
180-438	36705-36713	pictures	_	
180-439	36714-36716	in	_	
180-440	36717-36724	cocaine	_	
180-441	36725-36734	addiction	_	
180-442	36735-36739	Gene	_	
180-443	36740-36741	x	_	
180-444	36742-36752	abstinence	_	
180-445	36753-36760	effects	_	
180-446	36761-36763	on	_	
180-447	36764-36768	drug	_	
180-448	36769-36772	cue	_	
180-449	36773-36783	reactivity	_	
180-450	36784-36786	in	_	
180-451	36787-36796	addiction	_	
180-452	36796-36797	:	_	
180-453	36798-36808	multimodal	_	
180-454	36809-36817	evidence	_	
180-455	36818-36844	Extinction-reconsolidation	_	
180-456	36845-36855	boundaries	_	
180-457	36855-36856	:	_	
180-458	36857-36860	key	_	
180-459	36861-36863	to	_	
180-460	36864-36874	persistent	_	
180-461	36875-36886	attenuation	_	
180-462	36887-36889	of	_	
180-463	36890-36894	fear	_	
180-464	36895-36903	memories	_	
180-465	36904-36914	Functional	_	
180-466	36915-36922	anatomy	_	
180-467	36923-36925	of	_	
180-468	36926-36938	ventromedial	_	
180-469	36939-36949	prefrontal	_	
180-470	36950-36956	cortex	_	
180-471	36956-36957	:	_	
180-472	36958-36970	implications	_	
180-473	36971-36974	for	_	
180-474	36975-36979	mood	_	
180-475	36980-36983	and	_	
180-476	36984-36991	anxiety	_	
180-477	36992-37001	disorders	_	
180-478	37002-37005	The	_	
180-479	37006-37009	use	_	
180-480	37010-37012	of	_	
180-481	37013-37015	an	_	
180-482	37016-37026	unpleasant	_	
180-483	37027-37032	sound	_	
180-484	37033-37035	as	_	
180-485	37036-37038	an	_	
180-486	37039-37052	unconditional	_	
180-487	37053-37061	stimulus	_	
180-488	37062-37064	in	_	
180-489	37065-37066	a	_	
180-490	37067-37072	human	_	
180-491	37073-37081	aversive	_	
180-492	37082-37091	Pavlovian	_	
180-493	37092-37104	conditioning	_	
180-494	37105-37114	procedure	_	
180-495	37115-37125	Structural	_	
180-496	37126-37135	integrity	_	
180-497	37136-37138	of	_	
180-498	37139-37142	the	_	
180-499	37143-37153	prefrontal	_	
180-500	37154-37160	cortex	_	
180-501	37161-37170	modulates	_	
180-502	37171-37186	electrocortical	_	
180-503	37187-37198	sensitivity	_	
180-504	37199-37201	to	_	
180-505	37202-37208	reward	_	
180-506	37209-37219	Extinction	_	
180-507	37220-37228	circuits	_	
180-508	37229-37232	for	_	
180-509	37233-37237	fear	_	
180-510	37238-37241	and	_	
180-511	37242-37251	addiction	_	
180-512	37252-37259	overlap	_	
180-513	37260-37262	in	_	
180-514	37263-37273	prefrontal	_	
180-515	37274-37280	cortex	_	
180-516	37281-37291	Extinction	_	
180-517	37292-37300	learning	_	
180-518	37301-37303	in	_	
180-519	37304-37310	humans	_	
180-520	37310-37311	:	_	
180-521	37312-37316	role	_	
180-522	37317-37319	of	_	
180-523	37320-37323	the	_	
180-524	37324-37332	amygdala	_	
180-525	37333-37336	and	_	
180-526	37337-37342	vmPFC	_	
180-527	37343-37349	Impact	_	
180-528	37350-37352	of	_	
180-529	37353-37368	DCS-facilitated	_	
180-530	37369-37372	cue	_	
180-531	37373-37381	exposure	_	
180-532	37382-37389	therapy	_	
180-533	37390-37392	on	_	
180-534	37393-37398	brain	_	
180-535	37399-37409	activation	_	
180-536	37410-37412	to	_	
180-537	37413-37420	cocaine	_	
180-538	37421-37425	cues	_	
180-539	37426-37428	in	_	
180-540	37429-37436	cocaine	_	
180-541	37437-37447	dependence	_	
180-542	37448-37454	Neural	_	
180-543	37455-37465	mechanisms	_	
180-544	37466-37468	of	_	
180-545	37469-37479	extinction	_	
180-546	37480-37488	learning	_	
180-547	37489-37492	and	_	
180-548	37493-37502	retrieval	_	
180-549	37503-37521	Retrieval-specific	_	
180-550	37522-37533	endocytosis	_	
180-551	37534-37536	of	_	
180-552	37537-37542	GluA2	_	
180-553	37542-37543	-	_	
180-554	37543-37549	AMPARs	_	
180-555	37550-37559	underlies	_	
180-556	37560-37568	adaptive	_	
180-557	37569-37584	reconsolidation	_	
180-558	37585-37587	of	_	
180-559	37588-37598	contextual	_	
180-560	37599-37603	fear	_	
180-561	37604-37618	Post-Retrieval	_	
180-562	37619-37629	Extinction	_	
180-563	37630-37640	Attenuates	_	
180-564	37641-37648	Cocaine	_	
180-565	37649-37657	Memories	_	
180-566	37658-37669	Overlapping	_	
180-567	37670-37676	neural	_	
180-568	37677-37684	systems	_	
180-569	37685-37694	mediating	_	
180-570	37695-37705	extinction	_	
180-571	37705-37706	,	_	
180-572	37707-37715	reversal	_	
180-573	37716-37719	and	_	
180-574	37720-37730	regulation	_	
180-575	37731-37733	of	_	
180-576	37734-37738	fear	_	
180-577	37739-37749	Extinction	_	
180-578	37750-37756	during	_	
180-579	37757-37772	reconsolidation	_	
180-580	37773-37775	of	_	
180-581	37776-37782	threat	_	
180-582	37783-37789	memory	_	
180-583	37790-37800	diminishes	_	
180-584	37801-37811	prefrontal	_	
180-585	37812-37818	cortex	_	
180-586	37819-37830	involvement	_	
180-587	37831-37835	From	_	
180-588	37836-37840	fear	_	
180-589	37841-37843	to	_	
180-590	37844-37850	safety	_	
180-591	37851-37854	and	_	
180-592	37855-37859	back	_	
180-593	37859-37860	:	_	
180-594	37861-37869	reversal	_	
180-595	37870-37872	of	_	
180-596	37873-37877	fear	_	
180-597	37878-37880	in	_	
180-598	37881-37884	the	_	
180-599	37885-37890	human	_	
180-600	37891-37896	brain	_	
180-601	37897-37907	Preventing	_	
180-602	37908-37911	the	_	
180-603	37912-37918	return	_	
180-604	37919-37921	of	_	
180-605	37922-37926	fear	_	
180-606	37927-37929	in	_	
180-607	37930-37936	humans	_	
180-608	37937-37942	using	_	
180-609	37943-37958	reconsolidation	_	
180-610	37959-37965	update	_	
180-611	37966-37976	mechanisms	_	
180-612	37977-37980	Not	_	
180-613	37981-37983	so	_	
180-614	37984-37987	bad	_	
180-615	37987-37988	:	_	
180-616	37989-37998	avoidance	_	
180-617	37999-38002	and	_	
180-618	38003-38011	aversive	_	
180-619	38012-38023	discounting	_	
180-620	38024-38032	modulate	_	
180-621	38033-38039	threat	_	
180-622	38040-38049	appraisal	_	
180-623	38050-38052	in	_	
180-624	38053-38061	anterior	_	
180-625	38062-38071	cingulate	_	
180-626	38072-38075	and	_	
180-627	38076-38082	medial	_	
180-628	38083-38093	prefrontal	_	
180-629	38094-38100	cortex	_	
180-630	38101-38120	Cocaine-experienced	_	
180-631	38121-38125	rats	_	
180-632	38126-38133	exhibit	_	
180-633	38134-38142	learning	_	
180-634	38143-38151	deficits	_	
180-635	38152-38154	in	_	
180-636	38155-38156	a	_	
180-637	38157-38161	task	_	
180-638	38162-38171	sensitive	_	
180-639	38172-38174	to	_	
180-640	38175-38188	orbitofrontal	_	
180-641	38189-38195	cortex	_	
180-642	38196-38203	lesions	_	
180-643	38204-38215	Dissociable	_	
180-644	38216-38221	roles	_	
180-645	38222-38224	of	_	
180-646	38225-38234	prelimbic	_	
180-647	38235-38238	and	_	
180-648	38239-38250	infralimbic	_	
180-649	38251-38259	cortices	_	
180-650	38259-38260	,	_	
180-651	38261-38268	ventral	_	
180-652	38269-38280	hippocampus	_	
180-653	38280-38281	,	_	
180-654	38282-38285	and	_	
180-655	38286-38297	basolateral	_	
180-656	38298-38306	amygdala	_	
180-657	38307-38309	in	_	
180-658	38310-38313	the	_	
180-659	38314-38324	expression	_	
180-660	38325-38328	and	_	
180-661	38329-38339	extinction	_	
180-662	38340-38342	of	_	
180-663	38343-38354	conditioned	_	
180-664	38355-38359	fear	_	
180-665	38360-38365	Acute	_	
180-666	38366-38373	effects	_	
180-667	38374-38376	of	_	
180-668	38377-38384	cocaine	_	
180-669	38385-38388	and	_	
180-670	38389-38397	cannabis	_	
180-671	38398-38400	on	_	
180-672	38401-38409	reversal	_	
180-673	38410-38418	learning	_	
180-674	38419-38421	as	_	
180-675	38422-38423	a	_	
180-676	38424-38432	function	_	
180-677	38433-38435	of	_	
180-678	38436-38440	COMT	_	
180-679	38441-38444	and	_	
180-680	38445-38449	DRD2	_	
180-681	38450-38458	genotype	_	
180-682	38459-38465	Medial	_	
180-683	38466-38479	Orbitofrontal	_	
180-684	38480-38486	Cortex	_	
180-685	38487-38491	Gray	_	
180-686	38492-38498	Matter	_	
180-687	38499-38501	Is	_	
180-688	38502-38509	Reduced	_	
180-689	38510-38512	in	_	
180-690	38513-38522	Abstinent	_	
180-691	38523-38542	Substance-Dependent	_	
180-692	38543-38554	Individuals	_	
180-693	38555-38564	Targeting	_	
180-694	38565-38575	extinction	_	
180-695	38576-38579	and	_	
180-696	38580-38595	reconsolidation	_	
180-697	38596-38606	mechanisms	_	
180-698	38607-38609	to	_	
180-699	38610-38616	combat	_	
180-700	38617-38620	the	_	
180-701	38621-38627	impact	_	
180-702	38628-38630	of	_	
180-703	38631-38635	drug	_	
180-704	38636-38640	cues	_	
180-705	38641-38643	on	_	
180-706	38644-38653	addiction	_	
180-707	38654-38662	Training	_	
180-708	38663-38666	and	_	
180-709	38667-38674	quality	_	
180-710	38675-38684	assurance	_	
180-711	38685-38689	with	_	
180-712	38690-38693	the	_	
180-713	38694-38704	Structured	_	
180-714	38705-38713	Clinical	_	
180-715	38714-38723	Interview	_	
180-716	38724-38727	for	_	
180-717	38728-38734	DSM-IV	_	
180-718	38735-38736	(	_	
180-719	38736-38742	SCID-I	_	
180-720	38742-38743	/	_	
180-721	38743-38744	P	_	
180-722	38744-38745	)	_	
180-723	38746-38761	Methylphenidate	_	
180-724	38762-38772	attenuates	_	
180-725	38773-38779	limbic	_	
180-726	38780-38785	brain	_	
180-727	38786-38796	inhibition	_	
180-728	38797-38802	after	_	
180-729	38803-38815	cocaine-cues	_	
180-730	38816-38824	exposure	_	
180-731	38825-38827	in	_	
180-732	38828-38835	cocaine	_	
180-733	38836-38843	abusers	_	
180-734	38844-38851	Effects	_	
180-735	38852-38854	of	_	
180-736	38855-38867	cue-exposure	_	
180-737	38868-38877	treatment	_	
180-738	38878-38880	on	_	
180-739	38881-38887	neural	_	
180-740	38888-38891	cue	_	
180-741	38892-38902	reactivity	_	
180-742	38903-38905	in	_	
180-743	38906-38913	alcohol	_	
180-744	38914-38924	dependence	_	
180-745	38924-38925	:	_	
180-746	38926-38927	a	_	
180-747	38928-38938	randomized	_	
180-748	38939-38944	trial	_	
180-749	38945-38946	A	_	
180-750	38947-38953	memory	_	
180-751	38954-38974	retrieval-extinction	_	
180-752	38975-38984	procedure	_	
180-753	38985-38987	to	_	
180-754	38988-38995	prevent	_	
180-755	38996-39000	drug	_	
180-756	39001-39008	craving	_	
180-757	39009-39012	and	_	
180-758	39013-39020	relapse	_	
180-759	39021-39033	Ventromedial	_	
180-760	39034-39044	prefrontal	_	
180-761	39045-39051	cortex	_	
180-762	39052-39055	and	_	
180-763	39056-39059	the	_	
180-764	39060-39070	regulation	_	
180-765	39071-39073	of	_	
180-766	39074-39087	physiological	_	
180-767	39088-39095	arousal	_	
180-768	39096-39101	Study	_	
180-769	39102-39110	overview	_	
180-770	39111-39114	and	_	
180-771	39115-39127	conditioning	_	
180-772	39128-39136	paradigm	_	
180-773	39136-39137	.	_	

#Text=While in the MRI scanner and over the course of three scanning sessions, subjects learned to associate a cue (colored square), the CS, with a drug-related (CSD+), affectively pleasant (CSP+), or neutral (CS-) image.
181-1	39138-39143	While	_	
181-2	39144-39146	in	_	
181-3	39147-39150	the	_	
181-4	39151-39154	MRI	_	
181-5	39155-39162	scanner	_	
181-6	39163-39166	and	_	
181-7	39167-39171	over	_	
181-8	39172-39175	the	_	
181-9	39176-39182	course	_	
181-10	39183-39185	of	_	
181-11	39186-39191	three	_	
181-12	39192-39200	scanning	_	
181-13	39201-39209	sessions	_	
181-14	39209-39210	,	_	
181-15	39211-39219	subjects	_	
181-16	39220-39227	learned	_	
181-17	39228-39230	to	_	
181-18	39231-39240	associate	_	
181-19	39241-39242	a	_	
181-20	39243-39246	cue	_	
181-21	39247-39248	(	_	
181-22	39248-39255	colored	_	
181-23	39256-39262	square	_	
181-24	39262-39263	)	_	
181-25	39263-39264	,	_	
181-26	39265-39268	the	_	
181-27	39269-39271	CS	_	
181-28	39271-39272	,	_	
181-29	39273-39277	with	_	
181-30	39278-39279	a	_	
181-31	39280-39292	drug-related	_	
181-32	39293-39294	(	_	
181-33	39294-39297	CSD	_	
181-34	39297-39298	+	_	
181-35	39298-39299	)	_	
181-36	39299-39300	,	_	
181-37	39301-39312	affectively	_	
181-38	39313-39321	pleasant	_	
181-39	39322-39323	(	_	
181-40	39323-39326	CSP	_	
181-41	39326-39327	+	_	
181-42	39327-39328	)	_	
181-43	39328-39329	,	_	
181-44	39330-39332	or	_	
181-45	39333-39340	neutral	_	
181-46	39341-39342	(	_	
181-47	39342-39344	CS	_	
181-48	39344-39345	-	_	
181-49	39345-39346	)	_	
181-50	39347-39352	image	_	
181-51	39352-39353	.	_	

#Text=Following two reinforced presentations of the CS for each CS type (not shown), extinction training immediately followed acquisition, where the CS was presented repeatedly without the paired image.
182-1	39354-39363	Following	_	
182-2	39364-39367	two	_	
182-3	39368-39378	reinforced	_	
182-4	39379-39392	presentations	_	
182-5	39393-39395	of	_	
182-6	39396-39399	the	_	
182-7	39400-39402	CS	_	
182-8	39403-39406	for	_	
182-9	39407-39411	each	_	
182-10	39412-39414	CS	_	
182-11	39415-39419	type	_	
182-12	39420-39421	(	_	
182-13	39421-39424	not	_	
182-14	39425-39430	shown	_	
182-15	39430-39431	)	_	
182-16	39431-39432	,	_	
182-17	39433-39443	extinction	_	
182-18	39444-39452	training	_	
182-19	39453-39464	immediately	_	
182-20	39465-39473	followed	_	
182-21	39474-39485	acquisition	_	
182-22	39485-39486	,	_	
182-23	39487-39492	where	_	
182-24	39493-39496	the	_	
182-25	39497-39499	CS	_	
182-26	39500-39503	was	_	
182-27	39504-39513	presented	_	
182-28	39514-39524	repeatedly	_	
182-29	39525-39532	without	_	
182-30	39533-39536	the	_	
182-31	39537-39543	paired	_	
182-32	39544-39549	image	_	
182-33	39549-39550	.	_	

#Text=A second extinction training session took place 24 h later.
183-1	39551-39552	A	_	
183-2	39553-39559	second	_	
183-3	39560-39570	extinction	_	
183-4	39571-39579	training	_	
183-5	39580-39587	session	_	
183-6	39588-39592	took	_	
183-7	39593-39598	place	_	
183-8	39599-39601	24	_	
183-9	39602-39603	h	_	
183-10	39604-39609	later	_	
183-11	39609-39610	.	_	

#Text=A typical paired trial consisted of presentation of the CS for 3.5 s, followed by presentation of the US (the corresponding image) inside the CS for 1.5 s, a variable ~1.5 s fixation screen, and a 1 s screen requiring a non-contingent button press indicating whether the US appeared or not on that trial.
184-1	39611-39612	A	_	
184-2	39613-39620	typical	_	
184-3	39621-39627	paired	_	
184-4	39628-39633	trial	_	
184-5	39634-39643	consisted	_	
184-6	39644-39646	of	_	
184-7	39647-39659	presentation	_	
184-8	39660-39662	of	_	
184-9	39663-39666	the	_	
184-10	39667-39669	CS	_	
184-11	39670-39673	for	_	
184-12	39674-39677	3.5	_	
184-13	39678-39679	s	_	
184-14	39679-39680	,	_	
184-15	39681-39689	followed	_	
184-16	39690-39692	by	_	
184-17	39693-39705	presentation	_	
184-18	39706-39708	of	_	
184-19	39709-39712	the	_	
184-20	39713-39715	US	_	
184-21	39716-39717	(	_	
184-22	39717-39720	the	_	
184-23	39721-39734	corresponding	_	
184-24	39735-39740	image	_	
184-25	39740-39741	)	_	
184-26	39742-39748	inside	_	
184-27	39749-39752	the	_	
184-28	39753-39755	CS	_	
184-29	39756-39759	for	_	
184-30	39760-39763	1.5	_	
184-31	39764-39765	s	_	
184-32	39765-39766	,	_	
184-33	39767-39768	a	_	
184-34	39769-39777	variable	_	
184-35	39778-39779	~	_	
184-36	39779-39782	1.5	_	
184-37	39783-39784	s	_	
184-38	39785-39793	fixation	_	
184-39	39794-39800	screen	_	
184-40	39800-39801	,	_	
184-41	39802-39805	and	_	
184-42	39806-39807	a	_	
184-43	39808-39809	1	_	
184-44	39810-39811	s	_	
184-45	39812-39818	screen	_	
184-46	39819-39828	requiring	_	
184-47	39829-39830	a	_	
184-48	39831-39845	non-contingent	_	
184-49	39846-39852	button	_	
184-50	39853-39858	press	_	
184-51	39859-39869	indicating	_	
184-52	39870-39877	whether	_	
184-53	39878-39881	the	_	
184-54	39882-39884	US	_	
184-55	39885-39893	appeared	_	
184-56	39894-39896	or	_	
184-57	39897-39900	not	_	
184-58	39901-39903	on	_	
184-59	39904-39908	that	_	
184-60	39909-39914	trial	_	
184-61	39914-39915	.	_	

#Text=Following another variable ~1.5 s fixation screen, the next trial began.
185-1	39916-39925	Following	_	
185-2	39926-39933	another	_	
185-3	39934-39942	variable	_	
185-4	39943-39944	~	_	
185-5	39944-39947	1.5	_	
185-6	39948-39949	s	_	
185-7	39950-39958	fixation	_	
185-8	39959-39965	screen	_	
185-9	39965-39966	,	_	
185-10	39967-39970	the	_	
185-11	39971-39975	next	_	
185-12	39976-39981	trial	_	
185-13	39982-39987	began	_	
185-14	39987-39988	.	_	

#Text=Unpaired trials were identical to the paired trials with the exception that the CS remained on the screen for the entire 5 s.
186-1	39989-39997	Unpaired	_	
186-2	39998-40004	trials	_	
186-3	40005-40009	were	_	
186-4	40010-40019	identical	_	
186-5	40020-40022	to	_	
186-6	40023-40026	the	_	
186-7	40027-40033	paired	_	
186-8	40034-40040	trials	_	
186-9	40041-40045	with	_	
186-10	40046-40049	the	_	
186-11	40050-40059	exception	_	
186-12	40060-40064	that	_	
186-13	40065-40068	the	_	
186-14	40069-40071	CS	_	
186-15	40072-40080	remained	_	
186-16	40081-40083	on	_	
186-17	40084-40087	the	_	
186-18	40088-40094	screen	_	
186-19	40095-40098	for	_	
186-20	40099-40102	the	_	
186-21	40103-40109	entire	_	
186-22	40110-40111	5	_	
186-23	40112-40113	s	_	
186-24	40113-40114	.	_	

#Text=Modulation of left VMPFC activation by learning phase is valence-specific and correlates with psychophysiological response to the conditioned stimulus (CSD+) paired with a drug cue.
187-1	40115-40125	Modulation	_	
187-2	40126-40128	of	_	
187-3	40129-40133	left	_	
187-4	40134-40139	VMPFC	_	
187-5	40140-40150	activation	_	
187-6	40151-40153	by	_	
187-7	40154-40162	learning	_	
187-8	40163-40168	phase	_	
187-9	40169-40171	is	_	
187-10	40172-40188	valence-specific	_	
187-11	40189-40192	and	_	
187-12	40193-40203	correlates	_	
187-13	40204-40208	with	_	
187-14	40209-40228	psychophysiological	_	
187-15	40229-40237	response	_	
187-16	40238-40240	to	_	
187-17	40241-40244	the	_	
187-18	40245-40256	conditioned	_	
187-19	40257-40265	stimulus	_	
187-20	40266-40267	(	_	
187-21	40267-40270	CSD	_	
187-22	40270-40271	+	_	
187-23	40271-40272	)	_	
187-24	40273-40279	paired	_	
187-25	40280-40284	with	_	
187-26	40285-40286	a	_	
187-27	40287-40291	drug	_	
187-28	40292-40295	cue	_	
187-29	40295-40296	.	_	

#Text=(A) Plot shows left VMPFC activation for each learning phase (acquisition, day 1 extinction, day 2 extinction) as a function of cue-type [CSD+ (cue paired with drug-related image) and CSP+ (cue paired with pleasant image), both relative to the CS− (cue paired with neutral image)] and diagnostic group (cocaine users, controls).
188-1	40297-40298	(	_	
188-2	40298-40299	A	_	
188-3	40299-40300	)	_	
188-4	40301-40305	Plot	_	
188-5	40306-40311	shows	_	
188-6	40312-40316	left	_	
188-7	40317-40322	VMPFC	_	
188-8	40323-40333	activation	_	
188-9	40334-40337	for	_	
188-10	40338-40342	each	_	
188-11	40343-40351	learning	_	
188-12	40352-40357	phase	_	
188-13	40358-40359	(	_	
188-14	40359-40370	acquisition	_	
188-15	40370-40371	,	_	
188-16	40372-40375	day	_	
188-17	40376-40377	1	_	
188-18	40378-40388	extinction	_	
188-19	40388-40389	,	_	
188-20	40390-40393	day	_	
188-21	40394-40395	2	_	
188-22	40396-40406	extinction	_	
188-23	40406-40407	)	_	
188-24	40408-40410	as	_	
188-25	40411-40412	a	_	
188-26	40413-40421	function	_	
188-27	40422-40424	of	_	
188-28	40425-40433	cue-type	_	
188-29	40434-40435	[	_	
188-30	40435-40438	CSD	_	
188-31	40438-40439	+	_	
188-32	40440-40441	(	_	
188-33	40441-40444	cue	_	
188-34	40445-40451	paired	_	
188-35	40452-40456	with	_	
188-36	40457-40469	drug-related	_	
188-37	40470-40475	image	_	
188-38	40475-40476	)	_	
188-39	40477-40480	and	_	
188-40	40481-40484	CSP	_	
188-41	40484-40485	+	_	
188-42	40486-40487	(	_	
188-43	40487-40490	cue	_	
188-44	40491-40497	paired	_	
188-45	40498-40502	with	_	
188-46	40503-40511	pleasant	_	
188-47	40512-40517	image	_	
188-48	40517-40518	)	_	
188-49	40518-40519	,	_	
188-50	40520-40524	both	_	
188-51	40525-40533	relative	_	
188-52	40534-40536	to	_	
188-53	40537-40540	the	_	
188-54	40541-40543	CS	_	
188-55	40543-40544	−	_	
188-56	40545-40546	(	_	
188-57	40546-40549	cue	_	
188-58	40550-40556	paired	_	
188-59	40557-40561	with	_	
188-60	40562-40569	neutral	_	
188-61	40570-40575	image	_	
188-62	40575-40576	)	_	
188-63	40576-40577	]	_	
188-64	40578-40581	and	_	
188-65	40582-40592	diagnostic	_	
188-66	40593-40598	group	_	
188-67	40599-40600	(	_	
188-68	40600-40607	cocaine	_	
188-69	40608-40613	users	_	
188-70	40613-40614	,	_	
188-71	40615-40623	controls	_	
188-72	40623-40624	)	_	
188-73	40624-40625	.	_	

#Text=There was a 3-way interaction such that left VMPFC activation decreased in response to the CSP+ but increased in response to the CSD+ with extinction training in controls but not cocaine-addicted participants.
189-1	40626-40631	There	_	
189-2	40632-40635	was	_	
189-3	40636-40637	a	_	
189-4	40638-40639	3	_	
189-5	40639-40640	-	_	
189-6	40640-40643	way	_	
189-7	40644-40655	interaction	_	
189-8	40656-40660	such	_	
189-9	40661-40665	that	_	
189-10	40666-40670	left	_	
189-11	40671-40676	VMPFC	_	
189-12	40677-40687	activation	_	
189-13	40688-40697	decreased	_	
189-14	40698-40700	in	_	
189-15	40701-40709	response	_	
189-16	40710-40712	to	_	
189-17	40713-40716	the	_	
189-18	40717-40720	CSP	_	
189-19	40720-40721	+	_	
189-20	40722-40725	but	_	
189-21	40726-40735	increased	_	
189-22	40736-40738	in	_	
189-23	40739-40747	response	_	
189-24	40748-40750	to	_	
189-25	40751-40754	the	_	
189-26	40755-40758	CSD	_	
189-27	40758-40759	+	_	
189-28	40760-40764	with	_	
189-29	40765-40775	extinction	_	
189-30	40776-40784	training	_	
189-31	40785-40787	in	_	
189-32	40788-40796	controls	_	
189-33	40797-40800	but	_	
189-34	40801-40804	not	_	
189-35	40805-40821	cocaine-addicted	_	
189-36	40822-40834	participants	_	
189-37	40834-40835	.	_	

#Text=(B) Left VMPFC activation on day 2 extinction correlated with the success of day 1 extinction as indexed by reductions in skin conductance response (SCR) to the CSD+ relative to the CS− across subjects, pointing to a role of this region in the recall of extinction learning.
190-1	40836-40837	(	_	
190-2	40837-40838	B	_	
190-3	40838-40839	)	_	
190-4	40840-40844	Left	_	
190-5	40845-40850	VMPFC	_	
190-6	40851-40861	activation	_	
190-7	40862-40864	on	_	
190-8	40865-40868	day	_	
190-9	40869-40870	2	_	
190-10	40871-40881	extinction	_	
190-11	40882-40892	correlated	_	
190-12	40893-40897	with	_	
190-13	40898-40901	the	_	
190-14	40902-40909	success	_	
190-15	40910-40912	of	_	
190-16	40913-40916	day	_	
190-17	40917-40918	1	_	
190-18	40919-40929	extinction	_	
190-19	40930-40932	as	_	
190-20	40933-40940	indexed	_	
190-21	40941-40943	by	_	
190-22	40944-40954	reductions	_	
190-23	40955-40957	in	_	
190-24	40958-40962	skin	_	
190-25	40963-40974	conductance	_	
190-26	40975-40983	response	_	
190-27	40984-40985	(	_	
190-28	40985-40988	SCR	_	
190-29	40988-40989	)	_	
190-30	40990-40992	to	_	
190-31	40993-40996	the	_	
190-32	40997-41000	CSD	_	
190-33	41000-41001	+	_	
190-34	41002-41010	relative	_	
190-35	41011-41013	to	_	
190-36	41014-41017	the	_	
190-37	41018-41020	CS	_	
190-38	41020-41021	−	_	
190-39	41022-41028	across	_	
190-40	41029-41037	subjects	_	
190-41	41037-41038	,	_	
190-42	41039-41047	pointing	_	
190-43	41048-41050	to	_	
190-44	41051-41052	a	_	
190-45	41053-41057	role	_	
190-46	41058-41060	of	_	
190-47	41061-41065	this	_	
190-48	41066-41072	region	_	
190-49	41073-41075	in	_	
190-50	41076-41079	the	_	
190-51	41080-41086	recall	_	
190-52	41087-41089	of	_	
190-53	41090-41100	extinction	_	
190-54	41101-41109	learning	_	
190-55	41109-41110	.	_	

#Text=The overall pattern of results in the right VMPFC, as well as the correlation between right VMPFC activation and SCR, was similar albeit weaker (see Results).
191-1	41111-41114	The	_	
191-2	41115-41122	overall	_	
191-3	41123-41130	pattern	_	
191-4	41131-41133	of	_	
191-5	41134-41141	results	_	
191-6	41142-41144	in	_	
191-7	41145-41148	the	_	
191-8	41149-41154	right	_	
191-9	41155-41160	VMPFC	_	
191-10	41160-41161	,	_	
191-11	41162-41164	as	_	
191-12	41165-41169	well	_	
191-13	41170-41172	as	_	
191-14	41173-41176	the	_	
191-15	41177-41188	correlation	_	
191-16	41189-41196	between	_	
191-17	41197-41202	right	_	
191-18	41203-41208	VMPFC	_	
191-19	41209-41219	activation	_	
191-20	41220-41223	and	_	
191-21	41224-41227	SCR	_	
191-22	41227-41228	,	_	
191-23	41229-41232	was	_	
191-24	41233-41240	similar	_	
191-25	41241-41247	albeit	_	
191-26	41248-41254	weaker	_	
191-27	41255-41256	(	_	
191-28	41256-41259	see	_	
191-29	41260-41267	Results	_	
191-30	41267-41268	)	_	
191-31	41268-41269	.	_	

#Text=+P≤0.10, *P≤0.05, **P≤0.01.
192-1	41270-41271	+	_	
192-2	41271-41272	P	_	
192-3	41272-41273	≤	_	
192-4	41273-41277	0.10	_	
192-5	41277-41278	,	_	
192-6	41279-41280	*	_	
192-7	41280-41281	P	_	
192-8	41281-41282	≤	_	
192-9	41282-41286	0.05	_	
192-10	41286-41287	,	_	
192-11	41288-41289	*	_	
192-12	41289-41290	*	_	
192-13	41290-41291	P	_	
192-14	41291-41292	≤	_	
192-15	41292-41296	0.01	_	
192-16	41296-41297	.	_	

#Text=See also Figures S3–S5 and Tables S1–S2.
193-1	41298-41301	See	_	
193-2	41302-41306	also	_	
193-3	41307-41314	Figures	_	
193-4	41315-41317	S3	_	
193-5	41317-41318	–	_	
193-6	41318-41320	S5	_	
193-7	41321-41324	and	_	
193-8	41325-41331	Tables	_	
193-9	41332-41334	S1	_	
193-10	41334-41335	–	_	
193-11	41335-41337	S2	_	
193-12	41337-41338	.	_	

#Text=Modulation of striatum activation by learning phase is valence-specific across participants.
194-1	41339-41349	Modulation	_	
194-2	41350-41352	of	_	
194-3	41353-41361	striatum	_	
194-4	41362-41372	activation	_	
194-5	41373-41375	by	_	
194-6	41376-41384	learning	_	
194-7	41385-41390	phase	_	
194-8	41391-41393	is	_	
194-9	41394-41410	valence-specific	_	
194-10	41411-41417	across	_	
194-11	41418-41430	participants	_	
194-12	41430-41431	.	_	

#Text=(A) Plot shows average left and right striatum activation for each learning phase (acquisition, day 1 extinction, day 2 extinction) as a function of cue-type [CSD+ (cue paired with drug-related image) and CSP+ (cue paired with pleasant image), both relative to the CS− (cue paired with neutral image)] across controls and cocaine users.
195-1	41432-41433	(	_	
195-2	41433-41434	A	_	
195-3	41434-41435	)	_	
195-4	41436-41440	Plot	_	
195-5	41441-41446	shows	_	
195-6	41447-41454	average	_	
195-7	41455-41459	left	_	
195-8	41460-41463	and	_	
195-9	41464-41469	right	_	
195-10	41470-41478	striatum	_	
195-11	41479-41489	activation	_	
195-12	41490-41493	for	_	
195-13	41494-41498	each	_	
195-14	41499-41507	learning	_	
195-15	41508-41513	phase	_	
195-16	41514-41515	(	_	
195-17	41515-41526	acquisition	_	
195-18	41526-41527	,	_	
195-19	41528-41531	day	_	
195-20	41532-41533	1	_	
195-21	41534-41544	extinction	_	
195-22	41544-41545	,	_	
195-23	41546-41549	day	_	
195-24	41550-41551	2	_	
195-25	41552-41562	extinction	_	
195-26	41562-41563	)	_	
195-27	41564-41566	as	_	
195-28	41567-41568	a	_	
195-29	41569-41577	function	_	
195-30	41578-41580	of	_	
195-31	41581-41589	cue-type	_	
195-32	41590-41591	[	_	
195-33	41591-41594	CSD	_	
195-34	41594-41595	+	_	
195-35	41596-41597	(	_	
195-36	41597-41600	cue	_	
195-37	41601-41607	paired	_	
195-38	41608-41612	with	_	
195-39	41613-41625	drug-related	_	
195-40	41626-41631	image	_	
195-41	41631-41632	)	_	
195-42	41633-41636	and	_	
195-43	41637-41640	CSP	_	
195-44	41640-41641	+	_	
195-45	41642-41643	(	_	
195-46	41643-41646	cue	_	
195-47	41647-41653	paired	_	
195-48	41654-41658	with	_	
195-49	41659-41667	pleasant	_	
195-50	41668-41673	image	_	
195-51	41673-41674	)	_	
195-52	41674-41675	,	_	
195-53	41676-41680	both	_	
195-54	41681-41689	relative	_	
195-55	41690-41692	to	_	
195-56	41693-41696	the	_	
195-57	41697-41699	CS	_	
195-58	41699-41700	−	_	
195-59	41701-41702	(	_	
195-60	41702-41705	cue	_	
195-61	41706-41712	paired	_	
195-62	41713-41717	with	_	
195-63	41718-41725	neutral	_	
195-64	41726-41731	image	_	
195-65	41731-41732	)	_	
195-66	41732-41733	]	_	
195-67	41734-41740	across	_	
195-68	41741-41749	controls	_	
195-69	41750-41753	and	_	
195-70	41754-41761	cocaine	_	
195-71	41762-41767	users	_	
195-72	41767-41768	.	_	

#Text=There was a 2-way interaction such that, across participants, striatum activation decreased in response to the CSP+ but increased in response to the CSD+ with extinction training.
196-1	41769-41774	There	_	
196-2	41775-41778	was	_	
196-3	41779-41780	a	_	
196-4	41781-41782	2	_	
196-5	41782-41783	-	_	
196-6	41783-41786	way	_	
196-7	41787-41798	interaction	_	
196-8	41799-41803	such	_	
196-9	41804-41808	that	_	
196-10	41808-41809	,	_	
196-11	41810-41816	across	_	
196-12	41817-41829	participants	_	
196-13	41829-41830	,	_	
196-14	41831-41839	striatum	_	
196-15	41840-41850	activation	_	
196-16	41851-41860	decreased	_	
196-17	41861-41863	in	_	
196-18	41864-41872	response	_	
196-19	41873-41875	to	_	
196-20	41876-41879	the	_	
196-21	41880-41883	CSP	_	
196-22	41883-41884	+	_	
196-23	41885-41888	but	_	
196-24	41889-41898	increased	_	
196-25	41899-41901	in	_	
196-26	41902-41910	response	_	
196-27	41911-41913	to	_	
196-28	41914-41917	the	_	
196-29	41918-41921	CSD	_	
196-30	41921-41922	+	_	
196-31	41923-41927	with	_	
196-32	41928-41938	extinction	_	
196-33	41939-41947	training	_	
196-34	41947-41948	.	_	

#Text=+P≤0.10, *P≤0.05, **P≤0.01.
197-1	41949-41950	+	_	
197-2	41950-41951	P	_	
197-3	41951-41952	≤	_	
197-4	41952-41956	0.10	_	
197-5	41956-41957	,	_	
197-6	41958-41959	*	_	
197-7	41959-41960	P	_	
197-8	41960-41961	≤	_	
197-9	41961-41965	0.05	_	
197-10	41965-41966	,	_	
197-11	41967-41968	*	_	
197-12	41968-41969	*	_	
197-13	41969-41970	P	_	
197-14	41970-41971	≤	_	
197-15	41971-41975	0.01	_	
197-16	41975-41976	.	_	

#Text=See also Figures S3–S4 and Tables S1–S2.
198-1	41977-41980	See	_	
198-2	41981-41985	also	_	
198-3	41986-41993	Figures	_	
198-4	41994-41996	S3	_	
198-5	41996-41997	–	_	
198-6	41997-41999	S4	_	
198-7	42000-42003	and	_	
198-8	42004-42010	Tables	_	
198-9	42011-42013	S1	_	
198-10	42013-42014	–	_	
198-11	42014-42016	S2	_	
198-12	42016-42017	.	_	

#Text=VMPFC activation during day 1 extinction correlates with a reduction in craving from day 1 to day 2.
199-1	42018-42023	VMPFC	_	
199-2	42024-42034	activation	_	
199-3	42035-42041	during	_	
199-4	42042-42045	day	_	
199-5	42046-42047	1	_	
199-6	42048-42058	extinction	_	
199-7	42059-42069	correlates	_	
199-8	42070-42074	with	_	
199-9	42075-42076	a	_	
199-10	42077-42086	reduction	_	
199-11	42087-42089	in	_	
199-12	42090-42097	craving	_	
199-13	42098-42102	from	_	
199-14	42103-42106	day	_	
199-15	42107-42108	1	_	
199-16	42109-42111	to	_	
199-17	42112-42115	day	_	
199-18	42116-42117	2	_	
199-19	42117-42118	.	_	

#Text=Left VMPFC activation to the CSD+ relative to the CS− on day 1 extinction correlated with a reduction in craving from day 1 to day 2, showing that participants who were more successful at modulating activation in this region on day 1 extinction in response to the drug-relevant cue experienced less severe drug cravings a day later.
200-1	42119-42123	Left	_	
200-2	42124-42129	VMPFC	_	
200-3	42130-42140	activation	_	
200-4	42141-42143	to	_	
200-5	42144-42147	the	_	
200-6	42148-42151	CSD	_	
200-7	42151-42152	+	_	
200-8	42153-42161	relative	_	
200-9	42162-42164	to	_	
200-10	42165-42168	the	_	
200-11	42169-42171	CS	_	
200-12	42171-42172	−	_	
200-13	42173-42175	on	_	
200-14	42176-42179	day	_	
200-15	42180-42181	1	_	
200-16	42182-42192	extinction	_	
200-17	42193-42203	correlated	_	
200-18	42204-42208	with	_	
200-19	42209-42210	a	_	
200-20	42211-42220	reduction	_	
200-21	42221-42223	in	_	
200-22	42224-42231	craving	_	
200-23	42232-42236	from	_	
200-24	42237-42240	day	_	
200-25	42241-42242	1	_	
200-26	42243-42245	to	_	
200-27	42246-42249	day	_	
200-28	42250-42251	2	_	
200-29	42251-42252	,	_	
200-30	42253-42260	showing	_	
200-31	42261-42265	that	_	
200-32	42266-42278	participants	_	
200-33	42279-42282	who	_	
200-34	42283-42287	were	_	
200-35	42288-42292	more	_	
200-36	42293-42303	successful	_	
200-37	42304-42306	at	_	
200-38	42307-42317	modulating	_	
200-39	42318-42328	activation	_	
200-40	42329-42331	in	_	
200-41	42332-42336	this	_	
200-42	42337-42343	region	_	
200-43	42344-42346	on	_	
200-44	42347-42350	day	_	
200-45	42351-42352	1	_	
200-46	42353-42363	extinction	_	
200-47	42364-42366	in	_	
200-48	42367-42375	response	_	
200-49	42376-42378	to	_	
200-50	42379-42382	the	_	
200-51	42383-42396	drug-relevant	_	
200-52	42397-42400	cue	_	
200-53	42401-42412	experienced	_	
200-54	42413-42417	less	_	
200-55	42418-42424	severe	_	
200-56	42425-42429	drug	_	
200-57	42430-42438	cravings	_	
200-58	42439-42440	a	_	
200-59	42441-42444	day	_	
200-60	42445-42450	later	_	
200-61	42450-42451	.	_	

#Text=Demographic and drug use characteristics of the study sample.
201-1	42452-42463	Demographic	_	
201-2	42464-42467	and	_	
201-3	42468-42472	drug	_	
201-4	42473-42476	use	_	
201-5	42477-42492	characteristics	_	
201-6	42493-42495	of	_	
201-7	42496-42499	the	_	
201-8	42500-42505	study	_	
201-9	42506-42512	sample	_	
201-10	42512-42513	.	_	

#Text=Test\tControl (n=15)\tCocaine Users (n=18)\t \tDemographics\t \tAge (years)\tt31 = 0.3\t45.3 ± 1.6\t45.8 ± 1.1\t \tSex (male / female)\tχ2 = 0.6\t13 / 2\t17/ 1\t \tRace (African-American/Caucasian/Hispanic)\tχ2 = 0.8\t10 / 2 / 3\t12 / 4 / 2\t \tEducation (years)\tt31 = 1.7\t13.3 ± 0.4\t12.6 ± 0.3\t \tVerbal IQ: Wide Range Achievement Test III - Reading Scale\tt31 = 0.7\t94.0 ± 4.2\t90.0 ± 3.5\t \tNonverbal IQ: Wechsler Abbreviated Scale of Intelligence – Matrix Reasoning Scale\tt31 = 0.5\t8.4 ± 0.9\t8.9 ± 0.7\t \tState Depression: Beck Depression Inventory II a\tZ = 1.7\t3.2 ± 1.3\t7.6 ± 2.2\t \tSocioeconomic Status: Hollingshead Index a\tt28 = 1.3\t32.9 ± 3.4\t28.9 ± 2.4\t \tHandedness (laterality quotient)\tt31 = 0.5\t0.7 ± 0.2\t0.8 ± 0.2\t \tDrug Use\t \tCigarette smokers (current or past / nonsmokers)\tχ2 = 3.5\t6 / 9\t13 / 5\t \t Daily cigarettes (current smokers: n=5/11)\tZ = 1.0\t4.8 ± 1.7\t8.5 ± 2.3\t \tAlcohol use lifetime (years) (n=10/11)\tt19 = 0.8\t20.0 ± 3.1\t22.8 ± 2.2\t \tCocaine use lifetime (years)\t--\t--\t17.8 ± 1.6\t \tDuration of current abstinence/time since last cocaine use (days) b\t--\t--\t13.9 ± 7.4\t \tDays/week of cocaine use during the past 30 days\t--\t--\t2.6 ± 0.6\t \tCocaine urine status (positive / negative): day 1 | day 2\t--\t--\t6 / 12 | 4 / 14\t \tWithdrawal symptoms: 18-item CSSA (0–126): day 1 | day 2 c\t--\t--\t22.2 ± 3.6 | 11.8 ± 2.1\t \tCocaine craving: 5-item Questionnaire (0–45): day 1 | day 2 d\t--\t--\t20.1 ± 3.1 |15.5 ± 3.5\t \t
#Text=Data missing for one control and two cocaine users;
#Text=Data missing for two cocaine users;
#Text=day 1 vs. day 2 (t17 = 3.9, P=0.001);
#Text=day 1 vs. day 2 (t17 = 2.2, P=0.04);
#Text=Abbreviations: CSSA, Cocaine Selective Severity Assessment Scale;
#Text=Values are frequencies or means ± standard error of the mean (SEM).
202-1	42515-42519	Test	_	
202-2	42520-42527	Control	_	
202-3	42528-42529	(	_	
202-4	42529-42530	n	_	
202-5	42530-42531	=	_	
202-6	42531-42533	15	_	
202-7	42533-42534	)	_	
202-8	42535-42542	Cocaine	_	
202-9	42543-42548	Users	_	
202-10	42549-42550	(	_	
202-11	42550-42551	n	_	
202-12	42551-42552	=	_	
202-13	42552-42554	18	_	
202-14	42554-42555	)	_	
202-15	42558-42570	Demographics	_	
202-16	42573-42576	Age	_	
202-17	42577-42578	(	_	
202-18	42578-42583	years	_	
202-19	42583-42584	)	_	
202-20	42585-42588	t31	_	
202-21	42589-42590	=	_	
202-22	42591-42594	0.3	_	
202-23	42595-42599	45.3	_	
202-24	42600-42601	±	_	
202-25	42602-42605	1.6	_	
202-26	42606-42610	45.8	_	
202-27	42611-42612	±	_	
202-28	42613-42616	1.1	_	
202-29	42619-42622	Sex	_	
202-30	42623-42624	(	_	
202-31	42624-42628	male	_	
202-32	42629-42630	/	_	
202-33	42631-42637	female	_	
202-34	42637-42638	)	_	
202-35	42639-42641	χ2	_	
202-36	42642-42643	=	_	
202-37	42644-42647	0.6	_	
202-38	42648-42650	13	_	
202-39	42651-42652	/	_	
202-40	42653-42654	2	_	
202-41	42655-42657	17	_	
202-42	42657-42658	/	_	
202-43	42659-42660	1	_	
202-44	42663-42667	Race	_	
202-45	42668-42669	(	_	
202-46	42669-42685	African-American	_	
202-47	42685-42686	/	_	
202-48	42686-42695	Caucasian	_	
202-49	42695-42696	/	_	
202-50	42696-42704	Hispanic	_	
202-51	42704-42705	)	_	
202-52	42706-42708	χ2	_	
202-53	42709-42710	=	_	
202-54	42711-42714	0.8	_	
202-55	42715-42717	10	_	
202-56	42718-42719	/	_	
202-57	42720-42721	2	_	
202-58	42722-42723	/	_	
202-59	42724-42725	3	_	
202-60	42726-42728	12	_	
202-61	42729-42730	/	_	
202-62	42731-42732	4	_	
202-63	42733-42734	/	_	
202-64	42735-42736	2	_	
202-65	42739-42748	Education	_	
202-66	42749-42750	(	_	
202-67	42750-42755	years	_	
202-68	42755-42756	)	_	
202-69	42757-42760	t31	_	
202-70	42761-42762	=	_	
202-71	42763-42766	1.7	_	
202-72	42767-42771	13.3	_	
202-73	42772-42773	±	_	
202-74	42774-42777	0.4	_	
202-75	42778-42782	12.6	_	
202-76	42783-42784	±	_	
202-77	42785-42788	0.3	_	
202-78	42791-42797	Verbal	_	
202-79	42798-42800	IQ	_	
202-80	42800-42801	:	_	
202-81	42802-42806	Wide	_	
202-82	42807-42812	Range	_	
202-83	42813-42824	Achievement	_	
202-84	42825-42829	Test	_	
202-85	42830-42833	III	_	
202-86	42834-42835	-	_	
202-87	42836-42843	Reading	_	
202-88	42844-42849	Scale	_	
202-89	42850-42853	t31	_	
202-90	42854-42855	=	_	
202-91	42856-42859	0.7	_	
202-92	42860-42864	94.0	_	
202-93	42865-42866	±	_	
202-94	42867-42870	4.2	_	
202-95	42871-42875	90.0	_	
202-96	42876-42877	±	_	
202-97	42878-42881	3.5	_	
202-98	42884-42893	Nonverbal	_	
202-99	42894-42896	IQ	_	
202-100	42896-42897	:	_	
202-101	42898-42906	Wechsler	_	
202-102	42907-42918	Abbreviated	_	
202-103	42919-42924	Scale	_	
202-104	42925-42927	of	_	
202-105	42928-42940	Intelligence	_	
202-106	42941-42942	–	_	
202-107	42943-42949	Matrix	_	
202-108	42950-42959	Reasoning	_	
202-109	42960-42965	Scale	_	
202-110	42966-42969	t31	_	
202-111	42970-42971	=	_	
202-112	42972-42975	0.5	_	
202-113	42976-42979	8.4	_	
202-114	42980-42981	±	_	
202-115	42982-42985	0.9	_	
202-116	42986-42989	8.9	_	
202-117	42990-42991	±	_	
202-118	42992-42995	0.7	_	
202-119	42998-43003	State	_	
202-120	43004-43014	Depression	_	
202-121	43014-43015	:	_	
202-122	43016-43020	Beck	_	
202-123	43021-43031	Depression	_	
202-124	43032-43041	Inventory	_	
202-125	43042-43044	II	_	
202-126	43045-43046	a	_	
202-127	43047-43048	Z	_	
202-128	43049-43050	=	_	
202-129	43051-43054	1.7	_	
202-130	43055-43058	3.2	_	
202-131	43059-43060	±	_	
202-132	43061-43064	1.3	_	
202-133	43065-43068	7.6	_	
202-134	43069-43070	±	_	
202-135	43071-43074	2.2	_	
202-136	43077-43090	Socioeconomic	_	
202-137	43091-43097	Status	_	
202-138	43097-43098	:	_	
202-139	43099-43111	Hollingshead	_	
202-140	43112-43117	Index	_	
202-141	43118-43119	a	_	
202-142	43120-43123	t28	_	
202-143	43124-43125	=	_	
202-144	43126-43129	1.3	_	
202-145	43130-43134	32.9	_	
202-146	43135-43136	±	_	
202-147	43137-43140	3.4	_	
202-148	43141-43145	28.9	_	
202-149	43146-43147	±	_	
202-150	43148-43151	2.4	_	
202-151	43154-43164	Handedness	_	
202-152	43165-43166	(	_	
202-153	43166-43176	laterality	_	
202-154	43177-43185	quotient	_	
202-155	43185-43186	)	_	
202-156	43187-43190	t31	_	
202-157	43191-43192	=	_	
202-158	43193-43196	0.5	_	
202-159	43197-43200	0.7	_	
202-160	43201-43202	±	_	
202-161	43203-43206	0.2	_	
202-162	43207-43210	0.8	_	
202-163	43211-43212	±	_	
202-164	43213-43216	0.2	_	
202-165	43219-43223	Drug	_	
202-166	43224-43227	Use	_	
202-167	43230-43239	Cigarette	_	
202-168	43240-43247	smokers	_	
202-169	43248-43249	(	_	
202-170	43249-43256	current	_	
202-171	43257-43259	or	_	
202-172	43260-43264	past	_	
202-173	43265-43266	/	_	
202-174	43267-43277	nonsmokers	_	
202-175	43277-43278	)	_	
202-176	43279-43281	χ2	_	
202-177	43282-43283	=	_	
202-178	43284-43287	3.5	_	
202-179	43288-43289	6	_	
202-180	43290-43291	/	_	
202-181	43292-43293	9	_	
202-182	43294-43296	13	_	
202-183	43297-43298	/	_	
202-184	43299-43300	5	_	
202-185	43304-43309	Daily	_	
202-186	43310-43320	cigarettes	_	
202-187	43321-43322	(	_	
202-188	43322-43329	current	_	
202-189	43330-43337	smokers	_	
202-190	43337-43338	:	_	
202-191	43339-43340	n	_	
202-192	43340-43341	=	_	
202-193	43341-43342	5	_	
202-194	43342-43343	/	_	
202-195	43343-43345	11	_	
202-196	43345-43346	)	_	
202-197	43347-43348	Z	_	
202-198	43349-43350	=	_	
202-199	43351-43354	1.0	_	
202-200	43355-43358	4.8	_	
202-201	43359-43360	±	_	
202-202	43361-43364	1.7	_	
202-203	43365-43368	8.5	_	
202-204	43369-43370	±	_	
202-205	43371-43374	2.3	_	
202-206	43377-43384	Alcohol	_	
202-207	43385-43388	use	_	
202-208	43389-43397	lifetime	_	
202-209	43398-43399	(	_	
202-210	43399-43404	years	_	
202-211	43404-43405	)	_	
202-212	43406-43407	(	_	
202-213	43407-43408	n	_	
202-214	43408-43409	=	_	
202-215	43409-43411	10	_	
202-216	43411-43412	/	_	
202-217	43412-43414	11	_	
202-218	43414-43415	)	_	
202-219	43416-43419	t19	_	
202-220	43420-43421	=	_	
202-221	43422-43425	0.8	_	
202-222	43426-43430	20.0	_	
202-223	43431-43432	±	_	
202-224	43433-43436	3.1	_	
202-225	43437-43441	22.8	_	
202-226	43442-43443	±	_	
202-227	43444-43447	2.2	_	
202-228	43450-43457	Cocaine	_	
202-229	43458-43461	use	_	
202-230	43462-43470	lifetime	_	
202-231	43471-43472	(	_	
202-232	43472-43477	years	_	
202-233	43477-43478	)	_	
202-234	43479-43480	-	_	
202-235	43480-43481	-	_	
202-236	43482-43483	-	_	
202-237	43483-43484	-	_	
202-238	43485-43489	17.8	_	
202-239	43490-43491	±	_	
202-240	43492-43495	1.6	_	
202-241	43498-43506	Duration	_	
202-242	43507-43509	of	_	
202-243	43510-43517	current	_	
202-244	43518-43528	abstinence	_	
202-245	43528-43529	/	_	
202-246	43529-43533	time	_	
202-247	43534-43539	since	_	
202-248	43540-43544	last	_	
202-249	43545-43552	cocaine	_	
202-250	43553-43556	use	_	
202-251	43557-43558	(	_	
202-252	43558-43562	days	_	
202-253	43562-43563	)	_	
202-254	43564-43565	b	_	
202-255	43566-43567	-	_	
202-256	43567-43568	-	_	
202-257	43569-43570	-	_	
202-258	43570-43571	-	_	
202-259	43572-43576	13.9	_	
202-260	43577-43578	±	_	
202-261	43579-43582	7.4	_	
202-262	43585-43589	Days	_	
202-263	43589-43590	/	_	
202-264	43590-43594	week	_	
202-265	43595-43597	of	_	
202-266	43598-43605	cocaine	_	
202-267	43606-43609	use	_	
202-268	43610-43616	during	_	
202-269	43617-43620	the	_	
202-270	43621-43625	past	_	
202-271	43626-43628	30	_	
202-272	43629-43633	days	_	
202-273	43634-43635	-	_	
202-274	43635-43636	-	_	
202-275	43637-43638	-	_	
202-276	43638-43639	-	_	
202-277	43640-43643	2.6	_	
202-278	43644-43645	±	_	
202-279	43646-43649	0.6	_	
202-280	43652-43659	Cocaine	_	
202-281	43660-43665	urine	_	
202-282	43666-43672	status	_	
202-283	43673-43674	(	_	
202-284	43674-43682	positive	_	
202-285	43683-43684	/	_	
202-286	43685-43693	negative	_	
202-287	43693-43694	)	_	
202-288	43694-43695	:	_	
202-289	43696-43699	day	_	
202-290	43700-43701	1	_	
202-291	43702-43703	|	_	
202-292	43704-43707	day	_	
202-293	43708-43709	2	_	
202-294	43710-43711	-	_	
202-295	43711-43712	-	_	
202-296	43713-43714	-	_	
202-297	43714-43715	-	_	
202-298	43716-43717	6	_	
202-299	43718-43719	/	_	
202-300	43720-43722	12	_	
202-301	43723-43724	|	_	
202-302	43725-43726	4	_	
202-303	43727-43728	/	_	
202-304	43729-43731	14	_	
202-305	43734-43744	Withdrawal	_	
202-306	43745-43753	symptoms	_	
202-307	43753-43754	:	_	
202-308	43755-43757	18	_	
202-309	43757-43758	-	_	
202-310	43758-43762	item	_	
202-311	43763-43767	CSSA	_	
202-312	43768-43769	(	_	
202-313	43769-43770	0	_	
202-314	43770-43771	–	_	
202-315	43771-43774	126	_	
202-316	43774-43775	)	_	
202-317	43775-43776	:	_	
202-318	43777-43780	day	_	
202-319	43781-43782	1	_	
202-320	43783-43784	|	_	
202-321	43785-43788	day	_	
202-322	43789-43790	2	_	
202-323	43791-43792	c	_	
202-324	43793-43794	-	_	
202-325	43794-43795	-	_	
202-326	43796-43797	-	_	
202-327	43797-43798	-	_	
202-328	43799-43803	22.2	_	
202-329	43804-43805	±	_	
202-330	43806-43809	3.6	_	
202-331	43810-43811	|	_	
202-332	43812-43816	11.8	_	
202-333	43817-43818	±	_	
202-334	43819-43822	2.1	_	
202-335	43825-43832	Cocaine	_	
202-336	43833-43840	craving	_	
202-337	43840-43841	:	_	
202-338	43842-43843	5	_	
202-339	43843-43844	-	_	
202-340	43844-43848	item	_	
202-341	43849-43862	Questionnaire	_	
202-342	43863-43864	(	_	
202-343	43864-43865	0	_	
202-344	43865-43866	–	_	
202-345	43866-43868	45	_	
202-346	43868-43869	)	_	
202-347	43869-43870	:	_	
202-348	43871-43874	day	_	
202-349	43875-43876	1	_	
202-350	43877-43878	|	_	
202-351	43879-43882	day	_	
202-352	43883-43884	2	_	
202-353	43885-43886	d	_	
202-354	43887-43888	-	_	
202-355	43888-43889	-	_	
202-356	43890-43891	-	_	
202-357	43891-43892	-	_	
202-358	43893-43897	20.1	_	
202-359	43898-43899	±	_	
202-360	43900-43903	3.1	_	
202-361	43904-43905	|	_	
202-362	43905-43909	15.5	_	
202-363	43910-43911	±	_	
202-364	43912-43915	3.5	_	
202-365	43919-43923	Data	_	
202-366	43924-43931	missing	_	
202-367	43932-43935	for	_	
202-368	43936-43939	one	_	
202-369	43940-43947	control	_	
202-370	43948-43951	and	_	
202-371	43952-43955	two	_	
202-372	43956-43963	cocaine	_	
202-373	43964-43969	users	_	
202-374	43969-43970	;	_	
202-375	43971-43975	Data	_	
202-376	43976-43983	missing	_	
202-377	43984-43987	for	_	
202-378	43988-43991	two	_	
202-379	43992-43999	cocaine	_	
202-380	44000-44005	users	_	
202-381	44005-44006	;	_	
202-382	44007-44010	day	_	
202-383	44011-44012	1	_	
202-384	44013-44015	vs	_	
202-385	44015-44016	.	_	
202-386	44017-44020	day	_	
202-387	44021-44022	2	_	
202-388	44023-44024	(	_	
202-389	44024-44027	t17	_	
202-390	44028-44029	=	_	
202-391	44030-44033	3.9	_	
202-392	44033-44034	,	_	
202-393	44035-44036	P	_	
202-394	44036-44037	=	_	
202-395	44037-44042	0.001	_	
202-396	44042-44043	)	_	
202-397	44043-44044	;	_	
202-398	44045-44048	day	_	
202-399	44049-44050	1	_	
202-400	44051-44053	vs	_	
202-401	44053-44054	.	_	
202-402	44055-44058	day	_	
202-403	44059-44060	2	_	
202-404	44061-44062	(	_	
202-405	44062-44065	t17	_	
202-406	44066-44067	=	_	
202-407	44068-44071	2.2	_	
202-408	44071-44072	,	_	
202-409	44073-44074	P	_	
202-410	44074-44075	=	_	
202-411	44075-44079	0.04	_	
202-412	44079-44080	)	_	
202-413	44080-44081	;	_	
202-414	44082-44095	Abbreviations	_	
202-415	44095-44096	:	_	
202-416	44097-44101	CSSA	_	
202-417	44101-44102	,	_	
202-418	44103-44110	Cocaine	_	
202-419	44111-44120	Selective	_	
202-420	44121-44129	Severity	_	
202-421	44130-44140	Assessment	_	
202-422	44141-44146	Scale	_	
202-423	44146-44147	;	_	
202-424	44148-44154	Values	_	
202-425	44155-44158	are	_	
202-426	44159-44170	frequencies	_	
202-427	44171-44173	or	_	
202-428	44174-44179	means	_	
202-429	44180-44181	±	_	
202-430	44182-44190	standard	_	
202-431	44191-44196	error	_	
202-432	44197-44199	of	_	
202-433	44200-44203	the	_	
202-434	44204-44208	mean	_	
202-435	44209-44210	(	_	
202-436	44210-44213	SEM	_	
202-437	44213-44214	)	_	
202-438	44214-44215	.	_	
